emtricitabine profile

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV infection. It is a synthetic analog of cytidine that inhibits the activity of HIV reverse transcriptase, the enzyme responsible for converting viral RNA into viral DNA. Emtricitabine is typically administered in combination with other antiretroviral drugs. It is important because it has been shown to be effective in suppressing viral replication and reducing the risk of HIV-related complications. Emtricitabine is studied to understand its mechanisms of action, potential side effects, and to develop new and improved antiretroviral therapies.'

Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	60877
CHEMBL ID	885
CHEBI ID	31536
SCHEMBL ID	39708
MeSH ID	M0337569

Synonym
bw-524w91
coviracil
(2r-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone
drg-0208
emtriva
hsdb 7337
bw 524w91
5-fluoro-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-2'-deoxy-5-fluoro-3'-thiacytidine
bw 1592
ftc, (-)-
2(1h)-pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2r-cis)-
emtricitabine
143491-57-0
.beta.-l-(-)-(2r,5s)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
emtriva(tm)
bw524w91
524w91
4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
coviracil(tm)
(-)-.beta.-l-ftc
(-)-2',3'-dideoxy-5-fluoro-3'-thiacytidine
FTC ,
143491-54-7
(-)-ftc
4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1h)-one
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidin-2-one
DB00879
4-amino-5-fluoro-1-((2r,5s)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1h-pyrimidin-2-one
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-(2r,5s)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
4-amino-5-fluoro-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one ,
D01199
NCGC00164564-01
2(1h)-pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-(+-)-
2(1h)-pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-
2',3',5-ftc
c8h10fn3o3s
2(1h)-pyrimidinone, 4-amino-5-fluoro-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, rel-
HMS2089I05
CHEBI:31536 ,
(-)-emtricitabine
ftc-(-)
emtricitabinum
524-w-91
CHEMBL885
emtricitabine, (-)-
psi-5004
emtritabine
((-))-ftc
emtricitabine [usan:inn]
unii-g70b4etf4s
g70b4etf4s ,
ftc-((-))
tox21_112193
dtxsid0040129 ,
cas-143491-57-0
dtxcid8020129
145213-48-5
uls8902u4o ,
unii-uls8902u4o
HY-17427
CS-1370
MLS003882429
smr002533604
emtricitabine [ema epar]
emtricitabine component of eviplera
emtricitabine component of stribild
emtricitabine [usan]
truvada component emtricitabine
stribild component emtricitabine
odefsey component emtricitabine
emtricitabine [inn]
eviplera component emtricitabine
emtricitabine component of truvada
descovy component emtricitabine
emtricitabine [who-dd]
emtricitabine [mart.]
atripla component emtricitabine
emtricitabine component of atripla
emtricitabine [usp-rs]
5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (2r,5s)
emtricitabine [vandf]
emtricitabine [mi]
2(1h)-pyrimidinone, 4-amino-5-fluoro-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-
5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
emtricitabine component of descovy
descovy component of emtricitabine
emtricitabinum [who-ip latin]
emtricitabine component of odefsey
emtricitabine [orange book]
emtricitabine [hsdb]
emtricitabine [jan]
emtricitabine [who-ip]
emtricitabine component of genvoya
AM84393
S1704
AKOS015853098
AKOS015894950
2',3'-dideoxy-5-fluoro-3'-thiacytidine, dl-
CCG-220615
XQSPYNMVSIKCOC-NTSWFWBYSA-N
MLS006011987
MLS006011556
SCHEMBL39708
AB01275429-01
W-201248
W-201247
2',3'-dideoxy-3-thia-5-fluorocytidine
E1007
bdbm50107843
EX-A150
bw1592
gtpl11244
HMS3713L12
2(1h)-pyrimidinone, 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel-
rel-4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone
SW220172-1
Q422604
4-amino-5-fluoro-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone; (+)-2'-deoxy-3'-thia-5-fluorocytidine; (2s-cis)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone
ent-emtricitabine; emtricitabine ip impurity d
2(1h)-pyrimidinone,4-amino-5-fluoro-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-
AS-14099
2(1h)-pyrimidinone,4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-
NCGC00164564-06
D72669
M06302
NCGC00164564-09
CS1125
emtricitabine 100 microg/ml in acetonitrile
nsc-804863
nsc804863
NCGC00164564-10
BE165946
emtricitabine- bio-x
EN300-119501
Z1521553474

Excerpt	Reference	Relevance
"Emtricitabine is a drug class known as nucleoside reversing transcriptase inhibitors (NRTIs)."	( Emtricitabine. Abdelhameed, AS; Al-Kahtani, HM; Al-Majed, AA; Al-Qahtani, BM; Bakheit, AHH, 2020)	2.72
"TDF/emtricitabine is an effective and safe therapy for preventing HIV transmission. "	( HIV Preexposure Prophylaxis: A Review. Amico, KR; Mayer, KH; Riddell, J, 2018)	1.04
"Emtricitabine (FTC) is a first-line antiviral drug recommended for the treatment of AIDS during pregnancy. "	( Multiple Drug Transporters Contribute to the Placental Transfer of Emtricitabine. Bai, M; Jiang, H; Li, C; Lu, S; Ma, Z; Sun, D; Zeng, Q; Zhao, Y; Zheng, C; Zhou, H, 2019)	2.19
"1. Emtricitabine is a nucleoside reverse transcriptase inhibitor used in combination antiretroviral therapy of HIV (cART). "	( Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Ceckova, M; Cerveny, L; Müller, F; Reznicek, J; Staud, F, 2017)	2.52
"Emtricitabine (FTC) is an antiretroviral compound that inhibits the HIV-1 reverse transcriptase. "	( Characterization of emtricitabine related substances by liquid chromatography coupled to an ion trap mass spectrometer. Adams, E; Hoogmartens, J; Mamade, DA; Pendela, M; Van Schepdael, A, 2010)	2.13
"Emtricitabine is an NRTI used to treat HIV-1 infection. "	( Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Herman, RA; Modrzejewski, KA, 2004)	3.21
"Emtricitabine is a safe and effective option for HIV-1 infection in adults as part of a multidrug regimen. "	( Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Herman, RA; Modrzejewski, KA, 2004)	3.21
"Emtricitabine [Emtriva] is a nucleoside reverse transcriptase inhibitor (NRTI) with demonstrated potent activity against HIV and hepatitis B virus (HBV)."	( Emtricitabine/tenofovir disoproxil fumarate. , 2004)	2.49
"Emtricitabine (FTC) is a synthetic nucleoside analogue of cytosine, which is intracellularly phosforylated to form the active form emtricitabine 5'triphosphate (E5TP). "	( Emtricitabine (FTC) for the treatment of HIV infection. Nelson, M; Schiavone, M, 2004)	3.21
"Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV)."	( Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. Barry, DW; Borroto-Esoda, K; Cahn, P; Hinkle, J; Molina, JM; Mondou, E; Pearce, D; Powderly, W; Quinn, JB; Raffi, F; Rousseau, F; Saag, MS; Shaw, AL; Wolff, M, 2004)	2.08
"Emtricitabine (FTC) QD is a newly approved nucleoside reverse transcriptase inhibitor compared in this study to twice daily lamivudine (3TC BID)."	( A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. Benson, CA; Haas, DW; Lamarca, A; McDonald, CK; Mondou, E; Quinn, JB; Rousseau, F; Rublein, J; Steinhart, CR; van der Horst, C, 2004)	1.36
"Emtricitabine (FTC) is a potent deoxycytidine nucleoside analogue that was recently approved for the treatment of HIV infection. "	( Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. Begley, J; Harris, J; Rousseau, FS; St Claire, RL; Wakeford, C; Wang, LH, 2004)	2.01
"Emtricitabine (Emtriva) is an orally administered nucleoside reverse transcriptase inhibitor (NRTI) that is indicated in combination with other antiretroviral agents in the treatment of HIV infection in adults. "	( Emtricitabine: a review of its use in the management of HIV infection. Frampton, JE; Perry, CM, 2005)	3.21
"Emtricitabine is a once-daily nucleoside reverse transcriptase inhibitor (NRTI) that selectively and potently inhibits human immunodeficiency virus type 1 (HIV-1) replication. "	( Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Cox, SL; Molina, JM, 2005)	3.21
"Emtricitabine (FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. "	( Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Saag, MS, 2006)	3.22
"Emtricitabine is a nucleoside analogue approved for treatment of human immunodeficiency virus 1 with clinical activity against hepatitis B virus (HBV)."	( A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Anderson, J; Chan, S; Guan, R; Husa, P; Krastev, Z; Kung, N; Lee, SS; Lim, SG; Mondou, E; Ng, TM; Rigney, A; Rousseau, F; Shiffman, ML; Snow, A; Sorbel, J; Volfova, M; Washington, MK, 2006)	2.04
"Emtricitabine FTC is a cytosine analogue, recently introduced in clinical practice for the treatment of HIV patients. "	( Safety and efficacy of regimens containing emtricitabine in HIV-infected patients taking highly active antiretroviral therapy. Antinori, A; Borrelli, I; Liuzzi, G; Lorenzini, P; Marconi, P; Sette, P; Zaccarelli, M, 2006)	2.04
"Emtricitabine is a potent nucleoside reverse transcriptase inhibitor approved as a once-daily drug in combination with other antiretroviral agents for the treatment of HIV infection. "	( Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. Begley, JA; Blum, MR; Chittick, GE; Hui, J; Wang, LH; Zong, J, 2007)	2.07

Excerpt	Reference	Relevance
"Emtricitabine has both inhibitor and substrate characteristics with MRP1 in PBMCs in vitro, and does not interact with PI accumulation."	( Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. Bousquet, L; Didier, N; Farinotti, R; Mabondzo, A; Pruvost, A, 2008)	2.51
"Emtricitabine (FTC) has been reported to cause skin pigmentation (SP), and the incidence of SP associated with FTC varied with ethnicity, with a higher rate in African-American patients (8%). "	( Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients. Ajisawa, A; Fukutake, K; Kato, Y; Nakamura, T; Negishi, M; Odawara, T; Shirasaka, T; Tadokoro, T; Yamamoto, Y, 2011)	2.15

Excerpt	Reference	Relevance
"Emtricitabine use also for treatment of hepatitis B virus."	( Emtricitabine. Abdelhameed, AS; Al-Kahtani, HM; Al-Majed, AA; Al-Qahtani, BM; Bakheit, AHH, 2020)	2.72

Excerpt	Reference	Relevance
" Two subjects with rashes during the first 2 weeks of therapy were the only adverse events leading to study-drug discontinuation."	( Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Abrams, E; Blum, MR; Britto, P; Chittick, GE; Cunningham, C; Dickover, R; Draper, L; Flynn, P; Hu, C; Hughes, M; Kraimer, J; McKinney, RE; Ortiz, AA; Rathore, M; Reynolds, L; Rodman, J; Scites, M; Serchuck, LK; Smith, ME; Spector, S; Tran, P; Weinberg, A; Yogev, R, 2007)	0.58
"A once-daily regimen of emtricitabine, didanosine, and efavirenz proved to be safe and tolerable and demonstrated good immunologic and virologic efficacy in this 2-year study."	( Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Abrams, E; Blum, MR; Britto, P; Chittick, GE; Cunningham, C; Dickover, R; Draper, L; Flynn, P; Hu, C; Hughes, M; Kraimer, J; McKinney, RE; Ortiz, AA; Rathore, M; Reynolds, L; Rodman, J; Scites, M; Serchuck, LK; Smith, ME; Spector, S; Tran, P; Weinberg, A; Yogev, R, 2007)	0.89
" All other combinations exhibited more pronounced adverse effects on mitochondrial endpoints."	( Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Melkaoui, K; Setzer, B; Venhoff, N; Walker, UA, 2007)	0.61
" Three subjects (3%) discontinued the study for adverse events, 8 (7%) for virologic failure, and 1 died through a median follow-up of 164 weeks."	( Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects. Adda, N; Blum, MR; Cashat, M; Chittick, G; Harris, J; Hinkle, J; Ndiweni, D; Rousseau, F; Saez-Llorens, X; Violari, A; Wiznia, A; Yogev, R, 2008)	0.6
" Symptoms disappeared after discontinuation of antiretroviral therapy and we suggest that syncope may be a side effect to one of the three antiretroviral drugs that has not been described previously."	( Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection. Larsen, CS; Lybaek, D, 2008)	0.35
"100 patients were evaluated; 17 patients discontinued early including 6 for adverse events."	( Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. Cohen, C; Ebrahimi, R; Elion, R; Fisher, A; Flaherty, J; Kearney, B; McColl, D; Ortiz, R; Reddy, YS; Ruane, P; Ward, D, )	0.32
" Although frequency of severe renal toxicity was higher than has been reported in the literature, it was safe in patients with no comorbid renal conditions."	( Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. Bele, V; Dravid, A; Gupte, N; Joshi, K; Pujari, S, 2008)	0.58
" Significantly fewer drug-related clinical adverse events occurred in patients on raltegravir (n=124 [44."	( Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Barnard, RJ; Berger, DS; DeJesus, E; DiNubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Madruga, JV; Miller, MD; Nguyen, BY; Pollard, RB; Rodgers, AJ; Sklar, P; Williams-Diaz, A; Xu, X; Zhao, J, 2009)	0.35
" Treatment-related gastrointestinal adverse events were greater in patients taking lopinavir/ritonavir."	( Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R, 2010)	0.57
" Atazanavir/ritonavir had a better lipid profile and fewer gastrointestinal adverse events than lopinavir/ritonavir."	( Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R, 2010)	0.57
" The adverse event rate was similar between arms (except drug hypersensitivity, reported more in the abacavir/lamivudine arm)."	( Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C, 2010)	0.57
" Through 96 weeks, 77 subjects from each group discontinued prematurely; adverse or HIV-related events contributed to discontinuation of 36 subjects overall, with no significant differences between treatment groups."	( Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L, 2010)	0.57
" Ten percent (13/123) of the subjects discontinued the treatment due to adverse events."	( Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice. Blanch, J; Cervantes, M; Domingo, P; Ferrer, E; Knobel, H; Llibre, JM; Mallolas, J; Pedrol, E; Vallecillo, G, 2012)	0.6
" All regimens were safe and well tolerated."	( Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Bardeguez, A; Cotter, A; Fiscus, SA; Flynn, PM; Heckman, B; Huang, S; Jean-Philippe, P; Kearney, B; Mirochnick, M; Mofenson, LM; Purswani, M; Robbins, B; Rodman, J; Rooney, JF; Shapiro, DE; Thorpe, E; Van Rompay, KK; Watts, DH, 2011)	0.6
" The occurrence of treatment-related, moderate/severe adverse events was similar between treatment groups through 48 weeks of treatment."	( Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. Fredrick, LM; Gathe, J; Lawal, A; Nilius, AM; Podsadecki, TJ; Pulido, F; Reynes, J; Soto-Malave, R; Tian, M, )	0.33
" Overall incidences of all-causality treatment-related or grade 3/4 adverse events (AEs) or AE-related discontinuations were lower with lersivirine than with efavirenz, and serious AEs occurred at similar rates across treatment groups."	( Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. Cooper, DA; Craig, C; Goodrich, J; Kaplan, R; Lazzarin, A; Mori, J; Pozniak, A; Pulik, P; Tawadrous, M; Valdez, H; Vernazza, P; Wang, C; Weil, E, 2013)	0.39
"Overall, 71 of 281 raltegravir recipients (25%) and 98 of 282 efavirenz recipients (35%) discontinued the study; discontinuations due to adverse events occurred in 14 (5%) and 28 (10%) patients in the respective groups."	( Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y, 2013)	0.61
" Over the entire study, fewer patients experienced neuropsychiatric and drug-related adverse events in the raltegravir group than in the efavirenz group."	( Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y, 2013)	0.61
" We compared rates of upper digestive serious adverse events (sAEs) between TDF/FTC+EFV and TDF/FTC+ZDV patients during the first six months of treatment."	( Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G, 2013)	0.62
" We suggest that further early prescriptions of TDF+XTC+ZDV should be carefully monitored and that whenever possible, the rate of early upper digestive adverse events should be compared to that occurring in-patients taking other drug regimens."	( Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G, 2013)	0.62
"Combined prophylaxis with TDF/ETV nucleoside plus nucleotide analogs and cessation of immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective."	( Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. Braat, AE; Claas, EC; Coenraad, MJ; Knoester, M; van Hoek, B; Vossen, AC; Wesdorp, DJ, 2013)	0.39
" We assessed adherence (compared between groups and with nonstudy controls) and clinical and adverse events at weeks 1, 2 and 4, and efficacy at week 12."	( Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. Carr, A; Ingersoll, A; McAllister, J; McNulty, A; Read, P; Tong, WW, 2014)	0.78
"6% interrupted cART due to adverse events,19."	( Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. Aguirrebengoa, K; Arazo, P; Blanco, JR; Caro-Murillo, AM; Castaño, MA; Domingo, P; Ferrer, P; Gómez-Sirvent, JL; Olalla, J; Pedrol, E; Portilla, J; Pulido, F; Riera, M; Romero-Palacios, A; Vera, F, )	0.4
"In a population of HIV-infected subjects who were ≥50 years old, our study suggests that the use of FTC/TDF is generally safe and effective, with a longer persistence as compared to other regimens."	( Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. Aguirrebengoa, K; Arazo, P; Blanco, JR; Caro-Murillo, AM; Castaño, MA; Domingo, P; Ferrer, P; Gómez-Sirvent, JL; Olalla, J; Pedrol, E; Portilla, J; Pulido, F; Riera, M; Romero-Palacios, A; Vera, F, )	0.4
"Due to ongoing neuropsychiatric adverse events in some efavirenz (EFV)-treated patients, a switch to an alternative non-nucleoside reverse transcriptase inhibitor may be considered."	( Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Brinson, C; Cheng, AK; Chuck, SK; Cohen, C; Dejesus, E; Mills, AM; Ramanathan, S; Wang, MH; White, K; Williams, S; Yale, KL, )	0.36
" No subjects discontinued the study due to an adverse event."	( Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Brinson, C; Cheng, AK; Chuck, SK; Cohen, C; Dejesus, E; Mills, AM; Ramanathan, S; Wang, MH; White, K; Williams, S; Yale, KL, )	0.36
" No adverse events were observed, and there were no toxicological findings."	( Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Baum, MM; Brooks, AA; Butkyavichene, I; Dinh, CT; Lopez, G; Martin, A; Moss, JA; Smith, JM; Smith, TJ; Srinivasan, P, 2014)	0.4
" Bayesian fixed-effect network meta-analysis models adjusting for the type of nucleoside reverse transcriptase inhibitor backbone (tenofovir disoproxil fumarate/emtricitabine [TDF/FTC] or abacavir/lamivudine [ABC/3TC]) were used to evaluate week 48 efficacy (HIV-RNA suppression to <50 copies/mL and change in CD4+ cells/µL) and safety (lipid changes, adverse events, and discontinuations due to adverse events) of DTG relative to all other treatments."	( 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY, 2014)	0.6
" Dolutegravir had better or equivalent changes in total cholesterol, LDL, triglycerides, and lower odds of adverse events and discontinuation due to adverse events compared to all treatments."	( 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY, 2014)	0.4
" Adverse events and serious adverse events were summarised by treatment group."	( Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015)	0.42
" Adverse events were reported by 291 (91%) of 321 patients in the efavirenz 400 mg group and by 285 (92%) of 309 in the 600 mg group (p=0·48)."	( Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015)	0.42
" Fewer efavirenz-related adverse events were reported with the 400 mg efavirenz dose than with the 600 mg dose."	( Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015)	0.42
" Viral load, CD4 count, and adverse events were assessed at baseline, 24, and 48 weeks."	( Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054). Boissonnault, M; Costiniuk, C; Dion, H; Galanakis, C; Jenabian, MA; Lavoie, S; Longpré, D; Machouf, N; Thomas, R; Trottier, B; Vézina, S, )	0.13
" No serious adverse events were observed."	( Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054). Boissonnault, M; Costiniuk, C; Dion, H; Galanakis, C; Jenabian, MA; Lavoie, S; Longpré, D; Machouf, N; Thomas, R; Trottier, B; Vézina, S, )	0.13
" The study limitations include its retrospective design, the relatively short follow-up, and the absence of data concerning the severity of clinical adverse events; however, it does provide new information concerning the laboratory changes that occur in patients switching from PI-based or PI-sparing regimens to RTE STR."	( Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. Bossolasco, S; Castagna, A; Cernuschi, M; Cinque, P; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Nozza, S; Poli, A; Spagnuolo, V; Tambussi, G, 2015)	0.65
" For any biomedical prevention intervention, the bar for tolerating adverse effects in healthy persons is high compared to therapeutic interventions."	( Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Baeten, JM; Mugwanya, KK, 2016)	0.43
"TDF-based pre-exposure prophylaxis is a potent intervention against HIV acquisition when taken which is generally safe and well tolerated."	( Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Baeten, JM; Mugwanya, KK, 2016)	0.43
" However, tenofovir disoproxil fumarate is associated with renal and bone toxic effects; the novel prodrug tenofovir alafenamide achieves 90% lower plasma tenofovir concentrations."	( Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M, 2016)	0.64
" Seven patients in the tenofovir alafenamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to adverse events."	( Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M, 2016)	0.64
" There was no statistically significant differences in the risk difference for serious adverse events (5."	( An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F, 2016)	0.67
" The regimen was well tolerated and no discontinuations related to adverse events occurred."	( Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016)	0.65
" Relevant articles were hand-searched for renal (Grade 3-4 serum creatinine/estimated glomerular filtration rate elevations, renal adverse events [AEs], discontinuation due to renal AEs, and urinary biomarkers) and bone outcomes (bone mineral density [BMD] reductions, bone turnover markers, and fracture), and results compiled qualitatively."	( Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. Bedimo, R; Myers, J; Rosenblatt, L, 2016)	0.66
" Phase II and III randomized clinical trials evaluate the efficacy and safety of EVG/c/TAF/FTC and tenofovir disoproxil fumerate (TDF)-containing arms; renal impairment, bone mineral density, metabolic effects, and other adverse events are topics explored within this review."	( A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection. Angione, SA; Cherian, SM; Özdener, AE, 2018)	0.71
" The most common adverse events were diarrhea, nausea, and headache."	( A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection. Angione, SA; Cherian, SM; Özdener, AE, 2018)	0.71
" Data seem to suggest it may also be effective and safe in patients with mild to moderate renal impairment."	( A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection. Angione, SA; Cherian, SM; Özdener, AE, 2018)	0.71
"Patients initiating EVG/COBI/FTC/TDF were enrolled in the SCOLTA project, a multicenter observational study reporting grade 3-4 Adverse Events in subjects beginning new antiretroviral drug regimens."	( Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. Bandera, A; Bonfanti, P; Calza, L; Carenzi, L; Celesia, BM; Cordier, L; De Socio, GV; Di Biagio, A; Falasca, K; Gori, A; Madeddu, G; Maggi, P; Martinelli, C; Orofino, G; Pellicanò, GF; Quirino, T; Ricci, E; Rusconi, S; Squillace, N; Vichi, F, 2017)	0.71
" The safety of RPV/FTC/TDF (incidence of adverse events leading to discontinuation and laboratory abnormalities) and adherence to this regimen were evaluated, and the cost of switching was analysed."	( Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks. Arrabal-Durán, P; Chamorro-de-Vega, E; Gijón-Vidaurreta, P; Herranz-Alonso, A; Rodríguez-González, CG; Sanjurjo-Sáez, M, 2017)	0.75
" However, the relatively high rates of virological failure and treatment discontinuation because of adverse events make this combination a less favourable choice over other regimens currently available."	( Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks. Arrabal-Durán, P; Chamorro-de-Vega, E; Gijón-Vidaurreta, P; Herranz-Alonso, A; Rodríguez-González, CG; Sanjurjo-Sáez, M, 2017)	0.75
" Numbers of discontinuations related to adverse events (11 [1%] of 763 patients in the study group vs four [1%] of 378 patients in the control group) and grade 3-4 adverse events (52 [7%] patients vs 31 [8%] patients) were similar between the two groups."	( Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr Arribas, JR; Eron, JJ; Gathe, J; Hufkens, V; Lathouwers, E; Molina, JM; Negredo, E; Opsomer, M; Orkin, C; Petrovic, R; Van Landuyt, E; Vanveggel, S, 2018)	0.71
" Investigators monitored adverse events to assess safety."	( Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Aboud, M; Angelis, K; Blair, EA; Brinson, C; Castelli, F; Gartland, M; Girard, PM; Hung, CC; Kahl, LP; Llibre, JM; Smith, K; Underwood, M; Vandermeulen, K; Wynne, B, 2018)	0.48
" 395 (77%) of 513 participants in the dolutegravir-rilpivirine group and 364 (71%) of 511 participants in the CAR group reported adverse events."	( Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Aboud, M; Angelis, K; Blair, EA; Brinson, C; Castelli, F; Gartland, M; Girard, PM; Hung, CC; Kahl, LP; Llibre, JM; Smith, K; Underwood, M; Vandermeulen, K; Wynne, B, 2018)	0.48
" The overall incidence and severity of adverse events was similar between groups, although headache occurred more frequently in the bictegravir group than in the boosted protease inhibitor group."	( Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P, 2018)	0.72
"Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide might be a safe and efficacious alternative to continued boosted protease inhibitor therapy in adults with HIV-1 infection."	( Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P, 2018)	1.03
" Safety was assessed by adverse events (AEs), colposcopy, and culture-independent analysis of the vaginal microbiome (VMB)."	( Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F, 2018)	0.48
"An innovative pod-IVR delivery device with 3 different formulations delivering different regimens of ARV drugs vaginally appeared to be safe and acceptable and provided drug concentrations in CVFs and tissues exceeding concentrations achieved by highly protective oral dosing, suggesting that efficacy for vaginal HIV PrEP is achievable."	( Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F, 2018)	0.48
" EFV, relative to GSK3532795, had more serious adverse events (9% versus 5%) and adverse events leading to discontinuation (17% versus 5%)."	( Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial. Bogner, JR; DeGrosky, M; Dicker, IB; Gartland, M; Joshi, SR; Lataillade, M; Llamoso, C; Lombaard, J; Min, S; Molina, JM; Morales-Ramirez, J; Pene Dumitrescu, T; Stock, DA, 2018)	0.69
" The elvitegravir group showed more discontinuations because of renal adverse events (2."	( Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ Bagella, P; Baldin, G; Capetti, A; Ciccullo, A; Cossu, MV; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Rusconi, S; Sterrantino, G, 2019)	0.76
" The primary endpoint was the proportion of participants discontinuing due to adverse events (AEs) through Week 48."	( Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Cahn, P; Hanna, G; Hwang, C; Kumar, S; Martin, E; Molina, JM; Orkin, C; Rodgers, A; Sax, P; Squires, K; Teppler, H; Thompson, M; Xu, X, 2020)	0.56
" Few discontinued due to adverse events (2% D/C/F/TAF arm)."	( Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/ Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E, 2019)	0.72
" Adverse events were monitored to assess safety."	( Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. Bernasconi, E; Braun, DL; Buzzi, M; Calmy, A; Cavassini, M; Decosterd, LA; Egger, M; Günthard, HF; Limacher, A; Marinosci, A; Metzner, KJ; Schmid, P; Sculier, D; Stoeckle, M; Vernazza, P; Wandeler, G; Yerly, S, 2020)	0.82
" PrEP was well tolerated with only minor adverse events (grade 2) thought to be related to study drug, which included headache (n=4, 3%), gastrointestinal upset (n=8, 5%), and skin rash (n=2, 1%)."	( Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Bekker, LG; Dietrich, J; Fynn, L; Gill, K; Gray, G; Hosek, S; Johnson, L; Jones, K; Marcus, R; Mendel, E; Myer, L; Pidwell, T; Rooney, J; Slack, C; Spiegel, H; Strode, A; Wallace, M; Wiesner, L, 2020)	0.78
"In this cohort of self-selected South African adolescents at risk of HIV acquisition, PrEP appears safe and tolerable in those who continued use."	( Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Bekker, LG; Dietrich, J; Fynn, L; Gill, K; Gray, G; Hosek, S; Johnson, L; Jones, K; Marcus, R; Mendel, E; Myer, L; Pidwell, T; Rooney, J; Slack, C; Spiegel, H; Strode, A; Wallace, M; Wiesner, L, 2020)	0.78
"6%) patients because of adverse effects."	( Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ, 2021)	0.88
" Primary safety outcomes, compared pairwise among treatment groups, were the occurrence of a composite adverse pregnancy outcome (ie, either preterm delivery, the infant being born small for gestational age, stillbirth, or spontaneous abortion) in all participants with a pregnancy outcome, and the occurrence of grade 3 or higher maternal and infant adverse events in all randomised participants."	( Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021)	0.89
" Significantly fewer participants in the dolutegravir, emtricitabine, and tenofovir alafenamide fumarate group (52 [24%] of 216) had a composite adverse pregnancy outcome than those in the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group (70 [33%] of 213; estimated difference -8·8% [95% CI -17·3 to -0·3], p=0·043) or the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (69 [33%] of 211; -8·6% [-17·1 to -0·1], p=0·047)."	( Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021)	1.13
" The dolutegravir, emtricitabine, and tenofovir alafenamide fumarate regimen had the lowest frequency of composite adverse pregnancy outcomes and of neonatal deaths."	( Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021)	1.22
" Adverse events were reported in 8 (7%) patients."	( [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients]. Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J, 2021)	0.86
" However, we found a large difference between the high percentages of patients reporting an adverse event in three phase 3 clinical trials and our results."	( [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients]. Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J, 2021)	0.86
"Emtricitabine and tenofovir alafenamide is safe and effective for longer-term pre-exposure prophylaxis in cisgender men and transgender women who have sex with men."	( Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Asmuth, DM; Baeten, JM; Brainard, DM; Brunetta, JM; Carter, C; Cox, S; Das, M; Ebrahimi, R; Gilson, R; Henry, K; Kintu, A; Kronborg, G; Ogbuagu, O; Podzamczer, D; Ruane, PJ; Salazar, LC; Shao, Y; Spinner, CD; Whitlock, G; Wohl, D, 2021)	2.35
" Week 48 virologic suppression (HIV-1 RNA <50 copies/mL), resistance, adverse events (AEs), and laboratory parameters were assessed."	( Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K, 2021)	0.88
" Treatment-related adverse events occurred in 51 (15%) patients (all Grade 1-2) and led to 8 discontinuations."	( Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. Cruz, D; DeJesus, E; Hinestrosa, F; Nguyen, V; Patel, K; Rolle, CP, 2021)	0.86
" Almost half the users (49%) presented an adverse event, although these were mild and transient, 30 days after starting prophylaxis."	( HIV Pre-Exposure Prophylaxis (PrEP) in a Brazilian Clinical Setting: Adherence, Adverse Events, Sexual Behavior, and Sexually Transmitted Infections. Barbosa, AKP; Batista, JDL; Montarroyos, UR; Monteiro, P; Montenegro, D, 2022)	0.72
" Adverse events were observed in 15% of the patients, and the regimen was discontinued in only six patients."	( Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting. Aydin, OA; Bilge, B; Bolukcu, S; Dokmetas, I; Gumuser, F; Gunduz, A; Karaosmanoglu, HK; Mete, B; Tabak, F; Yildiz, DS, 2021)	0.87
"Real world data on the effectiveness and safety of E/C/F/TDF is comparable with the phase 3 trial results Adverse events are uncommon and manageable."	( Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting. Aydin, OA; Bilge, B; Bolukcu, S; Dokmetas, I; Gumuser, F; Gunduz, A; Karaosmanoglu, HK; Mete, B; Tabak, F; Yildiz, DS, 2021)	0.87
" This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through Wk96 among patients enrolled in the phase 3 AMBER (treatment-naïve) and EMERALD (virologically suppressed) studies of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg."	( Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD. Anderson, D; Baugh, B; Bejou, N; Campbell, J; Dunn, K; Luo, D; Seyedkazemi, S, )	0.53
"PrEP is safe and effective in MSM, serodiscordant couples and PWIDs."	( Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. Harrington, P; Hayes, C; Marshall, L; Moran, P; O Murchu, E; Ryan, M; Teljeur, C, 2022)	0.72
" As, this product is proposed for adults and adolescents safe from HIV but at high risk of infection, the question is to know if there is a safety concern about this use."	( [HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety?] Davani, S; Grandvuillemin, A; Jacomet, C; Lebeller, C; Schiestel, T; Valnet-Rabier, MB, )	0.37
"In both database, 808 cases correspond to an indication of HIV prexposure prophylaxis who represent 2058 adverse effects (AEs) mainly distributed in gastro-intestinal disorders (38."	( [HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety?] Davani, S; Grandvuillemin, A; Jacomet, C; Lebeller, C; Schiestel, T; Valnet-Rabier, MB, )	0.37
" We identify 24% of unexpected and potentially serious adverse effects in France mainly among chemsex users."	( [HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety?] Davani, S; Grandvuillemin, A; Jacomet, C; Lebeller, C; Schiestel, T; Valnet-Rabier, MB, )	0.37
"Gastrointestinal adverse events are common after treatment initiation but usually resolve within weeks."	( Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults. Liegeon, G, 2022)	0.99
"Oral tenofovir disoproxil-FTC for HIV PrEP appears safe and well tolerated for most individuals."	( Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults. Liegeon, G, 2022)	0.99
" Consistent with previous findings, we observed adverse local toxicity and necrosis near the tenofovir alafenamide implant site."	( Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model. Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A, 2022)	0.72
"Previous clinical data have shown that raltegravir-based antiretroviral therapy (ART) with fewer drug-drug interactions (DDIs) and adverse events (AEs) is a good regimen in patients with HIV infection who need cancer chemotherapy."	( Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer. Chen, T; Gui, F; Tan, J; Wei, G; Yang, J; Zhao, Y, 2022)	0.72
" No drug-related serious or grade 3 or 4 adverse events occurred."	( Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. Aurpibul, L; Best, BM; Campbell, H; Cassim, H; Cooper, E; Flynn, P; Gray, KP; Krotje, C; McCarthy, K; McFarland, E; Melvin, AJ; Moye, J; Ounchanum, P; Rungmaitree, S; Scheckter, R; Teppler, H; Tobin, NH; Townley, E; Wan, H; Yedla, M; Yee, KL, 2023)	0.91
" Only five participants experienced mild clinical adverse events attributed to the study drug (including headache, diarrhea, and nausea) and four participants had elevated serum creatinine (grade 1)."	( An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1. Bu Dou Re Xi Ti, GA; Dai, L; Gao, Y; Hua, W; Li, A; Li, J; Li, Z; Liu, A; Shao, Y; Sun, L; Wang, X; Wang, Z; Wu, RE; Xin, R; Ye, J; Zhang, H, 2022)	0.95
"A once daily, STR of BIC/FTC/TAF used as PEP was safe and well-tolerated with a high rate of completion and adherence in Chinese."	( An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1. Bu Dou Re Xi Ti, GA; Dai, L; Gao, Y; Hua, W; Li, A; Li, J; Li, Z; Liu, A; Shao, Y; Sun, L; Wang, X; Wang, Z; Wu, RE; Xin, R; Ye, J; Zhang, H, 2022)	0.95
" Across the studies, one grade 3/4 adverse event was considered drug-related (intermediate uveitis)."	( Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review. Castro, H; Collins, IJ; Jesson, J; Judd, A; Leroy, V; Milanzi, E; O'Rourke, J; Penazzato, M; Renaud, F; Townsend, CL; Vicari, M, 2023)	0.91
" We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in the first year following initiation among treatment-naïve people living with HIV (PLWH)."	( Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting. Castano, J; DeJesus, E; Hinestrosa, F; Nguyen, V; Patel, K; Rolle, CP, 2023)	0.91
" We analysed the incidence of adverse events (AEs), laboratory abnormalities, and changes in relevant tolerability parameters through 48 weeks."	( Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials. Avihingsanon, A; Chetchotisakd, P; Kiertiburanakul, S; Martin, H; Ratanasuwan, W; Siripassorn, K; Supparatpinyo, K; Wang, H; Wang, HY; Wong, T, 2023)	1.16
" Primary safety analyses were pairwise comparisons between ART regimens of the proportion of maternal and infant adverse events of grade 3 or higher up to 50 weeks post partum."	( Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L, 2023)	0.91
" Up to the week 50 post-partum visit, the estimated probability of experiencing an adverse event of grade 3 or higher was 25% in the dolutegravir, emtricitabine, and tenofovir alafenamide group; 31% in the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group; and 28% in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (no significant difference between groups)."	( Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L, 2023)	1.11
"01), but more tolerated injection sites adverse events (p < 0."	( Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis. Chen, X; Kou, L; Li, J; Li, Y; Wei, D; Xie, X, 2023)	1.13
" Virological reactions and adverse events to the treatment were recorded, and patient subjective feelings in the form of Electronic Patient Reporting Outcome (ePRO) were collected."	( Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China. Fu, Y; Gan, L; Kong, L; Long, H; Ma, S; Xie, X; Yang, X, 2023)	1.12
" By Week 24, no patients had discontinued the BIC/FTC/TAF treatment due to adverse events."	( Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China. Fu, Y; Gan, L; Kong, L; Long, H; Ma, S; Xie, X; Yang, X, 2023)	1.12
" Frequency of adverse events was similar between the treatment groups."	( Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. Adeyeye, A; Cardozo, N; Cohen, MS; Coutinho, C; Donnell, D; Eshleman, SH; Feliciano, KG; Ford, S; Franks, J; Grinsztejn, B; Hanscom, B; Jalil, E; Jennings, A; Khan, T; Landovitz, RJ; Lucas, J; Maia, B; Marzinke, MA; McCauley, M; Middelkoop, K; Psaros, C; Richardson, PA; Rinehart, AR; Rooney, JF; Safren, SA; Sanchez, N; Singh, Y; Sullivan, P; Valencia, J; Wang, Z, 2023)	0.91
" Our results suggest that injectable cabotegravir is a safe and effective pre-exposure prophylaxis option for transgender women."	( Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. Adeyeye, A; Cardozo, N; Cohen, MS; Coutinho, C; Donnell, D; Eshleman, SH; Feliciano, KG; Ford, S; Franks, J; Grinsztejn, B; Hanscom, B; Jalil, E; Jennings, A; Khan, T; Landovitz, RJ; Lucas, J; Maia, B; Marzinke, MA; McCauley, M; Middelkoop, K; Psaros, C; Richardson, PA; Rinehart, AR; Rooney, JF; Safren, SA; Sanchez, N; Singh, Y; Sullivan, P; Valencia, J; Wang, Z, 2023)	0.91
" The primary safety endpoint was grade 2 or higher adverse events during each randomised period of 24 weeks of ring and oral PrEP."	( Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Akello, CA; Anderson, P; Baeten, JM; Bekker, LG; Brown, ER; Bunge, K; Celum, C; Garcia, M; Hendrix, C; Hillier, SL; Hosek, S; Jacobson, C; Johnson, S; Levy, L; Livant, E; Macdonald, P; McClure, T; Milan, G; Muhlanga, F; Nair, G; Nakabiito, C; Nakalega, R; Ngure, K; Palanee-Phillips, T; Parikh, U; Reddy, K; Rooney, JF; Siziba, B; Soto-Torres, L; Steytler, J; Szydlo, D; Tahuringana, E; van der Straten, A, 2023)	1.14
" 54 grade 2 or higher product-related adverse events were reported during oral PrEP and five during dapivirine ring use, with no product-related serious adverse events."	( Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Akello, CA; Anderson, P; Baeten, JM; Bekker, LG; Brown, ER; Bunge, K; Celum, C; Garcia, M; Hendrix, C; Hillier, SL; Hosek, S; Jacobson, C; Johnson, S; Levy, L; Livant, E; Macdonald, P; McClure, T; Milan, G; Muhlanga, F; Nair, G; Nakabiito, C; Nakalega, R; Ngure, K; Palanee-Phillips, T; Parikh, U; Reddy, K; Rooney, JF; Siziba, B; Soto-Torres, L; Steytler, J; Szydlo, D; Tahuringana, E; van der Straten, A, 2023)	1.14
" We also measured changes from baseline in CD4 + cell counts, CD4/CD8 ratio, lipid parameters, weight, creatinine (Cr), estimated glomerular filtration rate (eGFR), and drug-related adverse effects (DRAEs)."	( Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1. Deng, Y; He, L; Li, J; Wang, Y; Wei, Y; Wen, L; Xu, R; Zhong, H, 2023)	1.14
" Adverse events were compared across treatment groups and time periods (blinded vs unblinded)."	( Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary anal Adeyeye, A; Anderson, PL; Berman, R; Clement, ME; Cohen, MS; Del Rio, C; Donnell, D; Eron, JJ; Eshleman, SH; Fields, SD; Grinsztejn, B; Hanscom, BS; Hendrix, CW; Kallas, EG; Kofron, RM; Landovitz, RJ; Lucas, JP; Magnus, M; Marzinke, MA; McCauley, M; Piwowar-Manning, EM; Richardson, PA; Rinehart, AR; Rooney, JF; Sanchez, J; Scott, H; Spinelli, MA; Sued, O; Sullivan, PA; Tran, HV, 2023)	1.12
" Adverse events were generally consistent with previous reports; incident hypertension in the long-acting PrEP group requires further investigation."	( Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary anal Adeyeye, A; Anderson, PL; Berman, R; Clement, ME; Cohen, MS; Del Rio, C; Donnell, D; Eron, JJ; Eshleman, SH; Fields, SD; Grinsztejn, B; Hanscom, BS; Hendrix, CW; Kallas, EG; Kofron, RM; Landovitz, RJ; Lucas, JP; Magnus, M; Marzinke, MA; McCauley, M; Piwowar-Manning, EM; Richardson, PA; Rinehart, AR; Rooney, JF; Sanchez, J; Scott, H; Spinelli, MA; Sued, O; Sullivan, PA; Tran, HV, 2023)	1.12
"In this first study of a long-acting HIV prevention agent in pregnancy, adverse pregnancy outcomes and complications were uncommon when DVR and TDF/FTC were used in the third trimester of pregnancy, suggesting a favorable safety profile for both prevention products."	( DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy. Balkus, JE; Bunge, K; Chakhtoura, N; Chappell, CA; Fairlie, L; Gadama, L; Hillier, SL; Matrimbira, M; Mayo, AJ; Mgodi, N; Nakabiito, C; Piper, J; Richardson, B; Szydlo, DW, 2024)	1.44

Excerpt	Reference	Relevance
" Pharmacokinetic parameters were generated by area/moment analysis."	( Pharmacokinetics of 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats. Abobo, CV; Boudinot, FD; Liotta, DC; Ni, L; Schinazi, RF, 1994)	0.29
" An indirect response pharmacodynamic model was fitted to link the plasma pharmacokinetics from a 28 day treatment with the nucleoside reverse transcription inhibitor emtricitabine [(-)-FTC], with the resulting virus depletion and recovery profiles in woodchucks chronically infected with woodchuck hepatitis B virus."	( Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucks. Gerin, JL; Hurwitz, SJ; Korba, BE; Liberman, I; Schinazi, RF; Tennant, BC, 2002)	0.74
" The following pharmacokinetic (PK) parameters were determined over 24 h at steady-state after 4 weeks of treatment: area under the plasma concentration vs."	( Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). Chene, G; Lascoux-Combes, C; Molina, JM; Perusat, S; Peytavin, G; Rozenbaum, W; Sereni, D, 2004)	0.65
" EFV Cmax and Cmin were lower than expected, but the data may have been slightly underestimated in this study."	( Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). Chene, G; Lascoux-Combes, C; Molina, JM; Perusat, S; Peytavin, G; Rozenbaum, W; Sereni, D, 2004)	0.65
" Plasma concentrations from a group of 54 rats, 12 pregnant rabbits and 60 dogs enrolled in large toxicity studies using a wide variety of oral doses, were compared using non-compartment pharmacokinetic modelling versus dose, treatment duration, species and gender."	( Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Hurwitz, SJ; Otto, MJ; Schinazi, RF, 2005)	0.33
" Pharmacokinetic parameters were dose proportional, and the maximum concentration of drug in serum at all doses exceeded the 90% effective concentration for wild-type HIV-1."	( Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients. Arastèh, K; Beard, A; Cartee, L; Drauz, D; Herzmann, C; Kreckel, P; Murphy, RL; Otto, MJ; Schinazi, RF; Schulbin, H, 2005)	0.33
" Pharmacokinetic (PK) blood draws were performed on days 7, 17, and 27."	( Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. Cheng, A; Kearney, BP; Ramanathan, S; Shen, G, 2007)	0.66
" As both drugs are extensively renally eliminated, a randomized, 3-way crossover study was conducted in 19 healthy volunteers to formally evaluate the potential pharmacokinetic interaction when the drugs are administered alone and together (ie, 200 mg emtricitabine qd for 7 days, 300 mg tenofovir disoproxil fumarate qd for 7 days, and 200 mg emtricitabine plus 300 mg tenofovir disoproxil fumarate qd for 7 days) with no washout between treatments."	( Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. Begley, JA; Blum, MR; Chittick, GE; Zong, J, 2007)	0.8
" Several phase I studies were conducted in healthy volunteers over the course of clinical development to evaluate whether pharmacokinetic drug-drug interactions exist between emtricitabine and other nucleoside antivirals that are extensively eliminated by renal excretion."	( Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. Begley, JA; Blum, MR; Chittick, GE; Hui, J; Wang, LH; Zong, J, 2007)	0.82
"An open-label, randomized, 3-way crossover, drug-drug interaction study of the investigational anti-HBV combination agent, emtricitabine/tenofovir DF and the antirejection agent, tacrolimus was conducted in healthy volunteers to evaluate the potential for a pharmacokinetic interaction between these drugs."	( Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Alianti, JR; Begley, JA; Blum, MR; Chittick, GE; Sorbel, JJ; Zong, J, 2008)	0.88
" Drug concentrations were measured by LC/MS/MS and steady state pharmacokinetic parameters were calculated for each drug using noncompartmental methods."	( Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Alianti, JR; Begley, JA; Blum, MR; Chittick, GE; Sorbel, JJ; Zong, J, 2008)	0.67
"The 90% confidence intervals (CIs) of the geometric least-squares mean ratio for AUCtau, Cmax and Ctau for each drug together vs."	( Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Alianti, JR; Begley, JA; Blum, MR; Chittick, GE; Sorbel, JJ; Zong, J, 2008)	0.67
"It was concluded that there was no clinically relevant pharmacokinetic interaction between emtricitabine/tenofovir DF and tacrolimus when administered together."	( Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Alianti, JR; Begley, JA; Blum, MR; Chittick, GE; Sorbel, JJ; Zong, J, 2008)	0.89
"6-h half-life (30%)."	( Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Arrivé, E; Avit, D; Blanche, S; Coffié, P; Dabis, F; Ekouévi, DK; Hirt, D; Lalsab, S; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S, 2009)	0.64
"Prospective, open-label, pharmacokinetic study in 12 HIV-infected patients stabilized on FPV/RTV 1400 mg/200 mg + tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) 300 mg/200 mg QD (TELEX II)."	( Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). Acosta, EP; Jennings, HC; Pakes, GE; Parks, DA; Taylor, C, )	0.6
" Four weeks after reducing RTV, changes in Cmin and AUC24h were: APV: +26%, +0."	( Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). Acosta, EP; Jennings, HC; Pakes, GE; Parks, DA; Taylor, C, )	0.4
"Nucleoside-sparing combination antiretroviral therapy (cART) regimens might be an attractive therapeutic option for HIV type-1 (HIV-1)-infected patients; however, the pharmacokinetic profiles of such regimens are frequently unknown."	( The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A, 2010)	0.36
"Fourteen HIV-1-infected patients (age 21-55 years, 64% male) on stable cART with plasma HIV RNA <50 copies/ml entered this Phase I pharmacokinetic study."	( The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A, 2010)	0.36
"A pharmacokinetic trial was conducted to evaluate the potential for once-daily etravirine in antiretroviral regimens without and with darunavir/ritonavir."	( Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J, 2010)	0.36
"Of 23 enrolled patients (male 87%, Caucasian 39%), pharmacokinetic profiles for etravirine were available for 21 and 20 patients on day 14 and 28, respectively."	( Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J, 2010)	0.36
"The International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT), formerly Pediatric AIDS Clinical Trials Group (PACTG), study P1026s is a prospective pharmacokinetic study of HIV-infected pregnant women taking antiretrovirals for clinical indications, including a cohort taking emtricitabine 200 mg once daily."	( Effect of pregnancy on emtricitabine pharmacokinetics. Barr, E; Best, BM; Burchett, S; Capparelli, E; Hu, C; Jennings, A; Li, H; Luo, W; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM, 2012)	0.87
" Mean [90% confidence interval (CI)] emtricitabine pharmacokinetic parameters during the third trimester vs."	( Effect of pregnancy on emtricitabine pharmacokinetics. Barr, E; Best, BM; Burchett, S; Capparelli, E; Hu, C; Jennings, A; Li, H; Luo, W; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM, 2012)	0.96
" Twenty-four-hour pharmacokinetic curves were recorded in the third trimester (preferably week 33) and postpartum (preferably week 4-6)."	( The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. Burger, DM; Colbers, AP; Giaquinto, C; Gingelmaier, A; Hawkins, DA; Ivanovic, J; Kabeya, K; Moltó, J; Rockstroh, JK; Sadiq, ST; Taylor, GP; Weizsäcker, K; Wyen, C, 2013)	0.63
"Although pharmacokinetic exposure of the NRTIs TDF and FTC during pregnancy is approximately 25% lower, this was not associated with virological failure in this study and did not result in mother-to-child transmission."	( The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. Burger, DM; Colbers, AP; Giaquinto, C; Gingelmaier, A; Hawkins, DA; Ivanovic, J; Kabeya, K; Moltó, J; Rockstroh, JK; Sadiq, ST; Taylor, GP; Weizsäcker, K; Wyen, C, 2013)	0.63
" Drug concentrations at two trough values of 12 and 24 h after dosing (C(12) and C(24)), area under the concentration-curve values (AUC), maximum drug concentration (C(max)), and the time at which this concentration occurred (T(max)) in plasma were estimated with noncompartmental pharmacokinetic methods and compared to data from a subset of white subjects randomized to the RAL twice a day (plus TDF/FTC) arm of the QDMRK study, a phase III study of the safety and efficacy of once daily versus twice daily RAL in treatment naive patients."	( Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. Blevins, S; Dumond, JB; Eron, JJ; Floris-Moore, M; Hudgens, MG; Kashuba, AD; Massengale, K; Pittard, D; Ragan, D; Richardson, A; Walsh, K; Wang, R; Wohl, DA, 2013)	0.39
" Noncompartmental pharmacokinetic analysis was used to estimate PK parameters [area under the concentration-time curve over 24 h (AUC0-24h ) and maximal concentration (Cmax )]."	( Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013)	0.39
" Compared with the general population, these elderly subjects had 8-13% decreased TFV AUC0-24h and Cmax , and 19-78% increased FTC and RTV AUC0-24h and Cmax ."	( Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013)	0.39
"To investigate pharmacokinetic interactions associated with coadministration of lersivirine with zidovudine, tenofovir disoproxil fumarate (DF)/emtricitabine (Truvada(®)) or abacavir/lamivudine (Epzicom(®)/Kivexa(®))."	( Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M, 2013)	0.81
" Pharmacokinetic parameters were calculated by standard non-compartmental methods."	( Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M, 2013)	0.61
" Augmentation in the values of Cmax (1."	( Pharmacokinetics and in vivo biodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine. Pai, RS; Singh, G, 2014)	0.61
" In this open-label, randomized, three-way crossover study, the pharmacokinetic profiles of elvitegravir, cobicistat, emtricitabine, and tenofovir were evaluated when administered with a standard breakfast, under fasting conditions, or with a nutritional protein-rich drink."	( Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study. Ikeda, A; Irie, S; Ishikawa, T; Kimura, M; Matsuki, S; Nishino, N; Shiomi, M, 2014)	0.83
" After a single dose, there were no differences in the mean AUC0-∞ values; however, there were significant differences in the mean Tmax values (1."	( Pharmacokinetics of single- and multiple-dose emtricitabine in healthy male Chinese volunteers. Han, WL; Huang, AL; Huang, WX; Shang, JC; Tan, R; Yan, B; Yang, JQ; Zhong, XN, 2014)	0.66
"The aims were to describe emtricitabine (FTC) pharmacokinetics in a large population of pregnant women during the different trimesters of pregnancy, and to explain FTC pharmacokinetic variability during pregnancy."	( Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics. Arrivé, E; Benaboud, S; Bouazza, N; Dabis, F; Fauchet, F; Foissac, F; Hirt, D; Pannier, E; Tréluyer, JM; Urien, S; Valade, E, 2014)	0.96
"This was an open-label, three-period, longitudinal pharmacokinetic study with patients serving as their own controls."	( Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S, 2015)	0.42
" Pharmacokinetic parameters were unchanged during administration with a low-fat meal, except for C24, which was significantly increased by 15% (1."	( Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S, 2015)	0.42
"A food effect was observed for steady-state pharmacokinetic parameters of rilpivirine (AUC0-24 and C24) when TDF/FTC/RPV was administered in the fasted state compared with the moderate-fat meal."	( Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S, 2015)	0.42
" The objective of this study was to assess the pharmacokinetic (PK) profile in older HIV-infected subjects (>60 years) switching combination antiretroviral therapy (cART) to a raltegravir (RAL) containing regimen."	( The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. Back, D; Barber, T; Boffito, M; Dickinson, L; Else, L; Jackson, A; Mora-Peris, B; Vera, JH; Winston, A, )	0.13
"2 years, n = 38) based on population pharmacokinetic analysis."	( The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. Back, D; Barber, T; Boffito, M; Dickinson, L; Else, L; Jackson, A; Mora-Peris, B; Vera, JH; Winston, A, )	0.13
" From the interaction between atazanavir and DTG via CYP3A4 and UGT1A1 and placental efflux transporter inhibition and considering the infant's probable enzymatic immaturity, the DTG elimination half-life was estimated to be 4-fold longer in neonates than in adults."	( Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. Amiel, C; Caseris, M; Charpentier, C; Descamps, D; Desnoyer, A; Farnoux, C; Lassel, L; Lê, MP; Pain, JB; Peytavin, G; Pialoux, G, 2015)	0.42
"Transplacental parameters estimated from ex vivo human placenta perfusion experiments were implemented in pregnancy-physiologically based pharmacokinetic (p-PBPK) models in order to predict fetal PK."	( Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Benaboud, S; Blanche, S; Bouazza, N; De Sousa Mendes, M; Foissac, F; Hirt, D; Lê, MP; Lui, G; Peytavin, G; Pressiat, C; Treluyer, JM; Urien, S; Valade, E; Vinot, C, 2016)	0.43
" We developed a population pharmacokinetic model for tenofovir and investigated the impacts of different dose reporting methods."	( Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods. Baeten, JM; Bangsberg, D; Celum, CL; Chaturvedula, A; Fossler, MJ; Goti, V; Haberer, JE; Hendrix, CW; Lu, Y; Sale, ME, 2016)	0.43
" A precise method is required to quantify the drug concentration in biological matrices to study pharmacokinetic behavior and tissue distribution profile in animals and/or humans."	( Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study. Destache, CJ; Mandal, S; Prathipati, PK, 2016)	0.7
" Physiologically based pharmacokinetic (PBPK) modeling offers an enhanced ability to predict age-related changes in pharmacokinetics in the pediatric population."	( Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants. Burckart, GJ; Duan, P; Fisher, JW; Wang, J; Yoshida, K; Zhang, L, 2017)	0.69
" Based on this study, linezolid and emtricitabine pediatric PBPK models incorporating the ontogeny in renal maturation describe the pharmacokinetic differences between adult and pediatric populations, even though the contribution of renal clearance to the total clearance of two drugs was very different (30 % for linezolid vs."	( Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants. Burckart, GJ; Duan, P; Fisher, JW; Wang, J; Yoshida, K; Zhang, L, 2017)	0.97
"Between May 22, 2013, and July 22, 2014, we enrolled 50 participants, and all 50 received the assigned treatment; 24 participated in the intensive pharmacokinetic assessment."	( Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016)	0.65
"The elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen was well tolerated and achieved component plasma pharmacokinetic exposures similar to those in adults."	( Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016)	0.94
"A randomized, open-label, clinical pharmacokinetic study of tenofovir in healthy adult volunteers without HIV or Hepatitis B infection in Thailand."	( A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. Baeten, J; Cressey, R; Cressey, TR; Drain, PK; Klinbuayaem, V; Kubiak, RW; Quame-Amaglo, J; Siriprakaisil, O; Sirirungsi, W; Sukrakanchana, PO; Than-In-At, K, 2017)	0.46
" The Data Convergence Interview (DCI) and the Pharmacokinetic Data Convergence Interview (PK-DCI) were brief, collaborative interactions conducted with participants during adherence counseling sessions to improve accurate measurement of adherence to study product use."	( Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017. Ayudhya, RPKN; Balán, IC; Brown, W; Carballo-Diéguez, A; Cranston, RD; Giguere, R; Hendrix, CW; Horn, S; Lama, JR; Marzinke, MA; McGowan, I; Patterson, K; Piper, JM, 2018)	0.48
"Intensive pharmacokinetic sampling of maternal dried blood spots (DBS), dried breast milk spots (DBMS) and infant DBS from 30 Ugandan and 29 Nigerian mothers receiving first-line ART and their infants was conducted."	( Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. Khoo, S; Kyohaire, I; Lamorde, M; Nakalema, S; Olagunju, A; Owen, A; Waitt, C, 2018)	0.74
" Population pharmacokinetic models were developed using measured intracellular metabolite, endogenous nucleotide competitors, and extracellular parent drug concentrations."	( A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N, 2018)	0.48
" Its clinical pharmacokinetic profile and influence on the cellular pharmacology of tenofovir diphosphate have not been reported."	( Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. Alexander, K; Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Hosek, S; Huhn, GD; Ibrahim, ME; Kerr, BJ; Kiser, JJ; MaWhinney, S; McHugh, C; Tilden, S, 2019)	0.51
"Tenofovir monoester Cmax and AUC0-4 were 59."	( Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. Alexander, K; Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Hosek, S; Huhn, GD; Ibrahim, ME; Kerr, BJ; Kiser, JJ; MaWhinney, S; McHugh, C; Tilden, S, 2019)	0.51
"We conducted a 3-arm randomized, pharmacokinetic study of tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg among adults living with human immunodeficiency virus."	( Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). Bacchetti, P; Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Punyati, P; Quame-Amaglo, J; Siriprakaisil, O; Sirirungsi, W; Sukrakanchana, PO; Tanasri, S, 2020)	0.77
" The goals of this study were to build maternal-fetal physiologically based pharmacokinetic (PBPK) models for acyclovir and emtricitabine, 2 anti(retro)viral drugs with active renal net secretion, and to (1) evaluate the predicted maternal PK at different stages of pregnancy; (2) predict the changes in PK target parameters following the current dosing regimen of these drugs throughout pregnancy; (3) evaluate the predicted concentrations of these drugs in the umbilical vein at delivery; (4) compare the model performance for predicting maternal PK of emtricitabine in the third trimester with that of previously published PBPK models; and (5) compare different previously published approaches for estimating the placental permeability of these 2 drugs."	( Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir. Best, BM; Burckart, GJ; Capparelli, EV; Dallmann, A; Green, DJ; Liu, XI; Mirochnick, M; Momper, JD; Rakhmanina, N; van den Anker, JN, 2020)	0.98
"3) were applied to determine pharmacokinetic parameters and assess demographic covariates and relationships with SNPs (SLCO3A1, SLCO1B1, NR1I2, NR1I3, CYP3A53, CYP3A422, ABCC2, ABCC10, ABCG2 and SCL47A1)."	( Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001 Boffito, M; Bonora, S; Cursley, A; D'Avolio, A; Di Perri, G; Dickinson, L; Fäetkenheuer, G; Gurjar, R; Molina, JM; Owen, A; Pozniak, A; Raffi, F; Richert, L; Stöhr, W; Vandekerckhove, L, 2020)	0.76
" No differences in TFV pharmacokinetic parameters during the washout were observed across the study arms."	( Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Quame-Amaglo, J; Siriprakaisil, O; Sukrakanchana, PO; Tawon, Y, 2020)	0.56
" We used mixed effects linear regression models to compare pharmacodynamic measures for each participant at predrug baseline, after PrEP alone, and after PrEP and DMPA."	( Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women. Achilles, SL; Chen, BA; Hendrix, CW; Marzinke, MA; Meyn, LA; Tarleton, J, 2020)	0.56
"Pregnant women receiving TAF 10 mg with cobicistat or TAF 25 mg without boosting as part of clinical care had intensive pharmacokinetic assessments performed during the second and third trimesters, and 6-12 weeks postpartum."	( Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A, 2021)	0.62
" Our objective was to develop and evaluate a novel, physiologically based pharmacokinetic modeling workflow for predicting perinatal and postnatal disposition of commonly used antiretroviral drugs administered prenatally to pregnant women living with human immunodeficiency virus."	( Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. Best, BM; Burckart, GJ; Cressey, TR; Dallmann, A; Green, DJ; Liu, XI; Mirochnick, M; Momper, JD; Rakhmanina, NY; van den Anker, JN, 2021)	0.83
"Neonatal physiologically based pharmacokinetic models generally captured the initial plasma concentrations after delivery but underestimated concentrations in the terminal phase."	( Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. Best, BM; Burckart, GJ; Cressey, TR; Dallmann, A; Green, DJ; Liu, XI; Mirochnick, M; Momper, JD; Rakhmanina, NY; van den Anker, JN, 2021)	0.83
"These findings demonstrate the general feasibility of applying physiologically based pharmacokinetic models to predict washout concentrations of transplacentally acquired drugs in newborns."	( Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. Best, BM; Burckart, GJ; Cressey, TR; Dallmann, A; Green, DJ; Liu, XI; Mirochnick, M; Momper, JD; Rakhmanina, NY; van den Anker, JN, 2021)	0.83
" This phase I, open-label, 2-period, 1-way study assessed potential pharmacokinetic (PK) interactions between GSK3640254 and tenofovir alafenamide/emtricitabine (TAF/FTC; including the metabolite tenofovir [TFV]) in healthy volunteers."	( A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants. Butcher, L; Davidson, AM; Johnson, M; Joshi, SR; Lataillade, M; Min, S; Pene Dumitrescu, T; Webster, L; Xu, J; Zhan, J; Zimmerman, E, 2021)	1.03
" The objective of this study was to apply physiologically based pharmacokinetic (PBPK) models in pediatric patients to investigate the absorption and pharmacokinetics of 4 drugs belonging to the Biopharmaceutics Classification System (BCS) class I administered as oral liquid formulations."	( Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups. Burckart, GJ; Dallmann, A; Liu, XI; van den Anker, JN, 2021)	0.62
" Physiologically based pharmacokinetic (PBPK) modelling is a non-invasive solution for understanding lymph node penetration of ARVs across multiple species."	( A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models. Cao, Y; Kashuba, ADM; Scholz, EMB, 2021)	0.62
"The Microbicide Trials Network-017 study was undertaken to characterize the safety, acceptability, pharmacokinetic (PK), and pharmacodynamic profile of the reduced-glycerin (RG) 1% tenofovir (RG-TFV) gel compared to oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)."	( An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. Brand, RM; Chitwarakorn, A; Cranston, RD; Curlin, ME; Doncel, G; Hendrix, CW; Holtz, TH; Johnson, S; Kunjara Na Ayudhya, RP; Marzinke, MA; McGowan, IM; Piper, J; Raengsakulrach, B; Rooney, JF; Schwartz, JL, 2022)	1.13
" A non-compartmental analysis was performed to estimate the main pharmacokinetic parameters."	( Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice. Barrail-Tran, A; Benzemrane, MS; Bourgeois, C; Gelé, T; Gouget, H; Labarthe, L; Lambotte, O; Le Calvez, P; Le Grand, R; Legrand, N, 2022)	0.97
"ARV plasma pharmacokinetic parameters in both strains were similar to those estimated in the clinical context."	( Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice. Barrail-Tran, A; Benzemrane, MS; Bourgeois, C; Gelé, T; Gouget, H; Labarthe, L; Lambotte, O; Le Calvez, P; Le Grand, R; Legrand, N, 2022)	0.97
"Our objective was to predict maternal and fetal drug disposition using a physiologically based pharmacokinetic (PBPK) modeling approach."	( Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach. Abduljalil, K; Jamei, M; Ning, J; Pansari, A, 2022)	0.98
" Predicted pharmacokinetic parameters were within twofold of the observed values."	( Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach. Abduljalil, K; Jamei, M; Ning, J; Pansari, A, 2022)	0.98
"Because pharmacokinetic changes in antiretroviral drugs (ARV), due to their concurrent administration with food or nutritional products, have become a clinical challenge, it is necessary to monitor the therapeutic efficacy of ARV in people living with the human immunodeficiency virus (PLWH)."	( Pharmacokinetic Outcomes of the Interactions of Antiretroviral Agents with Food and Supplements: A Systematic Review and Meta-Analysis. Leelakanok, N; Methaneethorn, J; Siritientong, T; Thet, D, 2022)	0.72
" Population pharmacokinetic (popPK) models and simulations would aid in understanding potential differences in emtricitabine/tenofovir disproxil fumarate (F/TDF) parent-metabolite concentrations in TGW on GAHT when compared to cisgender men (CGM) not exposed to GAHT."	( Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. Bakshi, RP; Chaturvedula, A; Fuchs, EJ; Hendrix, CW; Marzinke, MA; Shieh, E; Tanaudommongkon, A, 2022)	1.2
" At steady state, 8-9 blood samples were taken to construct pharmacokinetic curves."	( First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L, 2023)	0.91
" For each combination, tenofovir GM (CV%) AUCtau and Cmax remained below reference values in adults taking 25 mg TAF with a boosted protease inhibitors."	( First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L, 2023)	0.91

Excerpt	Reference	Relevance
"Emtricitabine is a potent nucleoside reverse transcriptase inhibitor approved as a once-daily drug in combination with other antiretroviral agents for the treatment of HIV infection."	( Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. Begley, JA; Blum, MR; Chittick, GE; Hui, J; Wang, LH; Zong, J, 2007)	2.07
" We evaluated the effect of preexisting drug-associated resistance mutations to the response in treatment-naive patients to therapy with emtricitabine (FTC) or stavudine (d4T) in combination with didanosine (ddI) and efavirenz (EFV)."	( Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. Bae, AS; Borroto-Esoda, K; Harris, JL; Hinkle, JE; Quinn, JB; Rousseau, FS; Waters, JM, 2007)	0.79
"We evaluated the mitochondrial toxicity of tenofovir (TFV), emtricitabine (FTC) and abacavir as carbovir (CBV) alone, with each other, and in combination with additional NRTIs."	( Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Melkaoui, K; Setzer, B; Venhoff, N; Walker, UA, 2007)	0.85
" Most data on safety and efficacy in this scenario initially came from clinical trials in which tenofovir was combined with non-nucleoside reverse transcriptase inhibitors."	( [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors]. Fiorante, S; Pulido, F, 2008)	0.35
"Emtricitabine, a nucleoside reverse transcriptase inhibitor (RTI), and tenofovir disoproxil fumarate (tenofovir DF), a nucleotide RTI, as a fixed-dose combination tablet (emtricitabine/tenofovir DF) for once-daily oral administration, are used as the nucleoside/nucleotide RTI backbone in combination with other antiretroviral agents, including ritonavir-boosted protease inhibitors (PIs), in the treatment of adults with HIV-1 infection."	( Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. Perry, CM, 2009)	3.24
"A new drug combination regimen, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate (TDF), is described for the treatment of HIV-1 infection."	( A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate. De Clercq, E, 2009)	0.81
"International, multicenter, open-label, 96-week noninferiority randomized trial of atazanavir/ritonavir 300/100 mg once daily vs lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed-dose tenofovir/emtricitabine 300/200 mg once daily, in antiretroviral-naive, HIV-1-infected patients."	( Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R, 2010)	0.75
"Forty-eight-week data are presented from this multicenter, randomized, open-label study comparing the safety profiles of abacavir/lamivudine and tenofovir/emtricitabine, both administered with efavirenz, in HLA-B*5701-negative HIV-1-infected adults."	( Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C, 2010)	0.77
"We retrospectively evaluated the durability and reasons for discontinuation of nevirapine (NVP) in combination with a tenofovir (TDF) and emtricitabine (FTC) or lamivudine (3TC)-containing antiretroviral therapy (ART) regimen in an Australian outpatient setting."	( Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE, 2011)	0.81
" nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients."	( Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011)	0.76
"ARTEN is a randomized, open-label, non-inferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg once daily, in antiretroviral-naive HIV-1 patients with CD4(+) T-cell counts <400 (men) and <250 cells/mm(3) (women)."	( Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011)	0.77
"NVP demonstrated at week 48 non-inferior antiviral efficacy compared with ATZ/r when given along with TDF/FTC, despite more drug-related discontinuations with NVP than ATZ/r."	( Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011)	0.59
" In order to improve ATV exposure, plasma and intracellular (IC) PK of ATV in patients administered with ATV 400 mg once daily and TDF/emtricitabine (FTC) and switched to ATV 200 mg twice daily were studied."	( Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Baietto, L; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Siccardi, M; Simiele, M; Tettoni, M; Trentini, L, 2011)	0.57
"Limited data are available on the use of unboosted atazanavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced HIV-infected patients."	( Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N, 2011)	0.37
" NRTIs used in combination with atazanavir were tenofovir, abacavir and emtricitabine/lamivudine in 36."	( Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N, 2011)	0.6
"In patients with virological suppression and no prior history of virological failure, a switch to unboosted atazanavir in combination with NRTIs is associated with a low probability of virological failure and a good safety profile."	( Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N, 2011)	0.37
"Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies/mL and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a double-blind, noninferiority study to receive raltegravir or efavirenz, each combined with tenofovir/emtricitabine."	( Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J, 2011)	0.81
"When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir produced durable viral suppression and immune restoration that was at least equivalent to efavirenz through 156 weeks of therapy."	( Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J, 2011)	0.89
" Mean plasma concentration-time profiles for atazanavir, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), darunavir (DRV, administered with ritonavir [RTV]), and drospirenone/ethinylestradiol were similar following co-administration of GSK2248761."	( Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ, 2012)	0.6
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients."	( Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A, 2013)	0.87
" The objective of this study was to compare changes in body composition between ritonavir-boosted atazanavir (ATV/r) and ritonavir-boosted lopinavir (LPV/r) over 96 weeks using data from a substudy of CASTLE, which compared once-daily ATV/r with twice-daily LPV/r, both in combination with tenofovir disoproxil fumarate/emtricitabine in treatment-naïve patients with HIV-1 infection."	( Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection. DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ, 2014)	0.78
"We report an unusual case of pulmonary aspergillosis in a patient with AIDS and we demonstrated the drug-drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine."	( Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess. Becker, A; Desprez, S; Froidure, M; Gagneux, M; Huguet, D; Leduc, D; Legout, L; Sifaoui, F; Vignoli, P, 2015)	0.84
"International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144."	( Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J, 2015)	0.82
" We compared the treatment responses to 3TC and FTC combined with TDF in boosted protease inhibitor (PI)-based cART for HIV-1-infected patients."	( Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. Gras, L; Rijnders, B; Rokx, C; van de Vijver, D; Verbon, A, 2016)	0.7
" The 3D regimen of 150/100 mg daily paritaprevir/ritonavir, 25 mg daily ombitasvir, and 400 mg twice-daily dasabuvir was administered alone or in combination with 200 mg daily of emtricitabine and 300 mg daily of tenofovir disoproxil fumarate (tenofovir DF), 25 mg daily of rilpivirine, or 400 mg of raltegravir twice daily."	( Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine. Awni, W; Dunbar, M; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R, 2016)	0.82
"To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients."	( Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study. Briz, V; De Ory, SJ; Falcon-Neyra, L; Fortuny, C; Frick, MA; González-Tomé, MI; López-Cortés, LF; Moreno, EB; Navarro Gómez, ML; Neth, O; Noguera-Julian, A; Olbrich, P; Palladino, C; Santos, JL; Soler-Palacín, P, 2016)	0.92
"We investigated whether a fixed-dose combination tablet of elvitegravir, cobicistat, emtricitabine, and tenofovirDF (Stribild) can be crushed and combined with enteral nutrition without influencing pharmacokinetics."	( Brief Report: Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With or Without Enteral Nutrition. Abbink, E; Burger, D; Colbers, A; Duisenberg-van Essenberg, M; Jongbloed-de Hoon, M; Kruijssen, M; van Crevel, R; Velthoven-Graafland, K, 2017)	0.68
" To the best of our knowledge, this is the first report of severe hypokalemia and proximal tubular renal dysfunction as a result of a possible drug-drug interaction between vinblastine, tenofovir and ritonavir-boosted atazanavir."	( Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Arcondo, F; Cordova, E; Morganti, L; Odzak, A; Rodriguez, C; Silva, M; Zylberman, M, 2017)	0.46
" We report a potential drug-drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case involving leucovorin as calcium salt."	( HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases. El-Sayed, D; Kang-Birken, SL; Prichard, J, )	0.35
" To evaluate potential drug-drug interactions between FHT and ART, we performed intensive measurements of the pharmacokinetic (PK) parameters of blood tenofovir (TFV), efavirenz (EFV), and estradiol (E2)."	( Drug-drug Interactions Among Thai Transgender Women Living with Human Immunodeficiency Undergoing Feminizing Hormone Therapy and Antiretroviral Therapy: The iFACT Study. Dalodom, T; Himmad, L; Hiransuthikul, A; Janamnuaysook, R; Kerr, SJ; Kongkapan, J; Mills, S; Pankam, T; Phanjaroen, K; Phanuphak, N; Phanuphak, P; Vannakit, R, 2021)	0.62
" Here, we evaluate TDF and FTC in combination with the broadly neutralizing antibody VRC01-N using a highly reproducible humanized mouse model."	( Highly synergistic drug combination prevents vaginal HIV infection in humanized mice. Baum, MM; Bobardt, M; Gallay, PA; Gunawardana, M; Moss, JA; Ramirez, CM, 2020)	0.56
" Confirmatory clinical trials may further define the in vivo triapine metabolic fate and quantify any drug-drug interactions."	( In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine. Beumer, JH; Chaphekar, N; Chu, E; Guo, J; Jones, R; Joshi, A; Kiesel, BF; Kunos, CA; Taylor, S; Venkataramanan, R, 2020)	0.56
"We assessed virological failure (VF) and resistance-associated mutations (RAMs) on dolutegravir maintenance regimens in combination with rilpivirine or with lamivudine or emtricitabine (xTC) and analysed the factors associated with VF."	( Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting. Allavena, C; Bani-Sadr, F; Cabie, A; Cuzin, L; Deschanvres, C; Duvivier, C; Hocqueloux, L; Joly, V; Lamaury, I; Palich, R; Raffi, F; Rey, D; Reynes, J; Robineau, O, 2021)	1.05
"The aim of this international multicentre study was to review potential drug-drug interactions (DDIs) for real-life coadministration of combination antiretroviral therapy (cART) and coronavirus disease 2019 (COVID-19)-specific medications."	( Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19). Antoniak, S; Begovac, J; Dragovic, G; Fleischhans, L; Gokengin, D; Harxhi, A; Hofman, S; Jilich, D; Kase, K; Kowalska, J; Lakatos, B; Matulionyte, R; Oprea, C; Papadopoulus, A; Rukhadze, N; Vassilenko, A; Vasyliev, M; Verhaz, A; Wasilewski, P; Yancheva, N, 2022)	0.72
"Lenacapavir warrants further investigation as a potential antiretroviral used orally and as injection in combination with other antiretroviral drugs."	( Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Baeten, JM; Benson, P; Berhe, M; Crofoot, G; Dvory-Sobol, H; Gupta, SK; Koenig, E; Liu, SY; McDonald, C; Ramgopal, M; Rhee, MS; Ruane, P; Sanchez, WE; Scribner, A; Sims, J; VanderVeen, LA, 2023)	0.91
" Heart transplant (HT) is a very effective therapeutic strategy for end-stage heart failure (HF); however, clinicians may be hesitant due to concerns of complex drug-drug interactions (DDIs) between ART and HT immunosuppressive regimens and the potential impact of ART on long-term HT outcomes."	( Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report. Almangour, TA; Chang, PP; Corbett, A; Farel, CE; Rodgers, JE; Skersick, PT, 2023)	0.91

Excerpt	Reference	Relevance
" Absorption of FTC after oral administration was rapid, with bioavailability averaging 73 +/- 6%."	( Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys. Boudinot, FD; Ibrahim, SS; Liotta, DC; Manning, C; McClure, HM; Schinazi, RF, 1992)	0.28
" The pharmacokinetics and bioavailability of 524W91 after oral dosing were studied in mice dosed with 10, 100, and 600 mg of 524W91 per kg of body weight by the oral and intravenous routes."	( Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. Frick, LW; Lambe, CU; Nelson, DJ; St John, L; Taylor, LC, 1994)	0.29
"1 liters/h/kg, and the oral bioavailability was 90% +/- 8%."	( Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Frick, LW; Furfine, ES; Furman, PA; Liotta, DC; Nelson, DJ; Painter, GR; St John, L; Taylor, LC, 1993)	0.29
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"This study evaluated the relative bioavailability and pharmacokinetics of elvitegravir (EVG), emtricitabine (FTC), tenofovir disoproxil fumarate (TDF), and a investigational pharmacoenhancer, cobicistat (GS-9350, COBI) coformulated as a fixed-dose combination tablet (FDC) compared with ritonavir-boosted EVG and FTC + TDF in healthy subjects."	( Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. German, P; Hui, J; Kearney, BP; Warren, D; West, S, 2010)	0.58
"39 fold) indicated significant enhancement in the rate and extent of bioavailability by the OPT-FTC NPs compared to pure drug."	( Pharmacokinetics and in vivo biodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine. Pai, RS; Singh, G, 2014)	0.61
" These findings suggest that elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate should be administered with food, and that the bioavailability of elvitegravir and tenofovir is not affected by the type of meal ingested."	( Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study. Ikeda, A; Irie, S; Ishikawa, T; Kimura, M; Matsuki, S; Nishino, N; Shiomi, M, 2014)	0.87
"Due to the differences between bioavailability of efavirenz (EFV) and tenofovir (TDF), the single-tablet regimen of EFV/emtricitabine (FTC)/TDF is not approved as initial antiretroviral therapy (ART) in Europe by the European Medical Agency."	( Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1. De Castro, N; Delaugerre, C; Flandre, P; Gallien, S; Molina, JM; Nguyen, N, 2015)	0.88
" This study investigated the differences in bioavailability between WHO-prequalified first-line antiretroviral generics by means of adjusted indirect comparisons to ensure interchangeability between these generics."	( Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons. García-Arieta, A; Gordon, J; Gwaza, L; Leufkens, H; Potthast, H; Stahl, M; Welink, J, 2017)	0.46
" The versatile HA-PQ10 entrapped all drugs and achieved an enhanced relative bioavailability of EFV, TDF, and FTC compared to the market formulation for potentially enhanced HIV treatment."	( 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery. Choonara, YE; du Toit, LC; Kondiah, PPPD; Kumar, P; Pillay, V; Siyawamwaya, M, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" BIC has demonstrated a high genetic barrier to resistance development in vitro, can be administered with or without food, and has a bioavailability of > 70%."	( Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J, 2019)	0.51
" The latter was further converted to two orally bioavailable prodrug forms, TDF and TAF, and both TDF and TAF were further combined with other antiviral drugs, thus giving rise to a broad array of antiviral drug combinations for the treatment of HIV infections."	( The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death. De Clercq, E, 2022)	0.72
"A crossover, randomized trial in healthy adults (NCT04244448) investigated the bioavailability of two off-label uses of BIC/TAF/FTC (50/200/25 mg), dissolved in water or crushed in apple compote, compared with the solid tablet."	( Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. Alix, A; Bois, J; Brucato, S; Dargere, S; Fournel, F; Fournier, A; Got, L; Gregoire, N; Hocqueloux, L; Lefeuvre, S; McNicholl, I; Parienti, JJ; Peyro-Saint-Paul, L; Prazuck, T; Valentin, C, 2022)	0.95

Excerpt	Relevance	Reference
"15 cells showed reductions in levels of HBV in serum and in intracellular levels of HBV when the mice were orally dosed with (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (FTC)."	( Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model. Condreay, LD; Daluge, SM; Ellis, MN; Furman, PA; Jansen, RW; Johnson, LC; Paff, MT; Painter, GR; Powdrill, TF; Selleseth, DW, 1994)	0.29
" The pharmacokinetics and bioavailability of 524W91 after oral dosing were studied in mice dosed with 10, 100, and 600 mg of 524W91 per kg of body weight by the oral and intravenous routes."	( Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. Frick, LW; Lambe, CU; Nelson, DJ; St John, L; Taylor, LC, 1994)	0.29
" This methodology was successfully applied to the determination of FTC-TP in PBMCs of patients infected with human immunodeficiency virus after oral administration of various dosing regimens of FTC monotherapy."	( Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Darque, A; Rousseau, F; Sommadossi, JP; Valette, G; Wang, LH; Zhou, XJ, 1999)	0.56
" Using data on viral replication kinetics and dynamics, we designed an accelerated (14 day) open-label study of single agent emtricitabine (formerly known as FTC)--a nucleoside reverse transcriptase inhibitor--to select a dosing regimen for further therapeutic study."	( Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). Delehanty, J; Kahn, JO; Mildvan, D; Quinn, JB; Rousseau, FS; Shepp, D; Simpson, JN; Sommadossi, JP; Thompson, M; van der Horst, C; Wakeford, C; Wang, LH, 2001)	0.74
" Emtricitabine was well tolerated over the 2-month dosing period."	( Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Delehanty, J; Fang, L; Gish, RG; Kessler, HA; Lang, W; Leung, NW; Mondou, E; Rigney, A; Rousseau, F; Snow, A; Trinh, H; Wang, LH; Wright, TL, 2002)	1.45
" Potency, tolerability, convenient dosing and a low rate of side effects are some of the main characteristics of this new drug."	( Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. Cahn, P, 2004)	1.77
" A phase I open-label trial was conducted in children to identify an FTC dosing regimen that would provide comparable plasma exposure to that observed in adults at 200 mg QD."	( Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Bakshi, SS; Chittick, GE; Emmanuel, PJ; Flynn, PM; Rathore, MH; Wang, LH; Wiznia, AA, 2004)	0.57
"Gilead Sciences is developing a fixed-dose co-formulation of two of its reverse transcriptase inhibitors, emtricitabine [Emtriva] and tenofovir disoproxil fumarate [Viread], for once-daily dosing in combination with other antiretrovirals for the treatment of HIV infection."	( Emtricitabine/tenofovir disoproxil fumarate. , 2004)	1.98
" FTC may be dosed once daily and in vitro is less associated with the M184V mutation, which is classically associated with failure of treatment with lamivudine."	( Emtricitabine (FTC) for the treatment of HIV infection. Nelson, M; Schiavone, M, 2004)	1.77
"Once daily (QD) dosing facilitates regimen simplification and adherence to antiretroviral therapy."	( A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. Benson, CA; Haas, DW; Lamarca, A; McDonald, CK; Mondou, E; Quinn, JB; Rousseau, F; Rublein, J; Steinhart, CR; van der Horst, C, 2004)	0.64
" This study highlights the importance of selecting animal species that demonstrate similar cytidine deaminase activity to humans when performing preclinical dosing studies on Racivir and other antiviral agents that are substrates for mammalian cytidine deaminases."	( Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Hurwitz, SJ; Otto, MJ; Schinazi, RF, 2005)	0.33
" In adult patients infected with HIV-1, emtricitabine has a convenient and simple dosing schedule of one 200-mg capsule once daily, and is as effective as lamivudine 150 mg twice daily and more effective than stavudine twice daily at suppressing plasma HIV-1 RNA when administered as part of a triple-drug regimen."	( Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Cox, SL; Molina, JM, 2005)	2.04
"Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors (NRTIs) with once-daily dosing approved for use in HIV-1 infection."	( In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Borroto-Esoda, K; Miller, MD; Myrick, F; Ray, AS; Vela, JE, 2006)	0.82
" However, early HAART often consisted of drugs with complex dosing schedules, strict food requirements, treatment-limiting adverse effects, and the need to take 16-20 pills/day."	( An update and review of antiretroviral therapy. Piacenti, FJ, 2006)	0.33
" Tenofovir requires surveillance of glomerular filtration rate and dosing interval adjustment when creatinine clearance is less than 50 ml/min and avoidance less than 30 ml/min."	( Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. Arribas López, JR; Muñoz de Benito, RM, 2006)	0.62
" Individually, these agents have long half-lifes that allow for once-daily dosing and may provide a pharmacologic bridge for the occasional missed dose."	( Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Best, B; Goicoechea, M, 2007)	0.74
" Lack of PK alteration for FTC, tenofovir (TFV), and GS-9137 was defined as a 90% confidence interval (CI) for the estimated ratio of geometric least squares means (coadministration/alone) between 70% and 143% for the primary PK parameters: maximum observed plasma concentration (Cmax), area under the plasma concentration-time curve over dosing interval (AUCtau), and trough concentration (Ctau)."	( Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. Cheng, A; Kearney, BP; Ramanathan, S; Shen, G, 2007)	0.66
"A novel, once-daily dosing regimen of 3 antiretroviral drugs, emtricitabine, didanosine, and efavirenz, was tested in 37 therapy-naive HIV-infected children and adolescents between 3 and 21 years of age (inclusive)."	( Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Abrams, E; Blum, MR; Britto, P; Chittick, GE; Cunningham, C; Dickover, R; Draper, L; Flynn, P; Hu, C; Hughes, M; Kraimer, J; McKinney, RE; Ortiz, AA; Rathore, M; Reynolds, L; Rodman, J; Scites, M; Serchuck, LK; Smith, ME; Spector, S; Tran, P; Weinberg, A; Yogev, R, 2007)	0.83
" This study evaluated the pharmacokinetics (PK) and bioequivalence of an investigational coformulation of EFV/FTC/TDF (test) single-tablet regimen compared with the commercially available individual dosage forms (EFV+FTC+TDF; reference treatment) in healthy subjects."	( Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. Hinkle, J; Hui, J; Kaul, S; Kearney, BP; Mathias, AA; Menning, M, 2007)	0.63
" Group 1 was treated subcutaneously with a human-equivalent dose of emtricitabine (FTC), group 2 received orally the human-equivalent dosing of both FTC and tenofovir-disoproxil fumarate (TDF), and group 3 received subcutaneously a similar dosing of FTC and a higher dose of tenofovir."	( Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. Adams, DR; Cong, ME; Delinsky, D; Folks, TM; García-Lerma, JG; Heneine, W; Jackson, E; Janssen, R; Johnson, JA; Kim, C; Lipscomb, J; Luo, W; Masciotra, S; Monsour, M; Otten, RA; Qari, SH; Schinazi, RF, 2008)	0.8
" FTC dose-linearity studies revealed that excretion parameters were not significantly different among dosing groups."	( Renal excretion of emtricitabine I: effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. Nakatani-Freshwater, T; Taft, DR, 2008)	0.67
" The pharmacokinetic profile of GS-9160 in healthy human volunteers revealed that once-daily dosing was not likely to achieve antiviral efficacy; hence, the clinical development of this compound was discontinued."	( Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Chen, J; Chen, X; Geleziunas, R; Hesselgesser, J; Jin, H; Jones, GS; Kim, CU; Tsiang, M; Wright, M; Yu, F; Zeynalzadegan, A, 2009)	0.35
" A new combination therapy consisting of the TFV pro-drug (300 mg) and another reverse transcriptase inhibitor, emtricitabine (FTC, 200 mg) has become available in a convenient once-daily dosage form (Truvada)."	( The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. Bushman, L; Delahunty, T; Fletcher, CV; Robbins, B, 2009)	0.83
"Once-daily treatment with ritonavir-boosted saquinavir was well tolerated and resulted in similar saquinavir drug exposure despite much lower ritonavir concentrations when compared with a twice-daily dosing schedule."	( Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. Bickel, M; Bodtländer, A; Gute, P; Klauke, S; Knecht, GK; Kurowski, M; Lutz, T; Stephan, C; von Hentig, N, 2009)	0.55
" Daily drug dosage was 300 mg Tenofovir, 200mg Emtricitabine and 400 mg Nevirapine once daily."	( Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial). Flux, K; Gholam, P; Hartmann, M; Hueter, E; Weberschock, T, 2009)	0.83
" Irrespective of the dosing strategy used, the rsIL-7gly administration transiently increased proliferation of both central memory and naive cells, in both CD4(+) and CD8(+) subsets, without increasing SIV levels in the blood."	( Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses. Assouline, B; Axthelm, MK; Legasse, A; Leone, A; Lifson, JD; Morre, M; Okoye, A; Piatak, M; Picker, LJ; Rohankhedkar, M; Sodora, DL; Villinger, F, 2010)	0.36
" Emergence of postbaseline resistance mutations occurred at similar low rates in each dosing group."	( Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L, 2010)	0.57
" Relative to ritonavir-boosted EVG, the geometric least-squares means ratios (GMR) [90% confidence interval (CI)] for EVG area under plasma concentration-time curve from time zero until the end of the dosing interval (AUC)tau, maximum concentration (Cmax), and trough concentration (Ctau) were 118 (110 to 126), 108 (100 to 116), and 110 (95."	( Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. German, P; Hui, J; Kearney, BP; Warren, D; West, S, 2010)	0.36
"Addition of darunavir/ritonavir to etravirine, all dosed once daily, did not have a clinically significant effect on the pharmacokinetics of etravirine."	( Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J, 2010)	0.36
" This review identifies important cellular pharmacology considerations for tenofovir and emtricitabine, which include drug penetration into relevant tissues and cell types, race/ethnicity/pharmacogenetics, gender, cellular activation state and appropriate episodic or alternative dosing strategies based on pharmacokinetic principles."	( Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. Anderson, PL; Gardner, EM; Grant, RM; Kiser, JJ; Meditz, A; Rower, JE, 2011)	0.85
" Decreases in estimated glomerular filtration rate occurred within the first few weeks of dosing in participants receiving EVG/COBI/FTC/TDF, remained within the normal range and did not progress at week 24 or 48; no participant experienced a clinical adverse event or discontinued study drug due to changes in serum creatinine or renal function."	( Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K, 2011)	0.59
"Among the 3 trials, 522 subjects were treated with FTC dosed once daily and 841 subjects were treated with 3TC dosed twice daily."	( Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. Borroto-Esoda, K; Chen, SS; Harris, J; Margot, N; McColl, DJ; Miller, MD, )	0.35
" Dosage of 200 mg might provide an option to patients showing suboptimal ATV exposure with standard unboosted dosing."	( Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Baietto, L; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Siccardi, M; Simiele, M; Tettoni, M; Trentini, L, 2011)	0.37
" Low concentrations at birth support infant dosing as soon after birth as possible."	( Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Bardeguez, A; Cotter, A; Fiscus, SA; Flynn, PM; Heckman, B; Huang, S; Jean-Philippe, P; Kearney, B; Mirochnick, M; Mofenson, LM; Purswani, M; Robbins, B; Rodman, J; Rooney, JF; Shapiro, DE; Thorpe, E; Van Rompay, KK; Watts, DH, 2011)	0.6
"Atazanavir geometric mean (CV%) C(max), C(min) and AUC over the dosing interval were 2897 (46) ng/mL, 526 (57) ng/mL and 28 605 (46) ng · h/mL, respectively, and for lopinavir they were 10 655 (51) ng/mL, 5944 (68) ng/mL and 90 946 (59) ng · h/mL, respectively."	( Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L, 2012)	0.38
" Raltegravir must be dosed twice daily, as once daily raltegravir displays decreased virologic efficacy compared to twice daily dosing."	( Role of raltegravir in HIV-1 management. Bookstaver, PB; Bryant, JE; Millisor, VE; Rokas, KE; Shamroe, CL; Sutton, SS; Weissman, SB, 2012)	0.38
"Little is known about safety of and adherence to intermittent HIV PrEP regimens, which may be more feasible than daily dosing in some settings."	( Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. Anzala, O; Bangsberg, D; Barin, B; Chetty, P; Fast, P; Haberer, JE; Mark, D; Mugo, P; Mutua, G; Priddy, FH; Rooney, JF; Sanders, E, 2012)	0.38
"Adherence to intermittent dosing regimens, fixed doses, and in particular coitally-dependent doses, may be more difficult than adherence to daily dosing."	( Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. Anzala, O; Bangsberg, D; Barin, B; Chetty, P; Fast, P; Haberer, JE; Mark, D; Mugo, P; Mutua, G; Priddy, FH; Rooney, JF; Sanders, E, 2012)	0.38
" Adherence by type of ART and dosing frequency were compared by Brown-Mood median tests."	( Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. Buscher, A; Giordano, TP; Hartman, C; Kallen, MA, 2012)	0.38
" Optimal PrEP agents and dosing regimens now need to be identified."	( Considerations regarding antiretroviral chemoprophylaxis in MSM. Grulich, AE; Poynten, IM; Zablotska, I, 2012)	0.38
" Dosing was discontinued on day 30 and blood was collected on days 35, 45, and 60 during the washout period."	( Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Fernandez, C; Gardner, EM; Kiser, JJ; Langness, J; Meditz, A; Predhomme, J; Rower, JE; Zheng, JH, 2013)	0.78
" Vaginal dosing achieves measurable tenofovir concentrations in the rectum and vice versa."	( The clinical pharmacology of antiretrovirals for HIV prevention. Hendrix, CW, 2012)	0.38
" Directly observed dosing in a separate study, the STRAND trial, yielded TFV-DP concentrations that, when analyzed according to the iPrEx model, corresponded to an HIV-1 risk reduction of 76% for two doses per week, 96% for four doses per week, and 99% for seven doses per week."	( Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Anderson, PL; Bekker, LG; Buchbinder, S; Bushman, LR; Casapía, M; Chariyalertsak, S; Glidden, DV; Grant, RM; Guanira, JV; Kallás, EG; Lama, JR; Liu, A; Mayer, KH; McMahan, V; Montoya-Herrera, O; Schechter, M; Veloso, VG, 2012)	1.82
" Use of exact dosing data halved unexplained variability in ATV clearance."	( Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Savic, RM; Taburet, AM; Verstuyft, C; Vrijens, B, 2012)	0.38
" Drug concentrations at two trough values of 12 and 24 h after dosing (C(12) and C(24)), area under the concentration-curve values (AUC), maximum drug concentration (C(max)), and the time at which this concentration occurred (T(max)) in plasma were estimated with noncompartmental pharmacokinetic methods and compared to data from a subset of white subjects randomized to the RAL twice a day (plus TDF/FTC) arm of the QDMRK study, a phase III study of the safety and efficacy of once daily versus twice daily RAL in treatment naive patients."	( Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. Blevins, S; Dumond, JB; Eron, JJ; Floris-Moore, M; Hudgens, MG; Kashuba, AD; Massengale, K; Pittard, D; Ragan, D; Richardson, A; Walsh, K; Wang, R; Wohl, DA, 2013)	0.39
" Blood plasma (for TFV, FTC, EFV, ATV and RTV concentrations) and peripheral blood mononuclear cells [PBMCs; for tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) concentrations] were collected at 11 time-points over a 24-hour dosing interval."	( Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013)	0.59
" The MEMS-defined adherence for correct dosing (-0."	( Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Parienti, JJ; Taburet, AM; Vigan, M; Vrijens, B, 2013)	0.39
"Possible designs for a PrEP phase 3 efficacy trial are obtained by considering scenarios for potential experimental PrEP and control regimens, including consideration of placebo and active controls, longer acting PrEP and alternate dosing schedules."	( Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions. Chen, YQ; Donnell, D; Fleming, TR; Hughes, JP; Wang, L, 2013)	0.39
" As a fixed-dose combination tablet given once daily, EFV/FTC/TDF was the first available STR combining efficacy, tolerability and convenience, with the simplest dosing schedule and smallest numbers of pills of any ART combination therapy."	( Single-tablet regimens in HIV: does it really make a difference? Aldir, I; Horta, A; Serrado, M, 2014)	0.4
" Median MEMS adherence rates were 98% (IQR: 93-100) for daily PrEP regimen, 91% (IQR: 73-97) for fixed intermittent dosing and 45% (IQR: 20-63) for post-coital dosing."	( Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. Bahemuka, U; Bangsberg, DR; Barin, B; Bwanika, AN; Chetty, P; Fast, P; Haberer, JE; Kamali, A; Katende, D; Kibengo, FM; Mark, D; Priddy, FH; Rooney, JF; Ruzagira, E, 2013)	0.63
"Both daily and intermittent oral PrEP dosing regimens were safe."	( Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. Bahemuka, U; Bangsberg, DR; Barin, B; Bwanika, AN; Chetty, P; Fast, P; Haberer, JE; Kamali, A; Katende, D; Kibengo, FM; Mark, D; Priddy, FH; Rooney, JF; Ruzagira, E, 2013)	0.63
" The 90% confidence interval (CI) of the geometric mean ratio for rilpivirine, emtricitabine, tenofovir exposure was estimated for fed versus fasted dosing and light versus standard meal, with equivalence boundaries of 80 - 125%."	( Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. Cheng, A; Custodio, JM; Hepner, M; Kearney, BP; Ling, KH; Ramanathan, S; Yin, X, 2014)	0.92
"At weeks 12 and 24, all 49 dosed subjects remained suppressed on RPV/FTC/TDF."	( Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Brinson, C; Cheng, AK; Chuck, SK; Cohen, C; Dejesus, E; Mills, AM; Ramanathan, S; Wang, MH; White, K; Williams, S; Yale, KL, )	0.36
"The aims of this study were to describe emtricitabine concentration-time courses in a large population of HIV-1-infected adults, to evaluate the influence of renal function on emtricitabine disposition, and to assess current dosing adjustment recommendations."	( Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Benaboud, S; Bouazza, N; Fauchet, F; Foissac, F; Ghosn, J; Hirt, D; Tréluyer, JM; Urien, S; Valade, E; Viard, JP, 2014)	0.96
"Pill burden, dosing frequency, and concerns about safety and tolerability are important obstacles to maintaining adequate medication adherence."	( Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. Brinson, C; Cao, H; Cheng, A; Crofoot, G; Ebrahimi, R; Garner, W; Kulkarni, R; Mills, A; Ortiz, R; Rashbaum, B; Szwarcberg, J; Towner, W; Ward, D, )	0.36
"Plasma concentrations of tenofovir consistent with daily dosing were highly predictive of protection from HIV acquisition."	( HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. Baeten, JM; Bangsberg, DR; Brantley, J; Bumpus, NN; Celum, C; Donnell, D; Haberer, JE; Hendrix, C; Mugo, N; Mujugira, A; Ndase, P, 2014)	0.4
"Patients with HIV on antiretroviral therapy might benefit from regimen simplification to reduce pill burden and dosing frequency."	( Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K, 2014)	0.65
" Although effective intracellular drug concentrations persist for several days after stopping PrEP, a reasonable recommendation is to continue PrEP dosing for 4 weeks after the last potential HIV exposure, similar to recommendations for postexposure prophylaxis."	( Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Gardner, EM; Glidden, DV; Guida, LA; Kerr, BJ; Klein, B; Meditz, AL; Predhomme, JA; Rower, C; Seifert, SM; Zheng, JH, 2015)	0.42
" Enrolled patients underwent 24 h blood sampling with TDF/FTC/RPV dosing in the fasted state (day 42), with a low-fat meal (11 g of fat/353 kcal, day 49) and with a moderate-fat meal (19 g of fat/589 kcal, day 56; reference)."	( Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S, 2015)	0.42
" Less-than-daily oral dosing regimens and long-acting injectable medications could reduce pill burdens and facilitate adherence, and local delivery of PrEP medications to genital compartments via gels, rings and films may limit systemic drug exposure and potential toxicities."	( Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Krakower, DS; Mayer, KH, 2015)	0.42
" Net BMD loss by week 24 in participants with TFV-DP levels indicative of consistent dosing averaged -1."	( Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Anderson, PL; Bekker, LG; Buchbinder, S; Chariyalertsak, S; Chodacki, P; de Mendonca, LM; Glidden, DV; Gonzales, P; Grant, RM; Guanira, JV; Lama, JR; Liu, A; McMahan, V; Mulligan, K; Namwongprom, S; Ramirez-Cardich, ME; Schechter, M; Veloso, VG; Wang, F, 2015)	0.81
" These models can be applied to evaluate alternative dosing regimens to optimize drug therapy during pregnancy."	( Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Benaboud, S; Blanche, S; Bouazza, N; De Sousa Mendes, M; Foissac, F; Hirt, D; Treluyer, JM; Urien, S; Valade, E, 2015)	0.42
" EFV area under the plasma concentration-time curve over 1 dosing interval from time 0 to 24 hours postdose values were generally suboptimal (<110 μM × h) in subjects younger than 3 years treated with oral solution; these subjects switched to capsule sprinkle."	( Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922. Biguenet, S; Bunupuradah, T; Krystal, M; Lataillade, M; Pavia-Ruz, N; Rossouw, M; Sáez-Llorens, X; Seekins, D; Sevinsky, H; Taylor, M; Yang, R, 2015)	0.65
" HPTN 066 was conducted to establish objective, quantitative benchmarks for discrete, regular levels of adherence using directly observed dosing of tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC)."	( Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). Anderson, PL; Andrade, A; Bakshi, RP; Bumpus, NN; Bushman, LR; Donnell, D; Elharrar, V; Fuchs, EJ; Hendrix, CW; Kashuba, AD; Li, X; Marzinke, MA; Mayer, KH; McKinstry, L; Moore, A; Patterson, KB; Prince, HA; Radebaugh, C; Richardson, P; Shieh, E; Wang, R; Wiggins, I, 2016)	0.87
"Animal models have informed our understanding of early viral transmission events, which help guide event-driven PrEP dosing strategies."	( Nondaily preexposure prophylaxis for HIV prevention. Anderson, PL; García-Lerma, JG; Heneine, W, 2016)	0.43
"Event-driven dosing for TFV-based PrEP has promise for HIV prevention in MSM."	( Nondaily preexposure prophylaxis for HIV prevention. Anderson, PL; García-Lerma, JG; Heneine, W, 2016)	0.43
" In May 2014 the Centers for Disease Control and Prevention published updated practice guidelines recommending the use of preexposure prophylaxis (PrEP) with daily oral dosing of tenofovir/emtricitabine to help prevent HIV infection in high-risk individuals (strength of recommendation, A)."	( Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective. Conniff, J; Evensen, A, )	0.32
"77), 87 versus 86 % as recent dosing (>10 ng/ml; p = 0."	( Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial. Baeten, JM; Bangsberg, DR; Haberer, JE; Musinguzi, N; Muwonge, T; Thomas, K, 2016)	0.43
"A new simple, rapid stability indicating assay method has been developed and validated for the determination of emtricitabine, tenofovir disoproxil fumarate, elvitegravir and cobicistat using reverse-phase high-performance liquid chromatography in their pharmaceutical dosage form."	( A Validated Stability Indicating RP-HPLC Method for the Determination of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir and Cobicistat in Pharmaceutical Dosage Form. Avanapu, SR; Kumar, PR; Runja, C, )	0.57
" Monte-Carlo simulations were then performed to identify minimally effective dosing strategies to protect lower female genital tract and colorectal tissues."	( A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Nelson, JA; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N; Wulff, J; Yang, KH, 2016)	0.63
" These data provide a novel approach for future PrEP investigations that can optimize clinical trial dosing strategies."	( A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Nelson, JA; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N; Wulff, J; Yang, KH, 2016)	0.63
"Use of TDF/FTC did not appear to affect serum MPA levels, however we found lower than expected MPA concentrations at the end of the dosing interval among DMPA users in the FEM-PrEP trial, the cause of which are unknown."	( Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial. Agot, K; Callahan, R; Dorflinger, L; Jenkins, D; Nanda, K; Taylor, D; Van Damme, L; Wang, M, 2016)	0.43
" We evaluated concordance between reports of recent PrEP dosing collected via neutral interviewing and drug quantitation in the iPrEx open-label extension, where participants (n = 1172) had the choice to receive or not receive PrEP."	( Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. Amico, KR; Anderson, P; Avelino-Silva, VI; Grant, R; Guanira, J; McMahan, V; Mehrotra, M; Veloso, VG, 2016)	0.43
"Antiretroviral preexposure prophylaxis (PrEP) with once-daily dosing of tenofovir and tenofovir-emtricitabine was shown to be effective for preventing HIV-1 infection in individuals who had HIV-1-seropositive partners (the Partners PrEP Study)."	( Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods. Baeten, JM; Bangsberg, D; Celum, CL; Chaturvedula, A; Fossler, MJ; Goti, V; Haberer, JE; Hendrix, CW; Lu, Y; Sale, ME, 2016)	0.65
" We determined if emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS) can be used as a marker of recent dosing with tenofovir disoproxil fumarate-emtricitabine (TDF-FTC)."	( Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Anderson, PL; Bushman, LR; Campbell, K; Castillo-Mancilla, J; Coleman, S; Gardner, EM; Glidden, DV; Grant, R; Hosek, S; Liu, A; MaWhinney, S; McAllister, K; Seifert, S; Wilson, CM; Zheng, JH, 2016)	2.21
" Peak blood and breast milk samples were obtained 1-2 h after the maternal DOT PrEP dose, while maternal trough samples were obtained at the end of the PrEP dosing interval (i."	( Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. Baeten, JM; Celum, CL; Hendrix, CW; John-Stewart, G; Katabira, ET; Marzinke, M; Mugo, NR; Mugwanya, KK; Muthuri, G; Muwonge, TR; Ngure, K; Semiyaga, NB; Stergachis, A, 2016)	0.43
" Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP)."	( Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Chen, X; Kiser, JJ; MaWhinney, S; Seifert, SM; Zheng, JH, 2016)	0.69
" This study included once-daily dosing regimens of placebo, oral tenofovir disoproxil fumarate (TDF), and TDF in combination with emtricitabine (FTC), administered to HIV-uninfected members of serodiscordant couples."	( Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis. Baeten, JM; Bangsberg, D; Celum, C; Chaturvedula, A; Fossler, MJ; Haberer, JE; Hendrix, CW; Madrasi, K; Sale, M, 2017)	0.66
" However, adequacy of drug exposures after these administration routes are largely unknown, making dosing recommendations and the attainment of viral suppression challenging in this patient population."	( Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration. Anderson, M; Bailey, B; Balba, G; Brooks, KM; Garrett, KL; George, JM; Kuriakose, SS; Lane, HC; Maldarelli, F; Pau, AK, 2017)	0.68
" Topical (vaginal and rectal) dosing is a promising regimen for HIV PrEP as it leads to low systematic drug exposure."	( Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. Baum, MM; Chatterji, U; Gallay, PA; Gandarilla, A; Gunawardana, M; Kirchhoff, A; Marzinke, MA; Moss, JA; Pyles, RB, 2017)	0.46
"This is the first demonstration that intracellular atazanavir exposure remains unchanged during pregnancy supporting the standard 300/100 mg atazanavir/ritonavir dosing throughout pregnancy."	( Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. Bonito, A; Bonora, S; Calcagno, A; Casari, S; Castelli, F; D'Avolio, A; Di Perri, G; Domenighini, E; Focà, E; Quiros Roldan, E; Simiele, M; Trentini, L, 2017)	0.46
"The relative feasibility and acceptability of daily versus non-daily dosing of oral HIV pre-exposure prophylaxis (PrEP) among women are unknown."	( Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N, 2018)	0.48
" Participants were adult women (age ≥18 years) who received directly observed dosing once a week for 5 weeks followed by random assignment (1:1:1) at week 6 to one of three unblinded PrEP regimens for self-administered dosing over 24 weeks: daily; time-driven (twice a week plus a post-sex dose); or event-driven (one tablet both before and after sex)."	( Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N, 2018)	0.48
" 178 (93%) completed directly observed dosing and were randomly assigned one of the three PrEP regimens for the self-administered phase: 59 were allocated the daily regimen, 59 the time-driven regimen, and 60 the event-driven regimen."	( Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N, 2018)	0.48
"Daily PrEP dosing resulted in higher coverage of sex events, increased adherence to the regimen, and augmented drug concentrations than did either time-driven or event-driven dosing."	( Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N, 2018)	0.48
" We conducted a prospective, randomized, crossover pharmacokinetic study of TFV-DP in DBS during 33%, 67%, or 100% of daily dosing under directly observed therapy (DOT)."	( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Anderson, PL; Buchbinder, S; Bushman, LR; Campbell, K; Castillo-Mancilla, JR; Gardner, EM; Ibrahim, M; Kiser, JJ; Liu, AY; MaWhinney, S; McHugh, C; Morrow, M; Seifert, SM; Wagner, T, 2018)	0.75
"Nondaily dosing of oral preexposure prophylaxis (PrEP) may provide equivalent coverage of sex events compared with daily dosing."	( Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Amico, KR; Anderson, PL; Chitwarakorn, A; Curlin, ME; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hirsch-Moverman, Y; Holtz, TH; Hughes, JP; Li, M; Loquere, A; Mannheimer, S; Marzinke, MA; McKinstry, L; McNicholl, JM; Piwowar-Manning, E; Rooney, JF; Stirratt, M; van Griensven, F, 2018)	0.48
"At-risk men and transgender women who have sex with men were randomly assigned to 1 of 3 dosing regimens: 1 tablet daily, 1 tablet twice weekly with a postsex dose (time-driven), or 1 tablet before and after sex (event-driven), and were followed for coverage of sex events with pre- and postsex dosing measured by weekly self-report, drug concentrations, and electronic drug monitoring."	( Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Amico, KR; Anderson, PL; Chitwarakorn, A; Curlin, ME; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hirsch-Moverman, Y; Holtz, TH; Hughes, JP; Li, M; Loquere, A; Mannheimer, S; Marzinke, MA; McKinstry, L; McNicholl, JM; Piwowar-Manning, E; Rooney, JF; Stirratt, M; van Griensven, F, 2018)	0.48
"Daily dosing recommendations increased coverage and protective drug concentrations in the Harlem cohort, while daily and nondaily regimens led to comparably favorable outcomes in Bangkok, where participants had higher levels of education and employment."	( Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Amico, KR; Anderson, PL; Chitwarakorn, A; Curlin, ME; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hirsch-Moverman, Y; Holtz, TH; Hughes, JP; Li, M; Loquere, A; Mannheimer, S; Marzinke, MA; McKinstry, L; McNicholl, JM; Piwowar-Manning, E; Rooney, JF; Stirratt, M; van Griensven, F, 2018)	0.48
" Four placebo-controlled randomized clinical trials have demonstrated that preexposure prophylaxis (PrEP) with daily dosing of TDF/emtricitabine significantly reduces HIV acquisition in men who have sex with men, high-risk heterosexuals, and injection drug users who share injection equipment."	( HIV Preexposure Prophylaxis: A Review. Amico, KR; Mayer, KH; Riddell, J, 2018)	0.69
" Offering a choice of dosing regimen to PrEP users may enable further personalization of HIV prevention strategies and enhance up-take, adherence and cost-effectiveness."	( Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. Achterbergh, RC; Davidovich, U; de Vries, HJ; Hogewoning, A; Hoornenborg, E; Prins, M; Sonder, GJ; van der Helm, JJ; van der Loeff, MFS; van Duijnhoven, YT, 2018)	0.48
" Intravaginal dosing with ARVs has shown to result in drug exposures in rectal tissues, thus raising the possibility of dual compartment protection."	( Efficacy of Vaginally Administered Gel Containing Emtricitabine and Tenofovir Against Repeated Rectal Simian Human Immunodeficiency Virus Exposures in Macaques. Dinh, C; Dobard, CW; Garcia-Lerma, G; Heneine, W; Khalil, G; Lipscomb, J; Makarova, N; Martin, A; Mitchell, J; Taylor, A; West-Deadwyler, R, 2018)	0.73
"The goal of this work was to evaluate dosing strategies for tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) with injection drug use with a pharmacokinetic/pharmacodynamics analysis of concentration data generated from two single-dose clinical studies conducted in healthy women."	( A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N, 2018)	0.69
"We assessed tenofovir hair concentrations in HIV-uninfected volunteers randomized to receive 100%, 67%, or 33% of daily dosing of TDF/FTC for 12 weeks (DOT-DBS, NCT02022657)."	( Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring. Anderson, PL; Bacchetti, P; Castillo-Mancilla, J; Gandhi, M; Koss, CA; Kuncze, K; Liu, AY; Louie, A; MaWhinney, S; McHugh, C; Morrow, M; Okochi, H; Seifert, S, 2018)	0.69
"Intravaginal rings (IVRs) for HIV pre-exposure prophylaxis (PrEP) theoretically overcome some adherence concerns associated with frequent dosing that can occur with oral or vaginal film/gel regimens."	( Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F, 2018)	0.48
" IM SMC concentrations were low relative to PBMC, as were EN concentrations, suggesting differences in cell phenotype and lineage in the MGT; these differences in phenotype and pharmacology may have an impact on selecting and dosing ARVs used in cure strategies."	( Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. Blake, KH; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Kashuba, ADM; Maas, BM; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C, 2019)	0.51
" At baseline (pre-switch) and at 12 weeks post-switch, we measured HIV-1 RNA in seminal plasma (SP) and blood plasma (BP), tenofovir (TFV) in SP and BP, and TFV-diphosphate (dp) in peripheral blood mononuclear cells (PBMCs) and seminal mononuclear cells (SMCs) at the end of the dosing interval (C24h)."	( Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40). Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM, 2019)	0.51
"HPTN 067 assessed the feasibility of daily and non-daily dosing of open-label emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)-based pre-exposure prophylaxis (PrEP)."	( Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. Amico, KR; Franks, J; Grant, RM; Hirsch-Moverman, Y; Hughes, JP; Li, M; Loquere, A; Mannheimer, S, 2019)	0.74
"Factors associated with sex-related PrEP adherence were assessed among men who have sex with men (MSM) randomized to one of 3 PrEP dosing arms in HPTN 067 in New York City."	( Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. Amico, KR; Franks, J; Grant, RM; Hirsch-Moverman, Y; Hughes, JP; Li, M; Loquere, A; Mannheimer, S, 2019)	0.51
" In the multivariable analyses, higher sex-related PrEP adherence was significantly associated with daily dosing arm, older age, employment, and higher PrEP adherence behavioral skills."	( Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. Amico, KR; Franks, J; Grant, RM; Hirsch-Moverman, Y; Hughes, JP; Li, M; Loquere, A; Mannheimer, S, 2019)	0.51
" Lifelong antiretroviral (ARV) drug combination dosing allows management as a chronic condition by suppressing circulating viral load to allow for a near-normal life; however, the daily burden of oral administration may lead to non-adherence and drug resistance development."	( Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Al-Khouja, A; Curley, P; Flexner, C; Hobson, JJ; Meyers, CF; Meyers, D; Owen, A; Rannard, SP; Siccardi, M, 2019)	0.51
"The USPSTF reviewed the evidence on the benefits of PrEP for the prevention of HIV infection with oral tenofovir disoproxil fumarate monotherapy or combined tenofovir disoproxil fumarate and emtricitabine and whether the benefits vary by risk group, population subgroup, or regimen or dosing strategy; the diagnostic accuracy of risk assessment tools to identify persons at high risk of HIV acquisition; the rates of adherence to PrEP in primary care settings; the association between adherence and effectiveness of PrEP; and the harms of PrEP when used for HIV prevention."	( Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. Barry, MJ; Cabana, M; Caughey, AB; Curry, SJ; Davidson, KW; Doubeni, CA; Epling, JW; Krist, AH; Kubik, M; Landefeld, CS; Mangione, CM; Owens, DK; Pbert, L; Silverstein, M; Simon, MA; Tseng, CW; Wong, JB, 2019)	0.7
" On-demand (2-1-1 dosing strategy for MSM) and injectable PrEP appear to be acceptable among participants in clinical trials."	( Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals. Beymer, MR; Holloway, IW; Landovitz, RJ; Pulsipher, C, 2019)	0.51
" Participants were randomized to receive controlled TDF/FTC dosing as (1) "perfect" adherence (daily); (2) "moderate" adherence (4 doses/week); or (3) "low" adherence (2 doses/week)."	( Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). Bacchetti, P; Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Punyati, P; Quame-Amaglo, J; Siriprakaisil, O; Sirirungsi, W; Sukrakanchana, PO; Tanasri, S, 2020)	0.56
"High urine FTC and TFV concentrations could provide an indication of adherence to daily oral dosing with TDF or TAF-based regimens used for treatment and prevention."	( Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men. Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A, 2019)	0.84
"The CROPrEP project, a real-world study of PrEP use, will recruit 1000 high-risk HIV-negative MSM participants from four cities in China, who will be able to choose between daily or event-driven dosing regimens, according to their preference."	( Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP). Chu, Z; Ding, H; Geng, W; Jia, Y; Jiang, Y; Leuba, SI; Mei, Z; Shang, H; Wang, H; Xu, J; Zhang, J; Zhang, Y, 2019)	0.51
" The goals of this study were to build maternal-fetal physiologically based pharmacokinetic (PBPK) models for acyclovir and emtricitabine, 2 anti(retro)viral drugs with active renal net secretion, and to (1) evaluate the predicted maternal PK at different stages of pregnancy; (2) predict the changes in PK target parameters following the current dosing regimen of these drugs throughout pregnancy; (3) evaluate the predicted concentrations of these drugs in the umbilical vein at delivery; (4) compare the model performance for predicting maternal PK of emtricitabine in the third trimester with that of previously published PBPK models; and (5) compare different previously published approaches for estimating the placental permeability of these 2 drugs."	( Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir. Best, BM; Burckart, GJ; Capparelli, EV; Dallmann, A; Green, DJ; Liu, XI; Mirochnick, M; Momper, JD; Rakhmanina, N; van den Anker, JN, 2020)	0.98
"Participants were randomly assigned to one of three self-administered dosing regimens for 24 weeks: daily, time-driven, or event-driven."	( HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013. Amico, KR; Chitwarakorn, A; Curlin, ME; Grant, RM; Holtz, TH; Hughes, JP; Li, M; Mock, PA; Varangrat, A, 2019)	0.51
" Regardless of these factors, Thai MSM and TGW maintained high adherence levels to oral PrEP dosing regimens and coverage of sexual exposures."	( HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013. Amico, KR; Chitwarakorn, A; Curlin, ME; Grant, RM; Holtz, TH; Hughes, JP; Li, M; Mock, PA; Varangrat, A, 2019)	0.51
" This study predicted the pharmacokinetics (PK) of three renally excreted antiretroviral drugs in the elderly population and compared them with known exposures in renal impairment, to evaluate the need for dosing adjustments."	( Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Chetty, M; De Sousa Mendes, M, 2019)	0.51
" The majority of virtual patients had exposures that did not require dosage adjustments."	( Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Chetty, M; De Sousa Mendes, M, 2019)	0.51
"Comparison of the exposure in the elderly with exposure observed in patients with different levels of renal impairment, indicated that a dosage adjustment may not be required in elderly patients on lamivudine, emtricitabine and the majority of the patients on tenofovir."	( Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Chetty, M; De Sousa Mendes, M, 2019)	0.7
" We found that standard dosing strategies in preclinical species closely mimicked tissue concentrations in humans for some, but not all, ARVs."	( Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs. Adamson, L; Akkina, R; Blake, K; Burgunder, EM; Devanathan, AS; Garcia, JV; Kashuba, ADM; Kovarova, M; Luciw, P; Pirone, JR; Remling-Mulder, L; Rosen, EP; Schauer, AP; Srinivas, N; Sykes, C; White, NR, 2019)	0.51
" Pericoital PrEP dosing seems to be effective in preventing HIV transmission among men who have sex with men, but has not been evaluated in women."	( PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention. Allan-Blitz, LT; Mayer, KH, 2019)	0.51
"PrEP has been shown to be safe and effective when used consistently, but new approaches to enhance uptake, adherence, and convenience with less-frequent dosing are under study, suggesting that new models and modalities will evolve to optimize impact."	( PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention. Allan-Blitz, LT; Mayer, KH, 2019)	0.51
" With the assistance of therapeutic drug monitoring, dolutegravir dosing was increased to 150 mg daily."	( Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV. Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T, 2020)	0.56
" In this perspective, we summarize data related to on-demand PrEP, describe advantages and disadvantages for this alternative dosing strategy, and provide clinical counseling points."	( On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know. Saberi, P; Scott, HM, 2020)	0.81
" Beside the analytical profile, the degradation and stability of Emtricitabine, its pharmacology and pharmacokinetics, Pharmaceutical Applications, Mechanism of Action, dosage forms and dose, ADME profile, and interactions have been debated."	( Emtricitabine. Abdelhameed, AS; Al-Kahtani, HM; Al-Majed, AA; Al-Qahtani, BM; Bakheit, AHH, 2020)	2.24
" Recent dosing measures include antiretroviral levels in plasma or urine, as well as emtricitabine-triphosphate in dried blood spots (DBS) for those on tenofovir-emtricitabine-based therapy."	( Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. Anderson, PL; Castillo-Mancilla, J; Chai, PR; Gandhi, M; Haberer, JE; Spinelli, MA, 2020)	0.78
"\ Conclusions: The patients were generally satisfied with the change in medication and well nformed about the dosage and advantages of TAF over TDF, but less well informed about the possible adverse effects of TAF."	( Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine Bermejo-Vicedo, T; Gramage-Caro, T; Montero-Llorente, B; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M, 2020)	0.76
"TAF-DBS was a randomized, crossover clinical study of TFV-DP in DBS, following directly observed dosing of 33%, 67%, or 100% of daily TAF (25 mg)/FTC (200 mg)."	( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020)	0.83
" Together, these moieties provide complementary measures of cumulative adherence and recent dosing for TAF/FTC."	( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020)	0.83
" Plasma and urine samples were collected regularly during the 6-week dosing phase and for 4 weeks following drug cessation."	( Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Quame-Amaglo, J; Siriprakaisil, O; Sukrakanchana, PO; Tawon, Y, 2020)	0.56
" Participants in the intervention arm will be provided with remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP users every half an hour when a scheduled dosage is missed, and followed with just-in-time SMS medication reminders to clinicians half an hour when there is no supplement after the second just-in-time SMS reminder to PrEP users."	( Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol. Bao, R; Chen, Y; Chu, Z; Ding, H; Geng, W; He, X; Hu, Q; Hu, Z; Huang, X; Jiang, Y; Jin, X; Li, H; Li, S; Lv, W; Shang, H; Wang, H; Xu, J; Zhang, J; Zhang, L, 2020)	0.56
" The agents were vaginally dosed individually and in combination, and the efficacy of HIV-1 prevention was analyzed using the established, rigorous median-effect model."	( Highly synergistic drug combination prevents vaginal HIV infection in humanized mice. Baum, MM; Bobardt, M; Gallay, PA; Gunawardana, M; Moss, JA; Ramirez, CM, 2020)	0.56
"TGM and TGW on at least 6 months of stable sex hormone therapy containing testosterone or estradiol (respectively) were enrolled in a 4-week study of directly observed dosing of daily oral coformulated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF)."	( Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. Anderson, PL; Bhasin, S; Defechereux, PA; Deutsch, MB; Glidden, DV; Grant, RM; O'Neal, J; Pellegrini, M; Sevelius, J; Yager, J; Yu, M, 2021)	0.81
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."	( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)	0.72
" Glans swab emtricitabine and darunavir concentrations peaked 24 h after dosing (emtricitabine 14 ng/swab,	( Antiretroviral drug exposure in urethral and glans surface sampling of the penis. Conway-Washington, C; Dinh, C; Fountain, J; Garcia-Lerma, JG; Haaland, RE; Hall, L; Heneine, W; Kelley, CF; Lupo, LD; Martin, A, 2021)	1
"We document ARV dosing in the urethra and on the glans surface with high drug concentrations noted for emtricitabine and darunavir and lower tenofovir and elvitegravir concentrations."	( Antiretroviral drug exposure in urethral and glans surface sampling of the penis. Conway-Washington, C; Dinh, C; Fountain, J; Garcia-Lerma, JG; Haaland, RE; Hall, L; Heneine, W; Kelley, CF; Lupo, LD; Martin, A, 2021)	0.84
" Several studies have shown short but potent intermittent PrEP could provide comparable protection to daily PrEP in men, suggesting such dosing strategy might be useful in Chinese as well."	( Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China. Alnajebi, B; Huang, A; Ma, Q; Shang, J; Tan, R; Yan, B; Yang, J; Zhang, Y; Zhong, X, 2021)	0.62
"An open label study in 40 Chinese healthy volunteers, randomized to receive the WHO-recommended dose of tenofovir (300mg) at four different dosing intervals: twice weekly for 4 weeks; once daily for 4 weeks with one missing dose in weeks 2-4; once daily for 4 weeks with two missing doses in weeks 2-4; and once every other day for 12 days."	( Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China. Alnajebi, B; Huang, A; Ma, Q; Shang, J; Tan, R; Yan, B; Yang, J; Zhang, Y; Zhong, X, 2021)	0.62
" The trough concentrations (24h dosing interval) at the steady state were 51."	( Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China. Alnajebi, B; Huang, A; Ma, Q; Shang, J; Tan, R; Yan, B; Yang, J; Zhang, Y; Zhong, X, 2021)	0.62
" No studies have yet compared TFV-DP in PBMC from lower than daily dosing between prodrugs, which has potential implications for event-driven preexposure prophylaxis and pharmacologic forgiveness."	( Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, M; Kiser, JJ; MaWhinney, S; Morrow, M; Nemkov, C; Peterson, S; Yager, JL, 2021)	0.84
"HIV-negative adults were randomized to two 12-week DOT regimens of 33, 67 or 100% of daily dosing with emtricitabine (F)/TAF 200 mg/25 mg (TAF-DBS) or F/TDF 200 mg/300 mg (DOT-DBS), separated by a 12-week washout."	( Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, M; Kiser, JJ; MaWhinney, S; Morrow, M; Nemkov, C; Peterson, S; Yager, JL, 2021)	1.05
" Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) has been the flagship PrEP regimen, and data support a pericoital/on-demand "2-1-1" dosing schedule for men who have sex with men."	( Challenges and Opportunities for Preexposure Prophylaxis. Cambou, MC; Landovitz, RJ, )	0.4
" There are only 200 mg and 600 mg dosage forms of EFV in China."	( Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study. Han, J; Li, B; Liu, Y; Xiao, J; Zhang, L; Zhao, H, 2022)	0.72
" Final models were subjected to Monte Carlo simulations to compare drug exposure following once daily and on-demand (IPERGAY 2 + 1 + 1) dosing of F/TDF."	( Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. Bakshi, RP; Chaturvedula, A; Fuchs, EJ; Hendrix, CW; Marzinke, MA; Shieh, E; Tanaudommongkon, A, 2022)	0.99
" Simulations demonstrated that at least 2, weekly 2 + 1 + 1 cycles of on-demand dosing in TGW on GAHT is necessary for TFV-diphosphate to reach similar exposure after the initial week of on-demand dosing in CGM not on GAHT."	( Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. Bakshi, RP; Chaturvedula, A; Fuchs, EJ; Hendrix, CW; Marzinke, MA; Shieh, E; Tanaudommongkon, A, 2022)	0.99
"Daily dosing of tenofovir disoproxil fumarate, with or without emtricitabine, has high efficacy in preventing human immunodeficiency virus (HIV) infection when individuals are adherent."	( Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. Anderson, P; Baeten, JM; Celum, CL; Choopanya, K; Garcia-Cremades, M; Glidden, DV; Grant, R; Hendrix, CW; Jarlsberg, L; Jayachandran, P; Marrazzo, J; Martin, M; Savic, RM; Vanichseni, S; Vučićević, K, 2022)	0.96
" Dosing simulations indicated that high-risk women require full adherence to maintain protective levels."	( Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. Anderson, P; Baeten, JM; Celum, CL; Choopanya, K; Garcia-Cremades, M; Glidden, DV; Grant, R; Hendrix, CW; Jarlsberg, L; Jayachandran, P; Marrazzo, J; Martin, M; Savic, RM; Vanichseni, S; Vučićević, K, 2022)	0.72
" PrEP could be prescribed as a daily regimen with one pill per day or, in men who have sex with men (MSM) or in transgender women who have sex with men, as an on-demand regimen following the IPERGAY dosing recommendation."	( Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Algarte-Genin, M; Assoumou, L; Ben-Mechlia, M; Beniguel, L; Costagliola, D; Delaugerre, C; Ghosn, J; Goldwirt, L; Katlama, C; Le Mestre, S; Liegeon, G; Lourenco, J; Loze, B; Molina, JM; Mouhim, H; Ohayon, M; Pavie, J; Pialoux, G; Rojas-Castro, D; Slama, L; Spire, B; Surgers, L, 2022)	0.97
" At enrolment, 1540 (50·5%) of 3049 participants opted for daily PrEP dosing and 1509 (49·5%) opted for on-demand PrEP dosing; these proportions remained stable during follow-up."	( Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Algarte-Genin, M; Assoumou, L; Ben-Mechlia, M; Beniguel, L; Costagliola, D; Delaugerre, C; Ghosn, J; Goldwirt, L; Katlama, C; Le Mestre, S; Liegeon, G; Lourenco, J; Loze, B; Molina, JM; Mouhim, H; Ohayon, M; Pavie, J; Pialoux, G; Rojas-Castro, D; Slama, L; Spire, B; Surgers, L, 2022)	0.97
"To assess the impact on the estimated glomerular filtration rate (eGFR) of different tenofovir disoproxil/emtricitabine dosing regimens for HIV pre-exposure prophylaxis (PrEP)."	( Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study. Assoumou, L; Beniguel, L; Costagliola, D; Duvivier, C; El Mouhebb, M; Genin, M; Ghosn, J; Goldwirt, L; Liegeon, G; Molina, JM; Palacios, C; Palich, R; Rojas Castro, D; Slama, L; Surgers, L, 2022)	0.93
"On-demand PrEP dosing had a smaller impact on eGFR evolution than daily PrEP, but the difference was not clinically relevant."	( Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study. Assoumou, L; Beniguel, L; Costagliola, D; Duvivier, C; El Mouhebb, M; Genin, M; Ghosn, J; Goldwirt, L; Liegeon, G; Molina, JM; Palacios, C; Palich, R; Rojas Castro, D; Slama, L; Surgers, L, 2022)	0.72
" The availability of long-acting injectable PrEP that does not require daily dosing has the potential to improve uptake and adherence, particularly in high-risk individuals."	( Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis. Blair, HA, 2022)	0.72
" Due to binding interactions between polyvalent cations and bictegravir and the potential impact on antiretroviral efficacy, construction of a daily medication schedule to avoid interactions between the antiretroviral regimen and the supplements while promoting optimal dosing of each supplement was necessary; however there is currently no guidance on twice-daily cation dosing with coadministered bictegravir and limited guidance on multivitamin coadministration in this context."	( Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature. Buscemi, L; Mossholder, B, 2023)	0.91
" To better understand INSTI distribution and inform dosing selection we compared the pharmacology of two-dose boosted elvitegravir and unboosted bictegravir regimens in MSM."	( Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men. Conway-Washington, C; Dinh, C; Edwards, TE; Fountain, J; García-Lerma, JG; Haaland, RE; Hall, L; Heneine, WM; Holder, A; Kelley, CF; Lupo, LD; Martin, A; Massud, I, 2023)	0.91
"Mean bictegravir plasma concentrations remained above the 95% protein-adjusted effective concentration 96 h after dosing [273 (95% CI: 164-456) ng/mL] whereas elvitegravir plasma concentrations became undetectable 48 h after the second dose."	( Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men. Conway-Washington, C; Dinh, C; Edwards, TE; Fountain, J; García-Lerma, JG; Haaland, RE; Hall, L; Heneine, WM; Holder, A; Kelley, CF; Lupo, LD; Martin, A; Massud, I, 2023)	0.91
" Differing elvitegravir and bictegravir distribution may result in variable mucosal and systemic antiviral activity and can inform dosing strategies for event-driven HIV prevention."	( Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men. Conway-Washington, C; Dinh, C; Edwards, TE; Fountain, J; García-Lerma, JG; Haaland, RE; Hall, L; Heneine, WM; Holder, A; Kelley, CF; Lupo, LD; Martin, A; Massud, I, 2023)	0.91
"Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV."	( Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Baeten, JM; Benson, P; Berhe, M; Crofoot, G; Dvory-Sobol, H; Gupta, SK; Koenig, E; Liu, SY; McDonald, C; Ramgopal, M; Rhee, MS; Ruane, P; Sanchez, WE; Scribner, A; Sims, J; VanderVeen, LA, 2023)	0.91
"Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered."	( Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y, 2023)	0.91
" New non-vaccine biomedical products aimed at overcoming this global health challenge need to provide a range of safe, effective, and discreet dosage forms based on the delivery of one or more antiviral compounds."	( Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice. Baum, MM; Gallay, PA; Ramirez, CM, 2023)	0.91
" Due to the long dosing interval (8 weeks), long-acting cabotegravir has low compliance requirements for people at high risk of HIV infection."	( Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis. Chen, X; Kou, L; Li, J; Li, Y; Wei, D; Xie, X, 2023)	1.13
"As topical pre-exposure prophylaxis (PrEP) has been shown to cause immune modulation in rectal or cervical tissue, our aim was to examine the impact of oral PrEP on lymphoid and myeloid changes in the foreskin in response to dosing and timing of drug administration."	( A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin. Alinde, B; Besethi, A; Chiodi, F; Else, L; Fox, J; Gray, CM; Herrera, C; Kaleebu, P; Khoo, S; Leach, L; Lebina, L; Malhangu, B; Martinson, N; Mbangiwa, T; Motaung, B; Mugaba, S; Namubiru, P; Odoch, G; Opoka, D; Petkov, S; Pillay, AAP; Rametse, CL; Sebaa, S; Seiphetlo, TB; Serwanga, J; Ssemata, AS; Webb, EL, 2023)	0.91
" Daily emtricitabine/TAF was dosed according to World Health Organization (WHO)-recommended weight bands: 120/15 mg in children weighing 14 to <25 kg and 200/25 mg in those weighing ≥25 kg."	( First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L, 2023)	1.37
"In children, TAF combined with boosted PIs or dolutegravir and dosed according to WHO-recommended weight bands provides TAF and tenofovir concentrations previously demonstrated to be well tolerated and effective in adults."	( First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L, 2023)	0.91
"The efficacy of on-demand HIV pre-exposure prophylaxis (PrEP) for men in sub-Saharan Africa has not been evaluated, and the on-demand PrEP dosing requirement for insertive sex remains unknown."	( Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial. Alieu, A; Alinde, B; Callebaut, C; Chiodi, F; Else, L; Fox, J; Gray, CM; Herrera, C; Kaleebu, P; Khoo, S; Limakatso, L; Martinson, N; Mugaba, S; Muhumuza, R; Namubiru, P; O'Hagan, K; Odoch, G; Opoka, D; Penchala, SD; Petkov, S; Pillay, AD; Seatlholo, P; Seeley, J; Seiphetlo, TB; Serwanga, J; Ssemata, AS; Webb, EL; Weiss, H, 2023)	0.91
"Cabotegravir plus rilpivirine is the only approved complete long-acting regimen for the maintenance of HIV-1 virological suppression dosed every 2 months."	( Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F, 2023)	1.11
" Participants with HIV-1 RNA less than 50 copies per mL were randomly assigned (2:1), stratified by sex at birth and BMI, to either long-acting cabotegravir (600 mg) plus rilpivirine (900 mg) dosed intramuscularly every 2 months or to continue daily oral bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg)."	( Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F, 2023)	1.29
"These data support the use of long-acting cabotegravir plus rilpivirine dosed every 2 months as a complete antiretroviral regimen that has similar efficacy to a commonly used integrase strand transfer inhibitor-based first-line regimen, while addressing unmet psychosocial issues associated with daily oral treatment."	( Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F, 2023)	1.11
" Serum oestradiol concentrations were measured prior to medication dosing and 2, 4, 6 and 8 h post-dose."	( Oestradiol concentrations in trans women with HIV suppressed on unboosted integrase inhibitor regimens versus trans women without HIV taking oral oestradiol: a pilot study. Armstrong, I; Bourns, A; Chan, LYL; Fung, R; Halpenny, R; Hranilovic, S; Iyer, H; Jeyarajah, N; Kennedy, VL; Kia, H; Kovchazov, G; Lacombe-Duncan, A; Loutfy, M; McCully, J; Nguyen, Q; Persad, Y; Scarsi, KK; Tseng, A; Underhill, A; Weisdorf, T, 2023)	0.91
" Regimen Optimization in the setting of HIV suppression may reduce pill burden, and/or dosing frequency, enhance tolerability and/or decrease toxicity, prevent or mitigate DDIs, eliminate food/fluid requirements, relieve pill fatigue, decrease stigma or concerns associated with taking oral med, allow pregnancy, reduce costs (DHHS 2023)."	( Optimizing Antiretroviral Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in virologically suppressed PLWH. Andreoni, M, 2023)	1.16
" Studies in macaques found that shorter courses of PEP with INSTIs were effective, particularly if dosing occurred close to the time of retroviral exposure."	( Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions. Allan-Blitz, LT; Mayer, KH, 2023)	0.91

Role	Description
antiviral drug	A substance used in the prophylaxis or therapy of virus diseases.
HIV-1 reverse transcriptase inhibitor	An entity which inhibits the activity of HIV-1 reverse transcriptase.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pyrimidone	A pyrimidine carrying one or more oxo substituents.
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
monothioacetal	A thioacetal having the structure R2C(OR')(SR'). The term includes monothioketals, R =/= H, as a subclass.
nucleoside analogue	An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	21.1360	0.0008	11.3822	44.6684	AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Albumin	Homo sapiens (human)	Kd	44.0000	0.0893	3.3135	8.0000	AID1238542
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cellular response to starvation	Albumin	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Albumin	Homo sapiens (human)
cellular response to calcium ion starvation	Albumin	Homo sapiens (human)
cellular oxidant detoxification	Albumin	Homo sapiens (human)
transport	Albumin	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
oxygen binding	Albumin	Homo sapiens (human)
DNA binding	Albumin	Homo sapiens (human)
fatty acid binding	Albumin	Homo sapiens (human)
copper ion binding	Albumin	Homo sapiens (human)
protein binding	Albumin	Homo sapiens (human)
toxic substance binding	Albumin	Homo sapiens (human)
antioxidant activity	Albumin	Homo sapiens (human)
pyridoxal phosphate binding	Albumin	Homo sapiens (human)
identical protein binding	Albumin	Homo sapiens (human)
protein-folding chaperone binding	Albumin	Homo sapiens (human)
exogenous protein binding	Albumin	Homo sapiens (human)
enterobactin binding	Albumin	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Albumin	Homo sapiens (human)
extracellular space	Albumin	Homo sapiens (human)
nucleus	Albumin	Homo sapiens (human)
endoplasmic reticulum	Albumin	Homo sapiens (human)
endoplasmic reticulum lumen	Albumin	Homo sapiens (human)
Golgi apparatus	Albumin	Homo sapiens (human)
platelet alpha granule lumen	Albumin	Homo sapiens (human)
extracellular exosome	Albumin	Homo sapiens (human)
blood microparticle	Albumin	Homo sapiens (human)
protein-containing complex	Albumin	Homo sapiens (human)
cytoplasm	Albumin	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID404908	Cytotoxicity against human HL60 cells after 3 days by MTT assay	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.
AID541132	Selectivity ratio of EC50 for antiviral activity against NNRTI-resistant HIV1 harboring RTK103N mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID548585	Antiviral activity against HIV1 isolate 162 harboring reverse transcriptase A62V/V75I/F77L/Y115F/F116Y/Q151M/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548580	Antiviral activity against HIV1 isolate 070 harboring reverse transcriptase 65R/S68G mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548840	Antiviral activity against HIV1 isolate 217 harboring reverse transcriptase D67N/K70E/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID582411	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 41 +/- 25 %)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID548821	Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1298355	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level measured at 6 to 72 hrs post infection by qPCR method	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID422691	Ratio of IC50 for HIV1 with reverse transcriptase K70E/M184V mutation to IC50 for wild type HIV1	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID582405	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 979 pg)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID217731	Cytotoxicity was determined in the vero cells infected with HIV-I	1993	Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2	Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents.
AID541130	Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RTM184V mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID404912	Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.
AID369218	Antiviral activity against woodchuck hepatitis virus infected woodchucks assessed as log reduction of serum viral DNA per ml of serum after 4 weeks	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.
AID556527	Antiviral activity against Human immunodeficiency virus 1 clone 14682 harboring 122E, 135V, Q145V, 200A mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID154956	Anti-HIV-1 activity against human peripheral blood mononuclear (PBM) cells infected with HIV-1 strain LAV	1993	Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2	Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents.
AID541169	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541163	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92Q mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID548808	Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID46361	In vitro concentration required to decrease 50% of mitochondrial DNA content in CEM cells	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID548813	Antiviral activity against HIV1 isolate 060 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1447284	Cytotoxicity against human P4R5 MAGI cells after 2 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9	Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.
AID582431	Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver alkaline phosphatase activity at 15 mg/kg, po qd for 48 weeks	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID548802	Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID572768	Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID548832	Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582429	Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver alanine aminotransferase activity at 15 mg/kg, po qd for 48 weeks	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID541109	Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID147705	Inhibition of Newcastles disease virus replication by 50% (no effect at this concentration)	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
AID1238542	Binding affinity to human serum albumin with excitation at 280 nm after 2 hrs by spectrofluorimetric analysis	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
AID548826	Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID541174	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V, G140S and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID423280	Antiviral activity against multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID582409	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 27 pg)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1447282	Inhibition of HIV1 3B dinucleoside reverse transcriptase infected in human P4R5 MAGI cells assessed as reduction in viral infection after 2 hrs by Galacto-Star beta-galactosidase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9	Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.
AID582417	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in portal hepatitis at 15 mg/kg, po qd for 48 weeks	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582396	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 1495 +/- 890 pg)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582424	Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as effect on hematological parameters at 15 mg/kg, po qd for 48 weeks measured up to 60 weeks	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID541168	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1447283	Inhibition of HIV1 BaL dinucleoside reverse transcriptase infected in human P4R5 MAGI cells assessed as reduction in viral infection after 2 hrs by Galacto-Star beta-galactosidase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9	Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.
AID664467	Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay	2012	Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6	Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1652587	Antiviral activity against HIV2 ROD infected in human TK-deficient CEM/TK(-) cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy
AID541129	Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RTK65R mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID548587	Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548581	Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID423158	Antiviral activity against wild type HIV2 ROD produced from full length pROD9 infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID548809	Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582426	Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver alanine aminotransferase activity at 15 mg/kg, po qd measured on 4 to 24 weeks on 48 week study	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID548820	Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1587128	Half-life in human serum administered once daily	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	A Survey of the Structures of US FDA Approved Combination Drugs.
AID548574	Antiviral activity against HIV1 isolate 060 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219E mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID664466	Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay	2012	Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6	Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors.
AID422692	Ratio of IC50 for HIV1 with reverse transcriptase K70G/M184V mutation to IC50 for wild type HIV1	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID541135	Selectivity ratio of EC50 for antiviral activity against PI-resistant HIV1 harboring RTG48V, V82A and L90M mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541131	Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RT-6TAMs mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1780695	Therapeutic index, ratio of CC50 for human CEM-GXR cells infected with wild type HIV1 NL4-3 to EC50 for wild type HIV1 NL4-3 infected in human CEM-GXR cells
AID3033	Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID548800	Antiviral activity against HIV1 isolate 192 harboring reverse transcriptase M41L/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548817	Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548816	Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548584	Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID328843	Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID1780689	Cytotoxicity against human CEM-GXR cells infected with wild type HIV1 NL4-3 assessed as cell viability measured after 72 hrs by Flow cytometry assay
AID548824	Antiviral activity against HIV1 isolate 162 harboring reverse transcriptase A62V/V75I/F77L/Y115F/F116Y/Q151M/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548807	Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548835	Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID404909	Cytotoxicity against human HepG2 cells after 3 days by MTT assay	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.
AID1587129	Oral bioavailability in human administered once daily	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	A Survey of the Structures of US FDA Approved Combination Drugs.
AID86846	Inhibition of Duck HBV replication by 50% (no effect at this concentration)	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
AID548803	Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548837	Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548841	Antiviral activity against HIV1 isolate 220 harboring reverse transcriptase K70E/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID572767	Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID423283	Selectivity ratio of EC50 for wild type HIV2 ROD to EC50 for wild type HIV1 NL4-3 M184V variant	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID541134	Selectivity ratio of EC50 for antiviral activity against PI-resistant HIV1 harboring RTI84V, L90M mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID548819	Antiviral activity against HIV1 isolate 070 harboring reverse transcriptase 65R/S68G mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548579	Antiviral activity against HIV1 isolate 069 harboring reverse transcriptase D67E/T69SSG/V75M/M184V/L210W/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID328844	Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID548825	Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582398	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd for 48 weeks measured on 60th week	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582427	Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver sorbitol dehydrogenase activity at 15 mg/kg, po qd measured on 28 to 48 weeks on 48 week study	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID548586	Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID422693	Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by antivirogram biological cutoffs assay relative to wild type HIV1	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID548827	Antiviral activity against HIV1 isolate 180 harboring reverse transcriptase K65R mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID541166	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID422694	Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by vircotype clinical cutoffs assay relative to wild type HIV1	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID328845	Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548811	Antiviral activity against HIV1 isolate 220 harboring reverse transcriptase K70E/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1652586	Antiviral activity against HIV2 ROD infected in human CEM/0 cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy
AID548573	Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID556525	Antiviral activity against Human immunodeficiency virus 1 clone 38086 harboring K49R, V60I, I135V, Q145M, Q174H, G196E, Q207E, R211K, V245K mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID1780701	Cytotoxicity against human PBMC cells assessed as cell viability measured after 11 days by Viacount assay
AID548839	Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548833	Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582428	Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of serum gamma-glutamyltransferase activity at 15 mg/kg, po qd for 48 weeks	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582399	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in portal hepatitis at 15 mg/kg, po qd measured on 12th week on 48 weeks study	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID423281	Selectivity ratio of EC50 for multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase to EC50 for wild type HIV1 NL4-3	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID86856	Inhibition of Woodchuck HBV replication by 50% (no effect at this concentration)	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
AID1652588	Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days
AID582414	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd measured on 36th week on 48 weeks study	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID548798	Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548577	Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID152644	Cytotoxicity against human peripheral blood mononuclear (PBM) cells infected with HIV-I	1993	Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2	Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents.
AID1298361	Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level measured at 6 to 72 hrs post infection by qPCR method	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID86024	Inhibition of HSV-1 replication by 50% (no effect at this concentration)	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
AID1780683	Antiviral activity against wild type HIV1 NL4-3 infected in human CEM-GXR cells assessed as inhibition of viral replication measured after 3 days by Flowcytometry assay
AID582403	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 3.3 +/- 1.6 log10 ng/ml)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID216378	Inhibition of Vesicular stomatis virus replication by 50% (no effect at this concentration)	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
AID548571	Antiviral activity against HIV1 isolate 056 expressing wild type reverse transcriptase gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548818	Antiviral activity against HIV1 isolate 069 harboring reverse transcriptase D67E/T69SSG/V75M/M184V/L210W/T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID556524	Antiviral activity against Human immunodeficiency virus 1 clone pNL4-3-Q145M harboring K102Q, Q145M, S162C, K277R, I293V mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID328842	Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID582404	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks (Rvb = 995 +/- 736 pg)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID548836	Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID572769	Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID548799	Antiviral activity against HIV1 isolate 188 harboring reverse transcriptase T215Y/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID541162	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID582397	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd measured on 12th week on 48 weeks study	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID86358	Inhibition of hepatitis B virus replication in the HepAD38 cell line.	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID541175	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S and Q148H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID81419	Inhibition of HIV-1 replication by 50% (no effect at this concentration)	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
AID582423	Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as change in body weight at 15 mg/kg, po qd for 48 weeks measured up to 60 weeks	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID582395	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 1132 +/- 738 pg)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582425	Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver sorbitol dehydrogenase activity at 15 mg/kg, po qd measured on 4 to 24 weeks on 48 week study	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID548572	Antiviral activity against HIV1 isolate 057 expressing wild type reverse transcriptase gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID548583	Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548823	Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582402	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd for 48 weeks (Rvb = 3.8 +/- 1.3 log10 ng/ml)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1290154	Antiviral activity against subtype B X4 tropic HIV1 3B infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	A Parallel Synthesis Approach to the Identification of Novel Diheteroarylamide-Based Compounds Blocking HIV Replication: Potential Inhibitors of HIV-1 Pre-mRNA Alternative Splicing.
AID541173	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K and Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID588997	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MPR3	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID588996	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MRP2	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID548831	Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID46362	In vitro concentration required to inhibit 50% of CEM cell growth	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID548806	Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582430	Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver aspartate aminotransferase activity at 15 mg/kg, po qd for 48 weeks	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1780702	Anti-HIV activity against HIV1 Bal infected in human PBMC assessed as inhibition of viral infection measured after 11 days by ELISA method
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID548578	Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582400	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 4.3 +/- 1.5 log10 ng/ml)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID328846	Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID548805	Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID106908	Concentration required to inhibit 50% of HIV activity in MT-2 cells	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID548838	Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548575	Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID423157	Antiviral activity against wild type HIV1 NL4-3 produced from full length pR9deltaApa infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID3034	Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID423282	Selectivity ratio of EC50 for wild type HIV2 ROD to EC50 for wild type HIV1 NL4-3	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID548812	Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID582401	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 3.8 +/- 1.3 log10 ng/ml)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582413	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 26 %)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID548830	Antiviral activity against HIV1 isolate 192 harboring reverse transcriptase M41L/T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548814	Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582408	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks (Rvb = 34 +/- 20 pg)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1780703	Anti-HIV activity against HIV1 3B infected in human PBMC assessed as inhibition of viral infection measured after 11 days by ELISA method
AID548582	Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID541133	Selectivity ratio of EC50 for antiviral activity against NNRTI-resistant HIV1 harboring RTY181C mutant gene to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541170	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID548576	Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582415	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd for 48 weeks	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID548588	Antiviral activity against HIV1 isolate 180 harboring reverse transcriptase K65R mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID556526	Antiviral activity against Human immunodeficiency virus 1 clone Q9016 harboring K122E, Q145M, I202V, F214L mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID548815	Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1780690	Cytotoxicity against human CEM-GXR cells infected with wild type HIV1 97USSN54 assessed as cell viability measured after 72 hrs by Flow cytometry assay
AID541167	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID582412	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd for 48 weeks study (Rvb = 35 +/- 27 %)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID541165	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID582410	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 55 +/- 32 %)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID541171	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M and E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID548829	Antiviral activity against HIV1 isolate 188 harboring reverse transcriptase T215Y/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID541164	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID582406	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 46 +/- 25 pg)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID548804	Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1780696	Therapeutic index, ratio of CC50 for human CEM-GXR cells infected with wild type HIV1 97USSN54 to EC50 for wild type HIV1 97USSN54 infected in human CEM-GXR cells
AID541161	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring T66I mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID548801	Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548828	Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1780684	Antiviral activity against wild type HIV1 97USSN54 infected in human CEM-GXR cells assessed as inhibition of viral replication measured after 3 days by Flowcytometry assay
AID541172	Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID86359	The concentration of compound which inhibits hepatitis B virus replication in the HepAD38 cell line.	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548810	Antiviral activity against HIV1 isolate 217 harboring reverse transcriptase D67N/K70E/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID664468	Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay	2012	Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6	Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors.
AID1652585	Antiviral activity against HIV1 3B infected in human CEM/0 cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy
AID582407	Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 33 +/- 21 pg)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID548822	Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID310045	Cytotoxicity against human HepG2 cells after 9 days by MTT assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID548834	Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID328841	Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	25 (1.53)	18.2507
2000's	228 (13.92)	29.6817
2010's	915 (55.86)	24.3611
2020's	470 (28.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	464 (27.20%)	5.53%
Reviews	194 (11.37%)	6.00%
Case Studies	120 (7.03%)	4.05%
Observational	52 (3.05%)	0.25%
Other	876 (51.35%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (372)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-infected Infants and Children 3 Months to 6 Years of Age. [NCT00364793]	Phase 1/Phase 2	56 participants (Actual)	Interventional	2007-02-28	Completed
A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA™ [NCT00369941]	Phase 3	566 participants (Actual)	Interventional	2006-08-31	Completed
[NCT01274780]	Phase 4	180 participants (Actual)	Interventional	2011-05-31	Completed
Phase III Multicenter Randomized Trial Evaluating in Patients at the Time of the Primary HIV-1 Infection, the Impact on the Viral Reservoir of a Combination Including Tenofovir/Emtricitabine and Dolutegravir or Tenofovir/Emtricitabine and Darunavir/Cobici [NCT02987530]	Phase 3	101 participants (Actual)	Interventional	2017-04-11	Completed
Bictegravir in the Elderly Living With HIV: Impact of Polypharmacy and Multimorbidity (BICEP) [NCT05064020]		162 participants (Anticipated)	Observational	2020-08-01	Active, not recruiting
DOT Diary Longitudinal Pilot: A Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men [NCT03771638]	Phase 4	100 participants (Actual)	Interventional	2019-02-01	Completed
UNCPM 22314 - Evaluating the Safety of Pregnancy, Infant and Maternal Health Outcomes Among PrEP Users in Malawi [NCT06158126]		621 participants (Anticipated)	Observational [Patient Registry]	2024-01-01	Not yet recruiting
Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Efavirenz Once Daily Over 10 Days Following Drug Intake Cessation in Healthy Volunteers [NCT01108926]	Phase 1	19 participants (Actual)	Interventional	2010-06-30	Completed
Phase 3B, Randomized, Open-Label, Safety, and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs [NCT04140266]	Phase 3	394 participants (Actual)	Interventional	2020-09-24	Completed
A Prospective, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Raltegravir + Truvada Versus Kaletra + Truvada, for Post-exposure Prophylaxis in Health Care Workers [NCT01234116]	Phase 4	16 participants (Actual)	Interventional	2011-02-28	Completed
Virtual PrEP: Rendering PrEP Delivery More Efficient Using an mHealth Intervention and TAF/FTC [NCT05159531]	Phase 4	142 participants (Anticipated)	Interventional	2023-05-01	Recruiting
The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers [NCT04950530]	Phase 1	20 participants (Anticipated)	Interventional	2022-12-22	Recruiting
F/TAF Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis (TAF4TRANS) [NCT04616963]	Phase 4	64 participants (Actual)	Interventional	2019-10-24	Active, not recruiting
Immediate Initiation of Antiretroviral Therapy During Acute HIV Infection [NCT02656511]	Phase 4	74 participants (Anticipated)	Interventional	2015-12-31	Active, not recruiting
Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression [NCT01174914]	Phase 2	171 participants (Actual)	Interventional	2008-03-31	Completed
A Multicenter, Randomized, Double-Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir For The Treatment Of Antiretroviral-Naive Hiv-Infected Patients With Ccr5-Tropic Hiv-1 [NCT01345630]	Phase 3	813 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to See termination reason in detailed description.)
Optimal Combination Therapy After Nevirapine Exposure [NCT00089505]	Phase 3	745 participants (Actual)	Interventional	2006-11-30	Completed
Bioequivalence of Tenofovir and Emtricitabine Following Overencapsulation [NCT02968576]		25 participants (Actual)	Interventional	2016-12-31	Completed
A Phase 4, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Antiretroviral Treatment-experienced Human Immunodeficie [NCT04388904]	Phase 4	75 participants (Actual)	Interventional	2021-09-01	Active, not recruiting
I-BrEATHe - Interactions Between Antiretrovirals And Transgender Hormones [NCT04050371]	Phase 4	48 participants (Actual)	Interventional	2017-08-03	Completed
Simplified Model of Linkage and Retention to Healthcare System, Using a Mobil Unit and a Same-day Test and Treat Approach Among Excluded Population. [NCT05405751]	Phase 4	100 participants (Actual)	Interventional	2022-07-04	Active, not recruiting
An Open Label Study Evaluating the Safety and Efficacy of Switching From Rilpivirine/Emtricitabine/Tenofovir Alafenamide in Combination With Dolutegravir, to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Combination With Doravirine, in Male HIV+ Subj [NCT04538040]	Phase 4	20 participants (Actual)	Interventional	2019-12-19	Completed
"Assessment of a New Boosting Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers" [NCT03202511]	Early Phase 1	15 participants (Actual)	Interventional	2017-06-23	Completed
A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants [NCT04233879]	Phase 3	599 participants (Actual)	Interventional	2020-02-28	Active, not recruiting
Extracellular and Intracellular TFV/FTC Residues After a Single Dose in HIV-Negative Men and Women: Implications for Pre-exposure HIV Prophylaxis Dosing of Truvada® [NCT01326221]		12 participants (Actual)	Observational	2008-10-31	Completed
The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients [NCT03789968]		411 participants (Actual)	Observational	2019-09-01	Completed
"Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)" [NCT02104700]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2014-04-30	Completed
Bioequivalence of Crushed and Whole Genvoya Tablets (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate) [NCT03717129]	Phase 4	12 participants (Actual)	Interventional	2019-04-15	Completed
Study on the Drug Interaction of HS-10234 and Emtricitabine in Healthy Subjects [NCT04477096]	Phase 1	36 participants (Actual)	Interventional	2020-08-03	Completed
Body Composition Sub-study of the D2EFT Trial [NCT03675815]	Phase 4	155 participants (Actual)	Interventional	2019-12-05	Active, not recruiting
A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects [NCT00118898]	Phase 3	1,864 participants (Actual)	Interventional	2005-09-30	Completed
Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine [NCT00099632]	Phase 2	484 participants (Actual)	Interventional	2006-03-31	Completed
A Phase 3, Randomized, Multicenter Study of the Treatment of Antiretroviral-Naive HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs Combivir (Lamivudine/Zidovudine) and Efavirenz [NCT00112047]	Phase 3	517 participants (Actual)	Interventional	2003-07-31	Completed
An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 ≥ 250 Cells/mm3 and HIV Virus Load ≥ 50,000 cp/mL [NCT01583439]		11 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Low Accrual.)
Advanced HIV: Outcomes for Rapid ART [NCT05526118]		50 participants (Anticipated)	Observational	2022-08-30	Not yet recruiting
The Stability and Bioequivalence of Tenofovir, Emtricitabine and Efavirenz (Atripla) in an Extemporaneously Prepared Oral Liquid Formulation Compared With the Commercially Available Tablet Formulation [NCT00862823]	Phase 4	14 participants (Actual)	Interventional	2009-02-28	Completed
Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B [NCT03120494]	Phase 4	75 participants (Actual)	Interventional	2016-11-30	Enrolling by invitation
Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication - A Controlled, Mono Center, Three-arm, Randomized Phase I Study. [NCT02203461]	Phase 1	30 participants (Actual)	Interventional	2014-07-31	Completed
Bioequivalence Study of Efavirenz, Emtricitabine and Tenofovir in Healthy Volunteers, After Administering a Single Dose of a Fixed Dose Combination of the Test Formulation With Respect to the Reference Product, Atripla ® From Gador S.A [NCT03309566]	Phase 4	24 participants (Actual)	Interventional	2016-09-04	Completed
Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT) [NCT01352715]	Phase 3	515 participants (Actual)	Interventional	2012-03-13	Completed
Switching Tenofovir/Emtricitabine/Efavirenz to Tenofovir/Emtricitabine/Rilpivirine Versus Continuing Tenofovir/Emtricitabine/Efavirenz in HIV1-infected Patients With Complete Virological Suppression [NCT03251690]		246 participants (Actual)	Interventional	2016-10-27	Completed
Structural and Partnership Factors Affecting Adherence to Pre-exposure Prophylaxis (PREP)Among Young Men Who Have Sex With Men [NCT02411630]		167 participants (Actual)	Observational	2013-06-30	Completed
"Efficacy, Safety, and Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 Infection." [NCT03502005]	Phase 4	100 participants (Actual)	Interventional	2018-03-01	Completed
The Cellular Pharmacology of F-TAF in Dried Blood Spots [NCT02962739]	Phase 1	38 participants (Actual)	Interventional	2016-03-31	Completed
Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients [NCT02327702]	Phase 4	200 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
Demonstration Project of Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin [NCT02237027]	Phase 4	361 participants (Actual)	Interventional	2014-10-31	Completed
Pre-exposure Option for Reducing HIV in the UK: an Open-label Randomisation to Immediate or Deferred Daily Truvada for HIV Negative Gay Men.(PROUD) [NCT02065986]	Phase 4	544 participants (Actual)	Interventional	2012-10-31	Completed
Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults Without Baseline Genotyping Test (D2ARLING Study) [NCT04549467]	Phase 4	244 participants (Actual)	Interventional	2020-11-17	Active, not recruiting
Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF) [NCT04054089]	Phase 4	66 participants (Anticipated)	Interventional	2019-09-30	Not yet recruiting
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV [NCT03549312]	Phase 4	25 participants (Anticipated)	Interventional	2018-02-01	Recruiting
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD [NCT04500847]	Phase 1	35 participants (Anticipated)	Interventional	2021-12-17	Recruiting
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-n [NCT02831764]	Phase 3	722 participants (Actual)	Interventional	2016-07-18	Completed
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Vir [NCT02831673]	Phase 3	719 participants (Actual)	Interventional	2016-07-21	Completed
A Phase 1, Open-label Study in Healthy Participants to Investigate the Effect of Multiple-dose JNJ-56136379 on the Single-dose Pharmacokinetics of Bictegravir, Emtricitabine, and Tenofovir Alafenamide [NCT04853524]	Phase 1	0 participants (Actual)	Interventional	2021-05-06	Withdrawn(stopped due to Sponsor Decision)
A Prosp., Multic., Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From SOC ART in HIV-patients With Sustained Virological Suppr. [NCT02486133]	Phase 3	269 participants (Actual)	Interventional	2015-07-31	Completed
Change in Sleep Architecture and Neuropsychological Performance Following Switch From Atripla to Stribild. [NCT02283060]	Phase 4	30 participants (Anticipated)	Interventional	2014-09-30	Recruiting
HIV Infection and Gut Mucosal Immune Function: Longitudinal Analyses of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy [NCT02097381]		10 participants (Actual)	Interventional	2010-04-30	Active, not recruiting
Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program [NCT03394196]		152 participants (Actual)	Interventional	2018-07-04	Terminated(stopped due to COVID-19 and Funding)
Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning, ESCAPE Study [NCT02308332]	Phase 4	58 participants (Actual)	Interventional	2015-02-28	Completed
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint? [NCT00090779]	Phase 2	130 participants (Actual)	Interventional	2005-01-31	Terminated(stopped due to The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study.)
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]		1,578 participants (Actual)	Observational	2003-06-09	Completed
A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir [NCT02285374]	Phase 4	40 participants (Anticipated)	Interventional	2014-11-30	Not yet recruiting
Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 [NCT04880395]	Phase 4	230 participants (Anticipated)	Interventional	2021-05-20	Recruiting
DOT Diary (D2): Developing a Mobile App With Combined Automated DOT and Daily Sexual Diary for Monitoring and Improving PrEP Adherence: DOT Diary Optimization Pilot [NCT03387462]	Phase 4	20 participants (Actual)	Interventional	2018-02-28	Completed
Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population [NCT01180075]		85 participants (Actual)	Observational	2010-05-31	Completed
Phase II Pilot Study of Simplification to Maraviroc - Raltegravir Dual Therapy After 6 Months of Maraviroc - Raltegravir - Tenofovir - Emtricitabine Quadruple Therapy in ARV Treatment-naive, HIV-1-infected Patients With CCR5- Virus [NCT01291459]	Phase 2	40 participants (Anticipated)	Interventional	2011-09-30	Active, not recruiting
A Phase IV, Open-label, Multi Centre Pilot Study to Assess Changes in Cerebral Function Parameters in Patients Without Perceived Central Nervous System (CNS) Symptoms When Switched From a Fixed Dose Combination of Tenofovir/Emtricitabine/Efavirenz (Atripl [NCT02529059]	Phase 4	40 participants (Anticipated)	Interventional	2015-11-30	Completed
"Prevention of HIV in Île-de-France" [NCT03113123]		3,257 participants (Anticipated)	Interventional	2017-05-03	Recruiting
Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults or Adults Recommencing ART. [NCT01258439]	Phase 4	25 participants (Actual)	Interventional	2010-11-30	Completed
Pilot Single-Arm Clinical Trial to Evaluate the Efficacy, PK Interactions and Safety of Dolutegravir Plus 2 NRTIs in HIV-1-Infected Solid Organ Transplant Patients [NCT03360682]	Phase 4	20 participants (Anticipated)	Interventional	2018-04-12	Active, not recruiting
Pharmacokinetics of EFV 400mg Once Daily During Pregnancy in HIV+ Women [NCT02499874]	Phase 1	26 participants (Actual)	Interventional	2015-08-31	Completed
Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants [NCT03048422]	Phase 3	643 participants (Actual)	Interventional	2018-01-19	Completed
Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals [NCT01293123]		2 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Did not meet enrollment goals)
Acceptability and Feasibility of a Pre-Exposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men (YMSM) [NCT01033942]	Phase 2	68 participants (Actual)	Interventional	2009-08-31	Completed
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study [NCT01003990]	Phase 3	710 participants (Actual)	Interventional	2002-10-31	Completed
A Pilot Study--randomized, Prospective, Single Site Trial Evaluating Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients [NCT00762892]	Phase 4	33 participants (Actual)	Interventional	2009-01-31	Completed
An Open-Label Study of a Once Daily Dose of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects [NCT00642291]	Phase 2	16 participants (Actual)	Interventional	2002-11-30	Completed
Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women [NCT00705679]	Phase 2	5,029 participants (Actual)	Interventional	2009-08-31	Completed
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection [NCT00959894]	Phase 2	80 participants (Actual)	Interventional	2009-09-30	Completed
A Study of Bioequivalence When Administering Biktarvy® (TAF/FTC/BIC) in the Form of a Solid/Crushed/Dissolved Tablet to Healthy Volunteers - SOLUBIC Study [NCT04244448]	Phase 1	18 participants (Actual)	Interventional	2019-12-02	Completed
A Randomized, Non-comparative, Phase IIb, Unblinded Trial, Evaluating the Efficacy and Safety of Tenofovir-emtricitabine or Lamivudine Plus Zidovudine, Lopinavir/Ritonavir, or Raltegravir, Among ARV-naïve HIV-2 Infected Adult Patients, in West Africa [NCT02150993]	Phase 2/Phase 3	210 participants (Actual)	Interventional	2016-01-26	Completed
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy in Persistently Non-adherent Children, Adolescents, and Young Adults Who Are Failing HAART and Have the M184V Resistance Mutation. [NCT01338025]	Phase 4	33 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Study was halted for lack of accrual)
Evaluation of the Capacity of a Weekly Strategy of 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV-1 Infected Patients With Undetectable Viral Load for at Least 12 Months, to Maintain a Virological Success With This Intermittent M [NCT02157311]	Phase 3	100 participants (Actual)	Interventional	2014-07-31	Completed
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites [NCT04301661]		25 participants (Actual)	Observational	2020-03-06	Completed
Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir/Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial [NCT04519125]	Phase 2/Phase 3	950 participants (Anticipated)	Interventional	2020-08-30	Not yet recruiting
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection [NCT02475915]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2015-01-31	Completed
A Single-dose, Open-label, Randomized, Crossover Study to Assess the Impact of Food on the Pharmacokinetics of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Administered as a Fixed-dose Combination Tablet, and the Relative Bioavailabilit [NCT02475135]	Phase 1	72 participants (Actual)	Interventional	2015-06-01	Completed
Effect of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Bictegravir/Emtricitabine/Tenofovir Alafenamide on the Circulatory microRNA Profile in Treatment naïve HIV Patients, and Its Correlation With Change in Body Weight [NCT05463783]	Phase 4	30 participants (Anticipated)	Interventional	2023-03-14	Recruiting
A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population [NCT03074786]	Phase 2	0 participants (Actual)	Interventional	2017-11-30	Withdrawn(stopped due to Study was transferred to partner who will conduct under its own IND)
The Role of Home Packs of HIV Post-Exposure Prophylaxis for Sexual Exposure (PEPSE) to Improve the Speed and Appropriate Uptake of PEPSE in High Risk Individuals [NCT04965662]	Phase 4	139 participants (Actual)	Interventional	2018-01-01	Completed
The Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate on HIV Pre-exposure Prophylaxis (PrEP) [NCT03197961]	Early Phase 1	15 participants (Actual)	Interventional	2017-11-17	Completed
A 48-week, Randomized, Open-label, 2-arm Study to Compare the Efficacy of Saquinavir/Ritonavir Twice Daily (BID) Plus Emtricitabine/Tenofovir Once Daily (QD) Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-naïve Human Immunodef [NCT00105079]	Phase 3	337 participants (Actual)	Interventional	2005-04-30	Completed
Randomized Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19 [NCT04890626]	Phase 3	2,193 participants (Anticipated)	Interventional	2020-04-04	Recruiting
An Open Label Randomized Clinical Trial, to Evaluate the Treatment With Darunavir/Ritonavir + Lamivudine Once Daily Versus Continuing With Darunavir/Ritonavir Once Daily + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject With Suppres [NCT02159599]	Phase 4	249 participants (Actual)	Interventional	2014-07-31	Completed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologica [NCT02603120]	Phase 3	567 participants (Actual)	Interventional	2015-11-11	Completed
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infe [NCT02016924]	Phase 2/Phase 3	130 participants (Anticipated)	Interventional	2014-01-16	Recruiting
Phase IV, Randomized, Multicenter and Double Clinical Trial Blind Designed to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities: MIND Study [NCT05549180]	Phase 4	84 participants (Actual)	Interventional	2022-10-06	Active, not recruiting
Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. [NCT02198443]	Phase 4	160 participants (Actual)	Interventional	2015-06-06	Completed
Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection: A Demonstration Project [NCT02206555]	Phase 4	327 participants (Actual)	Interventional	2014-11-14	Completed
Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects [NCT00549198]	Phase 4	392 participants (Actual)	Interventional	2007-06-30	Completed
Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples [NCT02572505]		0 participants (Actual)	Interventional	2015-11-30	Withdrawn
Phase IIb Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Tenofovir+Emtricitabine+Raltegravir or to Lamivudine+Abacavir+Raltegravir in Patients With Optimal Virological Control and Toxicity to the Current Co [NCT00958100]	Phase 2	40 participants (Actual)	Interventional	2009-08-31	Completed
Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study) [NCT04636437]	Phase 4	222 participants (Anticipated)	Interventional	2021-05-20	Recruiting
Adherence to a One Pill, Once-a-day Antiretroviral Regimen [NCT00990600]	Phase 3	212 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples [NCT00074581]	Phase 3	3,526 participants (Actual)	Interventional	2005-02-28	Completed
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants [NCT04424264]	Phase 1	18 participants (Actual)	Interventional	2019-12-05	Completed
An Open-Label One-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Subjects [NCT03836729]	Phase 1	16 participants (Actual)	Interventional	2019-02-11	Completed
Safety, Tolerability, and Adherence to a Raltegravir-based Antiretroviral Regimen for HIV Non-occupational Postexposure Prophylaxis [NCT01087840]	Phase 4	120 participants (Actual)	Interventional	2010-07-31	Completed
An Open-Label Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration of a Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine Fixed-Dose Combination Tablet in Healthy Japanese Adult Male Subjec [NCT02530060]	Phase 4	8 participants (Actual)	Interventional	2015-08-31	Completed
Pre-Exposure Prophylaxis With TDF/FTC to Prevent HIV-1 Acquisition in Young Men and Transgender Women of Color Who Have Sex With Men [NCT02367807]		50 participants (Actual)	Observational	2015-02-28	Completed
International Trial of Modified Directly Observed Therapy Versus Self-Administered Therapy for Participants With First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen [NCT00608569]		529 participants (Actual)	Interventional	2009-03-31	Completed
A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women [NCT03164564]	Phase 3	3,224 participants (Actual)	Interventional	2017-11-07	Active, not recruiting
An Open Label, Comparative, Randomized , Phase IV Pilot Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load [NCT05898841]	Phase 4	75 participants (Anticipated)	Interventional	2023-05-26	Recruiting
Multicentric, Non-inferiority, Randomized, Non-blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-infected Patients With Treatment Failure After 1st Line Antiretroviral Therapy (Cameroon, Burki [NCT00928187]	Phase 3	454 participants (Actual)	Interventional	2009-11-30	Completed
A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lamivudine Versus Boosted Darunavir and Emtricitabine/Tenofovir or Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects [NCT02770508]	Phase 4	145 participants (Actual)	Interventional	2015-11-30	Completed
APT-POCT-01: An Open Label, Pharmacokinetic Study of Plasma/Urine/Salivary Drug Concentrations Over Fourteen Days Following Drug Intake Cessation, In HIV-Uninfected Healthy Volunteers Dosing to Steady-state to Further Development of Point of Care Diagnost [NCT04302896]	Early Phase 1	30 participants (Actual)	Interventional	2020-08-31	Completed
Institute of HIV Research and Innovation (IHRI) [NCT04593680]		40 participants (Anticipated)	Interventional	2020-10-01	Recruiting
First-Phase Viral Decay Rates in Treatment-Naive Subjects Initiating Treatment With Raltegravir (RAL) and Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF): A Pilot Study [NCT00660972]	Phase 1	40 participants (Actual)	Interventional	2008-05-31	Completed
Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI) Treated With Multitarget Antiviral Therapy (MT-ART) [NCT04225325]	Phase 4	112 participants (Anticipated)	Interventional	2018-05-07	Recruiting
A Study to Evaluate Clinical Benefits and Drawbacks of Antiretroviral Drugs as Pre-exposure Prophylaxis to Prevent HIV Infection Under Real-life Conditions Among Persons Who Pursue High-risk Sexual Practices: The Seville HIV PrEP Cohort [NCT05492565]		500 participants (Anticipated)	Observational [Patient Registry]	2020-01-01	Enrolling by invitation
Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep) [NCT01040091]	Phase 1	34 participants (Actual)	Interventional	2009-12-31	Completed
"The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment-Nearly Naive Participants" [NCT00442962]	Phase 4	54 participants (Actual)	Interventional	2007-05-31	Completed
Closing a Critical HIV Prevention Gap: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) as Part of an HIV Combination Preventive Intervention for Sex Workers in Kolkata and Mysore-Mandya, India [NCT02148094]	Early Phase 1	1,325 participants (Actual)	Interventional	2016-01-31	Completed
A Pilot Study of Daily TDF/FTC-based PrEP Among High-risk Toronto MSM:The PREPARATORY-5 Study [NCT02149888]	Phase 4	52 participants (Actual)	Interventional	2014-10-31	Completed
Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention During Pregnancy and Postpartum in Adolescents and Young Women and Their Infants [NCT03386578]	Phase 2	390 participants (Actual)	Interventional	2018-07-03	Active, not recruiting
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women [NCT00869960]	Phase 4	24 participants (Actual)	Interventional	2009-03-31	Completed
Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Patients [NCT00752856]	Phase 2	51 participants (Actual)	Interventional	2008-08-26	Completed
COVER - Continuing Observation After Vicriviroc (VCV) Exposure Registry [NCT00705419]		180 participants (Actual)	Observational	2007-07-31	Completed
Pilot Study Of Novel Combination Of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Naïve HIV-Infected Patients With R5 HIV-1 [NCT00827112]	Phase 2	129 participants (Actual)	Interventional	2009-03-31	Completed
CID 0706 - Safety, Tolerability, Pharmacokinetic, and Metabolic Features of Raltegravir Among African-American Men and Women With HIV Infection [NCT00667433]	Phase 1	38 participants (Actual)	Interventional	2008-06-30	Completed
A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa With Continued Access to Emtricitabine [NCT00743340]	Phase 2	50 participants (Actual)	Interventional	2005-11-22	Completed
Effects of Antiviral Therapies on Epstein-Barr Virus Replication [NCT05957913]	Phase 2	50 participants (Anticipated)	Interventional	2023-06-05	Enrolling by invitation
Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects [NCT00759070]	Phase 4	50 participants (Anticipated)	Interventional	2008-09-30	Active, not recruiting
Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana [NCT00448669]	Phase 2/Phase 3	1,219 participants (Actual)	Interventional	2007-03-31	Completed
A Randomized, Open-label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily [NCT00711009]	Phase 3	206 participants (Actual)	Interventional	2008-07-31	Completed
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg. [NCT02583464]	Phase 1	24 participants (Actual)	Interventional	2014-09-30	Completed
A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Bioequivalence of Darunavir 800 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg, in the Presence of Cobicistat 150 mg, Administered as Either a Fixed-Dose Combination Tablet or [NCT02578550]	Phase 1	126 participants (Actual)	Interventional	2015-11-30	Completed
CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis [NCT00924898]	Phase 4	92 participants (Actual)	Interventional	2005-01-31	Completed
Open Randomized Study to Assess the Evolution of Plasma Lipid Profile by Lipidomic in Patients Infected With Human Immunodeficiency Virus (HIV-1) With Viral Suppression That Change Atripla® to Eviplera® Compared to Continue With Atripla® [NCT02547844]	Phase 4	30 participants (Actual)	Interventional	2015-09-30	Completed
Quantification of Estradiol's Impact on Nucleotides in Different Cellular Populations of the Lower Gastrointestinal Tract [NCT03917420]	Phase 1	10 participants (Actual)	Interventional	2019-03-26	Completed
Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants [NCT04862975]		200 participants (Anticipated)	Observational	2024-01-08	Not yet recruiting
Decay Kinetics of HIV With the Integrase Inhibitor Raltegravir [NCT00863668]		0 participants (Actual)	Interventional	2009-03-31	Withdrawn
CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics [NCT00666055]		11 participants (Actual)	Observational	2008-03-31	Completed
Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics) [NCT02832778]	Phase 1	35 participants (Anticipated)	Interventional	2016-11-21	Recruiting
Pharmacokinetic and Safety Pilotstudy of RAltegravir and Atazanavir in a Once DAily Dose Regimen in HIV-1 Infected Patients (PRADA) [NCT00943540]	Phase 2	20 participants (Anticipated)	Interventional	2009-07-31	Completed
Antiretroviral Therapy and the Hepatitis C Virus [NCT00545558]	Phase 1	18 participants (Actual)	Interventional	2006-04-30	Completed
Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects [NCT00551018]	Phase 2	218 participants (Actual)	Interventional	2007-12-31	Completed
Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa [NCT06138600]	Phase 3	200 participants (Anticipated)	Interventional	2023-11-01	Active, not recruiting
Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine [NCT03218085]		50 participants (Anticipated)	Observational	2017-07-14	Recruiting
A Multicenter, Open-label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-daily Darunavir Versus Atazanavir in HIV-infected Treatment-naive Adult Patients [NCT00757783]	Phase 4	68 participants (Actual)	Interventional	2008-10-31	Completed
A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adef [NCT00307489]	Phase 2	106 participants (Actual)	Interventional	2006-03-31	Completed
A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Combination With Tenofovir/Emtricitabine QD in Treatment [NCT00768989]	Phase 2	167 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Efficacy endpoint met, but overall experimental dosing regimen not considered optimal to support further clinical development in this population.)
The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment [NCT00811954]	Phase 3	1,814 participants (Actual)	Interventional	2009-05-31	Completed
A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintaine [NCT00724711]	Phase 4	312 participants (Actual)	Interventional	2008-07-31	Completed
A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the P [NCT00298363]	Phase 2	112 participants (Actual)	Interventional	2006-04-30	Completed
A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/Ritonavir With Lopinavir/Ritonavir, Each in Combination With Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment in Naive Subjects [NCT00272779]	Phase 3	1,057 participants (Actual)	Interventional	2005-11-30	Completed
Correcting Pre-Exposure Prophylaxis (PrEP) Dosing and Adherence Benchmarks in Pregnancy to Optimize HIV Prevention (PrEP-P): A Randomized Comparative Pharmacokinetic Trial [NCT03834909]	Phase 1	0 participants (Actual)	Interventional	2022-04-30	Withdrawn(stopped due to Study was not funded)
A Phase II Exploratory Study Examining Immunologic and Virologic Indices in Two Age-Differentiated Cohorts of HIV-Infected Subjects to Explore the Basis of Accelerated HIV-Disease Progression Associated With Aging [NCT00006144]	Phase 2	90 participants	Interventional	2000-10-31	Completed
An Open-Label Study of a Once Daily Dose of Emtricitabine in Combination With Other Antiretroviral Agents in HIV-Infected Pediatric Patients [NCT00017992]	Phase 2	100 participants	Interventional		Recruiting
IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project [NCT03058835]	Phase 4	125 participants (Actual)	Interventional	2016-09-30	Active, not recruiting
Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA) [NCT03954327]	Phase 2	37 participants (Actual)	Interventional	2021-03-01	Active, not recruiting
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl. A Prospective, Randomized, Multicentre, Open Clinical Study. [NCT00532168]	Phase 4	108 participants (Actual)	Interventional	2007-09-30	Completed
Effect of Tenofovir/Emtricitabine Short Course on Viral Clearance in Patients Recently Infected With SARS-COV2 (Covid-19) Not Requiring Hospitalization: a Phase IIB/III Multicenter Open-label Randomized Controlled Trial [NCT04685512]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2020-11-18	Completed
Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM) [NCT01033760]	Phase 3	90 participants (Actual)	Interventional	2010-04-30	Completed
A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens [NCT00357552]		123 participants (Actual)	Interventional	2008-01-31	Completed
A Randomised, Open-label, 96-week Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection. [NCT00335322]	Phase 4	329 participants (Actual)	Interventional	2007-02-28	Completed
An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naïve Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir (ANRS 143/NEAT 001) [NCT01066962]	Phase 3	800 participants (Actual)	Interventional	2010-08-31	Completed
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PE [NCT00084136]	Phase 4	1,571 participants (Actual)	Interventional	2005-05-31	Completed
Switching HIV-positive Women on Tenofovir/Emtricitabine Plus Boosted Atazanavir to RALtegravir Plus Boosted ATazanavir: A Pilot Randomized Clinical Trial Investigating 48-weeks Changes in Bone Mineral Density [NCT01902186]	Phase 4	4 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to Low enrollment)
Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission [NCT00204308]	Phase 2	400 participants (Actual)	Interventional	2005-03-31	Completed
Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication [NCT04222283]	Phase 4	27 participants (Anticipated)	Interventional	2020-08-17	Recruiting
Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project. [NCT01989611]		400 participants (Anticipated)	Interventional	2014-06-30	Active, not recruiting
Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde [NCT00573001]	Phase 3	120 participants (Actual)	Interventional	2008-07-31	Completed
CHAMPS: Choices For Adolescent Prevention Methods For South Africa. Pilot Study B: 'PlusPills' [NCT02213328]	Phase 2	148 participants (Actual)	Interventional	2015-04-30	Completed
HPTN 091: Integrating HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation for Transgender Women in the Americas: A Vanguard Study [NCT04742491]	Phase 2/Phase 3	307 participants (Actual)	Interventional	2021-03-26	Active, not recruiting
Randomized, Double-blinded, Controlled Trial of Intensive HAART Including Raltegravir, and Maraviroc, on HIV-1 Pro-viral DNA and Reservoir Decay in HIV-1-infected Individuals During the Acute/Early Infection [NCT01154673]	Phase 2/Phase 3	32 participants (Actual)	Interventional	2011-11-30	Completed
A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients [NCT00006208]	Phase 3	0 participants	Interventional	2000-08-31	Active, not recruiting
HIV Pre-exposure Prophylaxis Implementation Study in South Korea [NCT04583267]		200 participants (Anticipated)	Interventional	2018-08-28	Recruiting
Optimizing Access to Non-occupational Post Exposure Prophylaxis for HIV Using Contingency Management in Stimulant-Using Men Who Have Sex With Men [NCT01140880]	Phase 2	170 participants (Actual)	Interventional	2010-05-31	Completed
The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis [NCT02211690]	Phase 4	100 participants (Actual)	Interventional	2014-08-31	Completed
A Phase IV Open-label Evaluation of Safety, Tolerability and Patient Acceptance of Atazanavir Boosted With Ritonavir Combined With a Fixed-dose Formulation of Tenofovir DF and Emtricitabine for Non-occupational Prophylaxis Following Potential Exposure to [NCT01602822]	Phase 4	11 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Grade 3 elevation in liver function tests)
An Open-Label, Randomized Study Evaluating a Switch From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors Regimen Plus Any Third Agent to Either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazan [NCT01332227]	Phase 4	132 participants (Actual)	Interventional	2011-10-31	Completed
Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent mother-to Child Transmission of HIV-1 o, Resource-limited Settings: A Multicentre Randomized Phase 3 Clinical Trial [NCT00936195]	Phase 3	0 participants (Actual)	Interventional	2010-01-31	Withdrawn(stopped due to faillure to obtain insurance because of refusal from insurance companies)
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine. [NCT00808002]	Phase 3	30 participants (Actual)	Interventional	2009-02-28	Completed
Phase I Exploratory Pharmacodynamic Study of Tenofovir-Based Products [NCT02722343]	Phase 1	25 participants (Actual)	Interventional	2016-04-30	Completed
Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM [NCT00856323]	Phase 2	53 participants (Actual)	Interventional	2009-01-31	Completed
Open Label Extension (OLE) of the Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana [NCT04318210]		229 participants (Actual)	Interventional	2012-10-31	Completed
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed [NCT04132674]	Phase 4	40 participants (Anticipated)	Interventional	2018-11-26	Recruiting
Cardiovascular, Anthropometric, and Skeletal Effects of Antiretroviral Therapy (ART) Initiation With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Plus Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r), or Raltegravir (RAL): Metabolic Subs [NCT00851799]		334 participants (Actual)	Observational	2009-06-30	Completed
Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B [NCT00524173]	Phase 2	35 participants (Actual)	Interventional	2007-08-29	Terminated
The Effects of Switching From Dolutegravir/Lamivudine/Abacavir (d/l/a) to Bictegravir/Emtricitabine/Tenofovir Alafenamide (b/f/Taf) in Patients With Suppressed Viral Load on Neuropsychiatric Side Effects and Neurocognitive Function [NCT04155554]	Phase 3	100 participants (Anticipated)	Interventional	2020-01-29	Recruiting
Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients [NCT00677300]	Phase 4	85 participants (Actual)	Interventional	2009-01-31	Completed
Point of Care PrEP Delivery for Young Black/African American Men Who Have Sex With Men and Young Transgender Women at High Risk for HIV Infection [NCT04329442]		0 participants (Actual)	Interventional	2020-04-01	Withdrawn(stopped due to COVID-19 caused substantial barriers to recruitment.)
Use of Tenofovir/Emtricitabine With Immediate or Deferred Doxycycline 100mg PO Daily for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative Men Who Have Sex With Men: a Pilot Study of Dual Daily HIV and Syphilis PrEP. (The DuDHS Trial). [NCT02844634]	Phase 4	52 participants (Actual)	Interventional	2018-05-15	Active, not recruiting
Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection [NCT04240509]	Phase 4	100 participants (Anticipated)	Interventional	2019-11-01	Enrolling by invitation
A Phase IV Open-Label Evaluation of Safety, Tolerability and Patient Acceptance of Raltegravir (MK-0518) Combined With a Fixed-Dose Formulation of Tenofovir Following Potential Exposure to HIV-1 [NCT00594646]	Phase 4	100 participants (Actual)	Interventional	2008-02-29	Completed
Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere) [NCT01061151]	Phase 3	3,747 participants (Actual)	Interventional	2011-03-01	Completed
A Phase IV Open-label Evaluation of Safety, Tolerability and Acceptability of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Single-tablet Regimen for Non-occupational Prophylaxis Following Potential Exposure to HIV-1 [NCT01855867]	Phase 4	100 participants (Actual)	Interventional	2013-05-31	Completed
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women [NCT01394133]		0 participants (Actual)	Observational	2011-07-31	Withdrawn(stopped due to Lack of enrollment)
Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection [NCT02556333]	Phase 2	1 participants (Actual)	Interventional	2015-09-16	Terminated
Clinical, Control, Double-blind, Randomized Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19 [NCT04712357]		219 participants (Anticipated)	Interventional	2020-11-09	Recruiting
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males - A Sub-study of HPTN 083 [NCT04692077]	Phase 2	9 participants (Actual)	Interventional	2020-02-19	Completed
A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged >= 6 to <18 Years [NCT00799864]	Phase 2	54 participants (Actual)	Interventional	2011-01-07	Completed
A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Subjects to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg in the Presence of Cobicistat 150 mg When A [NCT04236453]	Phase 1	16 participants (Actual)	Interventional	2020-01-23	Terminated(stopped due to COVID-19 pandemic impacted the BE assessment of the trial. The clinical team decided to terminate the trial in order to start a new pivotal BE trial)
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs [NCT06101342]	Phase 2	250 participants (Anticipated)	Interventional	2023-12-13	Recruiting
Pilot Trial to Evaluate the Efficacy and Tolerance of a Simple Once Daily Combined Regimen Including Tenofovir (TDF), Emtricitabine (FTC) and Efavirenz (EFV) in HIV-1 Infected Patients Naive to Prior Antiretroviral Treatment in Senegal [NCT00158457]	Phase 3	40 participants (Actual)	Interventional	2004-06-30	Completed
Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine in Virologically-suppressed Adults Living With HIV on Bictegravir/Tenofovir Alafenamide/emtricitabine-the DYAD Study [NCT04585737]	Phase 4	222 participants (Actual)	Interventional	2020-09-22	Completed
Efficacy, Safety, and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-HBV Coinfection [NCT03797014]	Phase 4	28 participants (Actual)	Interventional	2019-04-30	Completed
Pegylated Interferon Alfa-2a Versus Emtricitabine / Tenofovir +/- Pegylated Interferon Alfa-2a for the Treatment of Chronic HBe-Ag Positive Hepatitis B Infection in HIV-Coinfected Patients - the PEGPLUS Trial [NCT00221286]	Phase 3	2 participants (Actual)	Interventional	2004-09-30	Terminated(stopped due to Lack of accrual)
Optimizing the Delivery of HIV Post-exposure Prophylaxis: A Randomized Controlled Trial of Text Messaging Support and Physician to Nurse Task-shifting [NCT03259698]	Phase 2	434 participants (Anticipated)	Interventional	2021-11-04	Recruiting
Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection [NCT00662545]	Phase 4	10 participants (Actual)	Interventional	2008-04-30	Completed
Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome [NCT03304717]	Phase 1/Phase 2	34 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Randomized, Double-blind, Placebo-controlled Trial of TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study) [NCT04405271]	Phase 3	1,378 participants (Anticipated)	Interventional	2020-07-31	Not yet recruiting
Treating HIV-infected Elite Controllers as a Model of HIV Remission [NCT01025427]	Phase 4	16 participants (Actual)	Interventional	2009-12-31	Completed
ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence [NCT03218592]	Phase 4	36 participants (Actual)	Interventional	2017-06-28	Completed
Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens [NCT03976752]	Phase 1	41 participants (Actual)	Interventional	2019-03-13	Completed
The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania [NCT00474435]	Phase 2	30 participants (Anticipated)	Interventional	2008-11-30	Recruiting
Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naive Patients With HIV/HBV Co-infection [NCT00476463]	Phase 2	24 participants (Actual)	Interventional	2005-04-30	Completed
The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP) [NCT01327651]	Phase 2	622 participants (Actual)	Interventional	2011-08-31	Completed
Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 C [NCT00528060]	Phase 2	35 participants (Actual)	Interventional	2008-01-31	Completed
Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study [NCT00537966]		2,017 participants (Anticipated)	Interventional	2002-01-31	Recruiting
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection [NCT04644029]	Phase 3	730 participants (Actual)	Interventional	2021-02-24	Active, not recruiting
A Randomized, Open Label, Multicenter Study Comparing the Safety and Efficacy of Once Daily Regimen Containing Epzicom or Truvada Combined With Ritonavir Boosted Atazanavir as Initial Therapy for HIV-1 Infection (ET Study) [NCT00544128]	Phase 4	109 participants (Actual)	Interventional	2007-10-31	Completed
Exploratory Pharmacokinetic and Pharmacodynamic Study of Oral F/TAF for the Prevention of HIV Acquisition [NCT02904369]	Phase 1	73 participants (Actual)	Interventional	2016-10-06	Completed
Phase IV, Open Label, Randomized, Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir Alafenamide/Emtricitabine/Darunavir/Cobicistat [NCT03685500]	Phase 4	78 participants (Actual)	Interventional	2018-12-04	Completed
A Pilot Study of Rapid HIV Treatment Initiation, Access and Engagement in Care (RHAE) [NCT03512964]		32 participants (Actual)	Interventional	2016-11-29	Completed
A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among Men Who Have Sex With Men (MSM) and Transgender Women in Los Angeles County [NCT01781806]	Phase 4	328 participants (Actual)	Interventional	2013-05-31	Completed
Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone [NCT00552240]	Phase 4	154 participants (Actual)	Interventional	2007-09-30	Completed
On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men [NCT01473472]	Phase 3	400 participants (Actual)	Interventional	2012-01-31	Completed
A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants [NCT00076791]	Phase 1	66 participants (Actual)	Interventional	2004-03-31	Completed
A Randomized, Open-Label Study Assessing Safety, Tolerability and Efficacy of an Induction-Maintenance Treatment Strategy Including Lopinavir/Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine Versus Efavirenz Plus Tenofovir Disoproxil Fumarat [NCT00121017]	Phase 2	200 participants	Interventional		Withdrawn
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men, and Are at High Risk for HIV [NCT04652700]	Phase 3	494 participants (Actual)	Interventional	2021-03-15	Completed
Tenofovir, Emtricitabine, and Nevirapine for Recently HIV-Infected Subjects: Can Short-Course, Once Daily Therapy Reduce the Viral Load at 12 Months From Estimated Date of Infection? [NCT00087464]		0 participants (Actual)	Interventional		Withdrawn(stopped due to study was withdrawn before any participants were recruited and enrolled)
Empiric Treatment for Suspected Acute HIV Infection in the Emergency Department [NCT03711253]	Phase 4	40 participants (Anticipated)	Interventional	2019-10-14	Active, not recruiting
Pharmacokinetics of Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-exposure Prophylaxis in Transgender Women Receiving Feminizing Hormone Therapy [NCT03270969]	Phase 1	15 participants (Actual)	Interventional	2018-01-05	Completed
Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naïve Patients With HIV/HBV co-Infection [NCT00127959]	Phase 4	24 participants	Interventional	2004-03-31	Completed
Clinical Trial: Backup With Combivir (AZT/3TC) or Single Dose (sd) Truvada (FTC/TDF) in Order to Avoid NNRTI Resistance After sd Nevirapine for the Prevention of Mother-to-child Transmission (MTCT) [NCT00346567]		566 participants (Actual)	Interventional	2006-06-30	Completed
A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Two Antiretroviral Therapeutic Strategies: A Dual PI-Based HAART Regimen Versus a Multi-NRTI ART Regimen, in ART-Experienced Children and Youth Who Have Experienced Virol [NCT00102206]	Phase 2	6 participants (Actual)	Interventional		Completed
A Phase 4, Single-Arm Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Combination With Emtricitabine in HIV-1 Infected Patients Experiencing Various Degrees of Renal Impairment [NCT00106379]	Phase 4	52 participants	Interventional	2004-10-31	Completed
A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa [NCT00444379]	Phase 4	224 participants (Actual)	Interventional	2007-04-30	Completed
A Phase 3b, Multi-center, Randomized, Parallel-group, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen Compared to Oral Bictegravir/Emtricitabine/Tenofov [NCT05979311]	Phase 3	412 participants (Anticipated)	Interventional	2023-12-29	Not yet recruiting
A Phase I Trial for the Evaluation of the Two-way Pharmacokinetic-pharmacodynamic (PD) Interaction of Gender Affirming Exogenous Estrogen (With Testosterone Suppression) on TDF/FTC PrEP in Transgender Women (TGW) [NCT04760691]	Phase 1	20 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo [NCT04334928]	Phase 3	1,002 participants (Actual)	Interventional	2020-04-15	Completed
Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women [NCT00625404]	Phase 3	2,120 participants (Actual)	Interventional	2009-05-31	Completed
A Multi-Center Comparison of Raltegravir to Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV-Infected Individuals Naive to Antiretroviral Therapy [NCT00632970]	Phase 4	6 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to no patients completed)
Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy [NCT01285050]	Phase 4	20 participants (Actual)	Interventional	2011-01-31	Completed
Pilot Study on Efficacy and Safety of a Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults. ANRS 091 MONTANA [NCT00196599]	Phase 2	39 participants	Interventional	1999-02-28	Completed
Randomized Order, Controlled, Double Blind, Crossover Early Phase 1 Pilot Study to Assess Safety and Pharmacokinetics of a Tenofovir Disoproxil Fumarate and Emtricitabine (TDF-FTC) Releasing IVR Over 28 Days Compared to Placebo [NCT03255915]	Early Phase 1	15 participants (Actual)	Interventional	2018-09-20	Active, not recruiting
A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects With Virologic Suppression on a Standard Regimen of Boosted Atazanavir, Tenofovir and Emtricitabine [NCT00931801]	Phase 4	43 participants (Actual)	Interventional	2009-12-31	Completed
Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia [NCT00334256]	Phase 2	72 participants (Actual)	Interventional	2006-10-31	Completed
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts [NCT01515813]	Phase 2	0 participants (Actual)	Interventional	2011-11-30	Withdrawn(stopped due to On 05/08/12, team working on revising protocol and re-open study under version 2.0)
Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC [NCT01533272]	Phase 4	240 participants (Actual)	Interventional	2012-02-29	Completed
Pilot Trial Evaluating Once Daily Triple Combination Antiretroviral Therapy With Tenofovir-Emtricitabine and Efavirenz in HIV-1 Infected Patients With Mycobacterium Tuberculosis Infection ANRS129 BKVIR [NCT00115609]	Phase 3	70 participants (Actual)	Interventional	2006-01-31	Completed
Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial [NCT00120367]	Phase 2	30 participants	Interventional	2005-04-30	Completed
Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients. ANRS HB 01 EMVIPEG. [NCT00391638]	Phase 2/Phase 3	56 participants (Actual)	Interventional	2007-01-31	Completed
A Randomized, Open-Label Study of 800 Mg Lopinavir/200 Mg Ritonavir QD in Combination With Tenofovir and Emtricitabine Vs. 400 Mg Lopinavir /100 Mg Ritonavir BID in Combination With Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects [NCT00043966]	Phase 3	200 participants	Interventional	2002-07-31	Completed
A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy [NCT00055120]	Phase 4	283 participants (Actual)	Interventional	2003-03-31	Completed
A Multicenter Clinical Trial to Evaluate the Feasibility and Outcome of Same-day Antiretroviral Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) Among Patients Testing Positive by HIV Confirmatory Tests [NCT04712058]		200 participants (Anticipated)	Interventional	2021-01-20	Recruiting
A Pilot Study to Measure the Clearance of Replication-Competent HIV-1 in Resting Memory CD4+ Cells in HIV-1-Infected Subjects Who Receive Enfuvirtide Plus Oral Combination Antiretroviral Therapy [NCT00051831]		19 participants (Actual)	Interventional	2003-10-31	Completed
A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation [NCT00036452]	Phase 2	402 participants (Actual)	Interventional		Completed
A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study. [NCT00192634]	Phase 4	357 participants (Actual)	Interventional	2005-12-31	Completed
Phase II Randomized Trial Comparing Efficacy and Safety of the Maintenance of a HAART Association Protease Inhibitor Containing Versus a Once Daily Antiretroviral Triple Association, in HIV Adult Patients With Undetectable Viral Load.ANRS 099 ALIZE [NCT00196612]	Phase 3	350 participants	Interventional	2001-04-30	Completed
IPrEP, Study #2: Evaluating the Effectiveness, Feasibility and Acceptability of Enhanced Pre-exposure Prophylaxis (PrEP) Packages for Young Female Sex Workers in Kisumu, Kenya [NCT03988387]		200 participants (Actual)	Interventional	2019-10-31	Completed
An Open Label Study to Examine the Characteristics of HIV Decay Following Introduction of Combination Antiretroviral Therapy Including Raltegravir During Primary and Chronic HIV Infection [NCT00641641]		16 participants (Actual)	Interventional	2008-03-31	Completed
A Single-dose, Open-label, Randomized, Crossover Study to Assess the Relative Bioavailability of the Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Administered Orally as a Whole Tablet, as a Split Table [NCT02984852]	Phase 1	30 participants (Actual)	Interventional	2016-12-31	Completed
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen [NCT01929759]		10 participants (Actual)	Interventional	2014-01-31	Completed
Acute HIV Infection - A Key Link for Transmission Prevention: A Randomized Pilot Study [NCT01450189]		46 participants (Actual)	Interventional	2011-10-31	Completed
Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals [NCT02251236]		14 participants (Actual)	Interventional	2016-01-31	Completed
Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection [NCT00885664]	Phase 4	60 participants (Actual)	Interventional	2005-10-31	Completed
A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women [NCT01910402]	Phase 3	499 participants (Actual)	Interventional	2013-08-22	Completed
A Phase 3, Open Label, Randomised, Parallel Group Study to Compare the Effect on Prevention and Resolution of Treatment Related Adverse Events of a Simplified, Once Daily Regimen of a Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus [NCT00323544]	Phase 3	220 participants	Interventional	2004-10-31	Completed
Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO [NCT00302822]	Phase 3	195 participants (Actual)	Interventional	2006-04-30	Completed
A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naïve Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC [NCT01620944]	Phase 3	3 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to Business objectives have changed)
Maraviroc Switch Central Nervous System (CNS) Substudy: a Substudy of MARCH, a Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N [NCT01637233]		28 participants (Actual)	Observational	2012-06-30	Completed
Maraviroc Switch Collaborative Study Renal Substudy [NCT01637259]	Phase 4	76 participants (Actual)	Interventional	2012-06-30	Completed
A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine [NCT01694407]	Phase 1	48 participants (Actual)	Interventional	2013-02-28	Completed
A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine [NCT01701882]	Phase 3	40 participants (Actual)	Interventional	2012-09-30	Completed
Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP) [NCT01715636]	Phase 4	100 participants (Actual)	Interventional	2012-12-31	Completed
Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study [NCT01772940]	Phase 4	425 participants (Actual)	Interventional	2008-12-31	Completed
Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine [NCT01778413]	Phase 4	60 participants (Actual)	Interventional	2013-05-31	Completed
An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age [NCT01335620]	Phase 4	19 participants (Actual)	Interventional	2011-04-30	Completed
Defining the Rectal Mucosa in Men Who Have Sex With Men at Risk of HIV Infection [NCT02401230]	Phase 4	86 participants (Actual)	Interventional	2015-03-31	Completed
ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients [NCT01605890]	Phase 2	30 participants (Actual)	Interventional	2012-07-31	Completed
Effects of Biectegravir-Emtricitabine-Tenofovir Alafenamide on Coronary Flow Reserve in Stable HIV Patients (B/F/TAF-CFR) - Pilot Study [NCT03656783]	Phase 3	25 participants (Actual)	Interventional	2018-09-14	Completed
Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects [NCT01803074]	Phase 2	107 participants (Actual)	Interventional	2013-04-04	Completed
Implementation of Onsite, Rapid Antiretroviral Therapy (ART) Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program [NCT04650269]	Phase 4	27 participants (Actual)	Interventional	2021-03-04	Active, not recruiting
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic [NCT01400412]	Phase 2	262 participants (Actual)	Interventional	2012-01-17	Completed
A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067 [NCT01352117]	Phase 3	192 participants (Actual)	Interventional	2011-11-18	Completed
Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women An Open-Label Randomised Control Study [NCT03227731]	Phase 2/Phase 3	540 participants (Actual)	Interventional	2017-09-28	Completed
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial [NCT04359095]	Phase 2/Phase 3	650 participants (Actual)	Interventional	2020-08-18	Completed
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV. [NCT03126370]	Phase 4	10 participants (Actual)	Interventional	2018-01-08	Completed
A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients [NCT00002362]	Phase 3	0 participants	Interventional	1999-08-31	Suspended
A Randomized, Open-Label Equivalence Study of FTC Versus Lamivudine in Patients on a Stable Triple Antiretroviral Therapy Regimen Containing Lamivudine, Stavudine or Zidovudine, and a Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor [NCT00002416]	Phase 3	390 participants	Interventional		Completed
An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretrovi [NCT00016718]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2001-08-31	Completed
A Phase III, Open-label, Single Centre, Single-arm, Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Raltegravir [NCT01195467]	Phase 3	40 participants (Actual)	Interventional	2010-10-31	Completed
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal [NCT02660905]	Phase 3	25 participants (Actual)	Interventional	2016-04-30	Completed
Efficacy, Tolerability and Acceptability of the Single Table Regimen (STR) Biktarvy® by Trans People Living With HIV (TPLWH) [NCT04944654]	Phase 4	1 participants (Actual)	Interventional	2023-01-07	Terminated(stopped due to Trial set up was delayed, funding support no longer available)
The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples [NCT03049176]		46 participants (Actual)	Observational	2017-03-13	Completed
Prospective, Randomised, Crossover, Double-Blind, Placebo-Controlled Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Un [NCT01458977]	Phase 4	48 participants (Actual)	Interventional	2012-01-31	Completed
Demonstration Project on the Feasibility to Implement a Pre-Exposure Oral Prophylaxis Program in Men Who Have Sex With Other Men and Transgender Women at Risk of Acquiring HIV [NCT03043326]		1,000 participants (Anticipated)	Observational	2017-01-23	Recruiting
Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women [NCT00729573]		518 participants (Actual)	Observational	2009-11-30	Completed
Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir [NCT01576731]	Phase 4	240 participants (Actual)	Interventional	2012-07-31	Completed
Bone Health in Aging HIV Infected Women: Improvement or Prevention of Changes in Bone Mineral Density by Switching Antiretroviral Agents. Is There an Optimal Time to Intervene? [NCT02815566]	Phase 4	34 participants (Actual)	Interventional	2017-09-12	Completed
Randomized Controlled Pilot Study of Highly Active Anti-Retroviral Therapy for Patients With Primary Biliary Cirrhosis [NCT01614405]		13 participants (Actual)	Interventional	2012-06-30	Completed
Evaluation of Pre-Exposure Prophylaxis (PrEP) Initiation, Retention, and Adherence in Pregnant and Breastfeeding Women [NCT03902418]		1,200 participants (Actual)	Observational	2019-08-01	Active, not recruiting
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study [NCT03425994]		275 participants (Actual)	Observational [Patient Registry]	2018-02-06	Active, not recruiting
A Phase I, Randomized, Single-Dose, Placebo-Controlled Trial to Evaluate the Safety and Pharmacokinetics of 524W91 [NCT00002335]	Phase 1	18 participants	Interventional		Completed
An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <500 Cells/mm^3 [NCT01632891]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2014-01-10	Completed
A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicis [NCT02431247]	Phase 3	725 participants (Actual)	Interventional	2015-07-06	Completed
Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE) [NCT01641367]	Phase 4	545 participants (Actual)	Interventional	2013-02-22	Completed
A Switch Clinical Trial of Antiretrovirals to Compare the Impact of Doravirine Versus Integrase Inhibitors With Backbone of Emtricitabine and Tenofovir Alafenamide on Instigators of Atherosclerosis in Persons With Chronic Treated HIV. [NCT04820933]	Early Phase 1	20 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy [NCT03965923]	Phase 3	859 participants (Actual)	Interventional	2020-01-09	Active, not recruiting
A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Adult Participants to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg in the Presence of Cobicistat 150 [NCT04661397]	Phase 1	37 participants (Actual)	Interventional	2021-01-05	Completed
A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1 [NCT03499483]	Phase 4	52 participants (Actual)	Interventional	2019-01-24	Completed
Express Testing and Same-day Initiation of PrEP [NCT05690815]		816 participants (Anticipated)	Observational	2023-01-24	Recruiting
Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples [NCT00557245]	Phase 3	4,758 participants (Actual)	Interventional	2008-05-31	Completed
An Open Label Trial of STRIBILD™ (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) for ARV-naïve HIV-2 Infected Adults in Dakar, Senegal [NCT02180438]	Phase 4	30 participants (Actual)	Interventional	2014-09-30	Completed
Pharmacokinetic Study of an Optimized Dose Ratio of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate: Expediting a UNIVERSAL First Line Regimen for All Children Living With HIV in Africa [NCT05993767]	Phase 2	50 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
An Open-Label, 48-Week Extension Study of Elvucitabine Administered In Combination With Background Antiretroviral Agents in Participants Who Have Completed 14 Days of Treatment in Protocol ACH443-014A. [NCT00380159]	Phase 2	4 participants (Actual)	Interventional	2006-09-30	Completed
Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on [NCT00365612]	Phase 4	300 participants (Anticipated)	Interventional	2006-07-31	Completed
Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV [NCT02495779]		54 participants (Actual)	Interventional	2015-07-31	Completed
Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients [NCT02327676]	Phase 4	200 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial [NCT03327155]	Phase 3	900 participants (Actual)	Interventional	2017-11-16	Completed
Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK- [NCT02116660]	Phase 2	11 participants (Actual)	Interventional	2014-09-03	Terminated(stopped due to This study was terminated early due to poor recruitment.)
MARaviroc-based Treatment Switch in HIV-positive Patients With HAND: Consequences of Reducing Antiretroviral-associated Neurotoxicity [NCT03163277]	Phase 4	38 participants (Actual)	Interventional	2017-05-15	Terminated(stopped due to Sloww accrual and COVID-19 related problems (impossible to perform LPs))
Emtricitabine for Naive Chinese Chronic Hepatitis B Patients [NCT02327663]	Phase 4	2,000 participants (Anticipated)	Interventional	2014-12-31	Not yet recruiting
Comprehensive HIV Prevention Package for MSM in Port Elizabeth [NCT02449733]		101 participants (Actual)	Interventional	2015-05-31	Completed
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084 [NCT04824131]	Phase 2	50 participants (Actual)	Interventional	2020-11-04	Completed
A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population [NCT03593655]	Phase 2	247 participants (Actual)	Interventional	2019-01-14	Completed
Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients [NCT02327689]	Phase 4	400 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects [NCT00654147]	Phase 2	44 participants (Actual)	Interventional	2008-04-30	Completed
The Efficacy, Safety, and Tolerability of Switching to a Bictegravir (BIC)/Emtricitabine(FTC)/Tenofovir Alafenamide (TAF) Regimen in Virally Suppressed HIV-Positive Patients Post-Renal Transplant [NCT04530630]	Phase 4	20 participants (Actual)	Interventional	2020-11-09	Active, not recruiting
Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients [NCT02327715]	Phase 4	200 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) in the United States [NCT01769456]	Phase 2	78 participants (Actual)	Interventional	2013-03-31	Completed
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers [NCT01276600]	Phase 1	32 participants (Actual)	Interventional	2011-01-31	Completed
Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa: a Phase 3b, Open-label, Hybrid Type 2 Implementation and Effectiveness Trial [NCT06133686]	Phase 3	400 participants (Anticipated)	Interventional	2024-04-01	Not yet recruiting
Delivery of Pre-exposure Prophylaxis to Individuals With High Sexual Risk of HIV Infection in Hong Kong - an Implementation Study [NCT04367688]		400 participants (Anticipated)	Observational	2020-03-01	Recruiting
Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth) [NCT01571128]		1,215 participants (Actual)	Interventional	2014-11-30	Completed
A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching [NCT01709084]	Phase 3	426 participants (Actual)	Interventional	2013-10-02	Completed
A Pilot Project to Operationalize the Prevention Strategy of Post Exposure Prophylaxis Following Sexual Exposure to HIV in Combination With Educational Programming and Behavioral Risk Reduction Strategies in Los Angeles County [NCT00949234]	Phase 2	267 participants (Actual)	Interventional	2010-03-31	Completed
Effect of Substituting Truvada for Combivir or Trizivir vs Continuing Combivir or Trizivir on Physiologic Correlates of Mitochondrial Function in Subjects Infected With Human Immunodeficiency Virus on Highly Active Antiretroviral Therapy [NCT00960622]	Phase 4	17 participants (Actual)	Interventional	2006-08-31	Completed
Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women [NCT03060785]	Phase 1	16 participants (Actual)	Interventional	2016-03-08	Completed
IPrEP: A Combination HIV Prevention Strategy for Young Women at Risk for HIV in Kisumu, Kenya IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya [NCT04898699]		120 participants (Anticipated)	Interventional	2021-10-31	Not yet recruiting
DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: an Open-label Randomized Clinical Trial [NCT04884139]	Phase 4	555 participants (Anticipated)	Interventional	2021-07-14	Active, not recruiting
A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United States [NCT06101329]	Phase 2	250 participants (Anticipated)	Interventional	2023-11-17	Recruiting
An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States [NCT00414518]		16 participants (Actual)	Interventional	2007-01-31	Completed
A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Met [NCT01270802]	Phase 4	30 participants (Actual)	Interventional	2011-04-30	Completed
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects [NCT00244712]	Phase 4	688 participants (Actual)	Interventional	2005-07-31	Completed
A Pilot Project to Assess the Safety and Tolerability of Truvada Plus Raltegravir as Post-exposure Prophylaxis (nPEP) Following Sexual Exposure to Human Immunodeficiency Virus (HIV) [NCT01214759]	Phase 4	103 participants (Actual)	Interventional	2011-05-31	Completed
A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings [NCT01435018]	Phase 3	334 participants (Actual)	Interventional	2013-10-01	Completed
Parrying the Pitfalls of PrEP: Preventing Premature PrEP Discontinuation and STIs Among MSM [NCT05072093]	Phase 4	200 participants (Anticipated)	Interventional	2021-11-20	Recruiting
The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community [NCT03120936]	Phase 4	158 participants (Actual)	Interventional	2017-08-08	Completed
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses [NCT02859558]	Phase 2	195 participants (Actual)	Interventional	2017-01-31	Active, not recruiting
Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks [NCT02470650]	Phase 4	150 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART [NCT01869634]	Phase 4	37 participants (Actual)	Interventional	2013-06-30	Completed
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 [NCT01777997]	Phase 4	38 participants (Actual)	Interventional	2013-04-25	Completed
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel [NCT01687218]	Phase 2	195 participants (Actual)	Interventional	2013-09-25	Completed
Combined HIV Adolescent PrEP and Prevention: On Demand Pre-exposure Prophylaxis to Provide Protection From HIV in Men - Using Foreskin Tissue to Estimate Protection (Phase II) [NCT03986970]	Phase 2	72 participants (Actual)	Interventional	2019-11-11	Completed
Community-based Venues for Delivery of Healthcare Services in Umlazi, South Africa: Proof of Concept Pilot Conducted in Hair Salons [NCT04222504]		500 participants (Anticipated)	Interventional	2021-02-08	Recruiting
Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for W [NCT02302547]	Phase 3	224 participants (Actual)	Interventional	2014-12-31	Completed
A Phase II Acceptability Study of Oral Emtricitabine/Tenofovir Alafenamide (F/TAF) vs Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for the Prevention of HIV Acquisition in Adolescent Girls and Young Women (AGYW) [NCT05458765]	Phase 2	330 participants (Actual)	Interventional	2022-06-21	Active, not recruiting
A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Expo [NCT01505114]	Phase 2	594 participants (Actual)	Interventional	2012-06-30	Completed
Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among Young Men Who Have Sex With Men (YMSM) in the United States [NCT01772823]	Phase 2	200 participants (Actual)	Interventional	2012-11-30	Completed
Advancing New Computer-based Health Outreach Regarding Sexual Behavior (ANCHORS) Study: UH3 Project [NCT04331704]	Phase 4	88 participants (Anticipated)	Interventional	2021-01-12	Recruiting
Prospective Pilot Study of the Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE) [NCT04249037]	Phase 4	10 participants (Actual)	Interventional	2020-12-15	Terminated(stopped due to Insufficient enrollment)
A Phase 4, Single-Arm Study of the Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients With Active Illicit Substance Use [NCT03998176]	Phase 4	43 participants (Actual)	Interventional	2019-10-09	Completed
"Phase IV, Single-center, Open Study to Evaluate the Benefits of the Start of Immediate Treatment Without Immunovirological Data (Same Day Treatment) Compared to Conventional Treatment With BIC / FTC / TAF (Bictegravir/Emtricitabina/Tenofovir) in Naive Pa [NCT05606055]	Phase 4	100 participants (Actual)	Interventional	2020-12-01	Completed
Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV in Brazilian Transgender Women [NCT03220152]	Phase 4	120 participants (Anticipated)	Interventional	2017-07-10	Recruiting
Decrease of Neuropsychiatric and Neurocognitive Side Effects Prevalence [NCT02447016]	Phase 4	25 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to no more participants taking atripla)
Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection [NCT04483674]	Phase 2	66 participants (Anticipated)	Interventional	2020-12-04	Recruiting
PrEP Adherence Monitoring Using Dried Blood Spots [NCT02022657]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2014-04-30	Completed
A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppres [NCT01641809]	Phase 2	244 participants (Actual)	Interventional	2012-08-06	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00016718 (3) [back to overview]	Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment.
NCT00016718 (3) [back to overview]	Proportion of Participants With Suppression of HIV Viral Load to Less Than 400 Copies/ml at Week 16
NCT00016718 (3) [back to overview]	Proportion of Participants With Suppression of HIV Viral Load to Less Than 50 Copies/ml at Week 16
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00074581 (2) [back to overview]	Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00074581 (2) [back to overview]	All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00084136 (18) [back to overview]	Time to Immunologic Failure (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Immunologic Failure (PI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(PI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Treatment Failure (PI Comparison)
NCT00084136 (18) [back to overview]	Time to Treatment Failure (NRTI Comparison)
NCT00084136 (18) [back to overview]	Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (PI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(PI Comparison)
NCT00084136 (18) [back to overview]	Change in CD4 Count From Screening to Weeks 24, 48, 96 (NRTI Comparison)
NCT00084136 (18) [back to overview]	Change in CD4 Count From Screening to Weeks 24, 48, 96 (PI Comparison)
NCT00084136 (18) [back to overview]	Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (PI Comparison)
NCT00084136 (18) [back to overview]	Time to First Dose Modification or Grade 3 or 4 Adverse Event (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to First Dose Modification or Grade 3 or 4 Adverse Event (PI Comparison)
NCT00089505 (9) [back to overview]	Percent of Participants Who Experienced Virologic Failure or Died
NCT00089505 (9) [back to overview]	Number of Participants Who Experienced HIV-related Disease Progression or Death
NCT00089505 (9) [back to overview]	Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.
NCT00089505 (9) [back to overview]	Number of Participants Who Experienced Virologic Failure or Died.
NCT00089505 (9) [back to overview]	Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality
NCT00089505 (9) [back to overview]	CD4 Count Change From Randomization
NCT00089505 (9) [back to overview]	Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month
NCT00089505 (9) [back to overview]	Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry
NCT00089505 (9) [back to overview]	Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry
NCT00090779 (9) [back to overview]	Time to Treatment Initiation or Death
NCT00090779 (9) [back to overview]	Time to Meeting the Clinical, Virologic, or Immunologic Criteria for Treatment Initiation or Re-initiation
NCT00090779 (9) [back to overview]	Change in CD4 Counts Cells/mm^3 From Week 36 for IT Arm and From Week 0 for DT Arm
NCT00090779 (9) [back to overview]	Ranked log10 HIV-1 RNA Viral Load (log10 Copies/mL) Averaged at Weeks 72 and 76 for the IT Arm and Ranked log10 HIV-1 RNA Viral Load (log10 Copies/mL) Averaged at Weeks 36 and 40 for the DT Arm
NCT00090779 (9) [back to overview]	Ranked Log10 HIV-1 RNA Viral Load (log10 Copies/mL) Averaged at 72 and 76 Weeks for the IT Arm and DT Arm
NCT00090779 (9) [back to overview]	Time From Study Entry in DT Arm Participants or From Week 36 in IT Arm Participants to Meeting the Clinical, Virologic, or Immunologic Criteria for Treatment Initiation or Re-initiation
NCT00090779 (9) [back to overview]	Number of Participants Meeting Clinical, Virologic, or Immunologic Criteria for Treatment Initiation or Re-initiation
NCT00090779 (9) [back to overview]	Number of Participants in IT Arm Off Treatment Before 36 Weeks
NCT00090779 (9) [back to overview]	Number of Participants Experiencing Either a CDC Category B or C Diagnosis, CD4<200 Cells/mm^3 or CD4 Percent <14%.
NCT00099632 (5) [back to overview]	Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping
NCT00099632 (5) [back to overview]	Number of Participants With New Circulating NRTI-resistant Variants Detected by Standard Composite (Bulk) Genotyping.
NCT00099632 (5) [back to overview]	Number of Participants With New PI-resistant Variants as Detected by Standard Composite (Bulk) Genotyping.
NCT00099632 (5) [back to overview]	Severe (Grade 3) and Higher Adverse Events and Any Grade Adverse Event That Leads to a Treatment Change From First Day of Study Treatment to Week 12
NCT00099632 (5) [back to overview]	Number of Participants Who Discontinued Study Treatment Prematurely
NCT00105079 (6) [back to overview]	Number of Patients Who Discontinued Treatment Due to Abnormal Laboratory Parameters
NCT00105079 (6) [back to overview]	Change From Baseline in Cluster Differentiation Antigen 4 Positive (CD4+) Lymphocyte Count
NCT00105079 (6) [back to overview]	Change From Baseline in HIV-1 RNA Viral Load
NCT00105079 (6) [back to overview]	Number of Patients With HIV-1 RNA Viral Load <50 and <400 Copies/mL
NCT00105079 (6) [back to overview]	Number of Participants Assessed for Adverse Events (AEs)
NCT00105079 (6) [back to overview]	Number of Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Viral Load <50 Copies/mL
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 48.
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Quality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Quality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Bothered With the Side Effects of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (General Satisfaction With Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Satisfaction With Convenience and Simplicity of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Satisfaction With Current Treatment Regimen to Control HIV): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Satisfaction With Tolerability of Current Treatment Regimen) Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144
NCT00112047 (53) [back to overview]	Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48
NCT00112047 (53) [back to overview]	Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96
NCT00112047 (53) [back to overview]	Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Change in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change in Limb Fat (kg) From Week 48 to Week 144
NCT00112047 (53) [back to overview]	Change in Limb Fat (kg) From Week 48 to Week 96
NCT00112047 (53) [back to overview]	Change in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change in Total Body Fat (kg) From Week 48 to Week 144
NCT00112047 (53) [back to overview]	Change in Total Body Fat (kg) From Week 48 to Week 96
NCT00112047 (53) [back to overview]	Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change in Trunk Fat (kg) From Week 48 to Week 144
NCT00112047 (53) [back to overview]	Change in Trunk Fat (kg) From Week 48 to Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 c/mL at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 96
NCT00118898 (22) [back to overview]	Number of Participants With Treatment Modification
NCT00118898 (22) [back to overview]	Number of Participants With Regimen Failure
NCT00118898 (22) [back to overview]	Amount of Study Follow-up
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing Treatment Modification
NCT00118898 (22) [back to overview]	Time From Treatment Dispensation to Regimen Failure (First Occurrence of Virologic Failure or Treatment Modification)
NCT00118898 (22) [back to overview]	Time From Treatment Dispensation to a Grade 3/4 Safety Event
NCT00118898 (22) [back to overview]	Time From Randomization to Virologic Failure
NCT00118898 (22) [back to overview]	Time From Treatment Dispensation to Treatment Modification
NCT00118898 (22) [back to overview]	The Number of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL
NCT00118898 (22) [back to overview]	Number of Participants With HIV-1 RNA Levels Less Than 200 Copies/mL
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing a Grade 3/4 Safety Event
NCT00118898 (22) [back to overview]	Change in Fasting Triglyceride Level From Baseline
NCT00118898 (22) [back to overview]	Change in Fasting Total Cholesterol Level From Baseline
NCT00118898 (22) [back to overview]	Change in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Level From Baseline
NCT00118898 (22) [back to overview]	Change in Fasting High-density Lipoprotein (HDL) Cholesterol Level From Baseline
NCT00118898 (22) [back to overview]	Number of Participants With a Grade 3/4 Safety Event
NCT00118898 (22) [back to overview]	Change in CD4 Count (Cells/mm3) From Baseline
NCT00118898 (22) [back to overview]	Number of Participants With Virologic Failure and Emergence of Major Resistance
NCT00118898 (22) [back to overview]	Number of Participants With Virologic Failure
NCT00118898 (22) [back to overview]	Number of Participants Experiencing Certain Targeted Clinical Events, Including Death, AIDS-defining Illness, and HIV-1 Related Events.
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing Virologic Failure
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing Regimen Failure
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48 by Missing=Failure (M=F), Switched Included Analysis.
NCT00244712 (14) [back to overview]	Median Change From Baseline in CD4+ Cells at Weeks 48 and 96
NCT00244712 (14) [back to overview]	Median Change From Baseline in HIV-1 RNA at Week 48 and 96
NCT00244712 (14) [back to overview]	Number of Confirmed Virologic Failure Participants at Week 96 With Genotypic Resistance to Lamivudine (3TC) and Emtricitabine (FTC) and Had Phenotypic Reduced Susceptibility
NCT00244712 (14) [back to overview]	Number of Confirmed Virologic Failure Participants Who Had Treatment-emergent Genotypic Resistance Through 96 Weeks
NCT00244712 (14) [back to overview]	Number of Participants Who Meet the Protocol-defined Virologic Failure (PDVF) Criteria at Week 96
NCT00244712 (14) [back to overview]	Number of Participants Who Reported a Suspected Abacavir Hypersensitivity Reaction (ABC HSR) Reaction or Proximal Renal Tubule Dysfunction
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Weeks 48 and 96 in Participants With Baseline HIV-1 RNA <100,000 Copies/mL
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Weeks 48 and 96 in Participants With Baseline HIV-1 RNA >=100,000 Copies/mL
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <400 Copies/mL at Weeks 48 and 96 in Participants With Baseline HIV-1 RNA <100,000 Copies/mL
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <400 Copies/mL at Weeks 48 and 96 in Participants With Baseline HIV-1 RNA >=100,000 Copies/mL
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <400 Copies/mL at Weeks 48 and 96
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Quality of Life as Measured by the Medical Outcomes Survey - Human Immunodeficiency Virus (MOS-HIV) at Week 48
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Quality of Life as Measured by the Medical Outcomes Survey - Human Immunodeficiency Virus (MOS-HIV) at Week 24
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Quality of Life as Measured by the Impact of Gastro-intestinal Toxicity at Week 12 (IBS-QoL)
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Fasting Tumor Necrosis Factor (TNF)-Alpha Asssociated With RS11030679
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Fasting Tumor Necrosis Factor (TNF)-Alpha Associated With IL6_5309
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Fasting Triglycerides Associated With RETN_734
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Fasting Triglycerides Associated With RETN_598
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Fasting Triglycerides Associated With RETN_2265
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Fasting Triglycerides Associated With RETN_097
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Fasting Triglycerides Associated With APOE_C130R
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Fasting Plasminogen Activator Inhibitor (PAI)-1 Associated With APOE_R176C
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Fasting Non-High Density Lipoprotein (HDL) Cholesterol Associated With RETN_097
NCT00272779 (88) [back to overview]	Mean Change From Baseline (BL) in Quality of Life as Measured by the Impact of Gastro-intestinal Toxicity at Week 4 (IBS-QoL)
NCT00272779 (88) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of ATV/RTV and LPV/RTV in the Presence of an ARV Regimen Including TDF at Week 4
NCT00272779 (88) [back to overview]	Terminal Elimination Half-life (T-half) of ATV/RTV and LPV/RTV in the Presence of an ARV Regimen Including TDF at Week 4
NCT00272779 (88) [back to overview]	Reduction of log10 HIV RNA Levels From Baseline to Week 48
NCT00272779 (88) [back to overview]	Reduction of log10 HIV RNA Levels From Baseline at Week 96
NCT00272779 (88) [back to overview]	Protein Binding Adjusted Effective Concentration (EC-90) of ATV and LPV When Dosed With RTV at Week 4
NCT00272779 (88) [back to overview]	Percentage of Participants With Lipoatrophy at Week 96
NCT00272779 (88) [back to overview]	Number of Participants With Human-immunodeficiency Virus- Ribonucleic Acid (HIV-RNA) < 50 Copies (c)/mL at Week 48
NCT00272779 (88) [back to overview]	Number of Participants With HIV RNA < 50 c/mL) at Week 96
NCT00272779 (88) [back to overview]	Number of Participants With HIV RNA < 400 c/mL) at Week 96
NCT00272779 (88) [back to overview]	Number of Participants With HIV RNA < 400 c/mL at Week 48
NCT00272779 (88) [back to overview]	Number of Participants With Confirmed Plasma HIV RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time to Loss of Virologic Response [TLOVR] Algorithm)
NCT00272779 (88) [back to overview]	Number of Participants Who Adhered to Regimen as Measured by Multicenter AIDS Cohort Study Adherence Questionnaire (MACS) at Week 48
NCT00272779 (88) [back to overview]	Minimum Plasma Concentration (Cmin) of ATV/RTV and LPV/RTV in the Presence of an ARV Regimen Including TDF at Week 4
NCT00272779 (88) [back to overview]	Mean Changes in Fasting Insulin at Week 96
NCT00272779 (88) [back to overview]	Mean Changes in Fasting Glucose at Week 96
NCT00272779 (88) [back to overview]	Mean Changes From Baseline in Body Weight at Week 96
NCT00272779 (88) [back to overview]	Mean Change in Weight From Baseline at Week 48
NCT00272779 (88) [back to overview]	Mean Change in Fasting Insulin at Week 48
NCT00272779 (88) [back to overview]	Mean Change in Fasting Glucose at Week 48
NCT00272779 (88) [back to overview]	Mean Change in Body Mass Index (BMI) in Participants at Week 48
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Waist-to-hip-ratio at Week 96
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Waist-to-hip-ratio at Week 48
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Waist Circumference at Week 96
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Waist Circumference at Week 48
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Trunk-to-limb Fat Ratio Measured by DEXA at Week 48
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Trunk-to-Limb Fat Ratio as Measured by Dual Energy X-ray Absorptiometry (DEXA) at Week 96
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count at Week 48
NCT00272779 (88) [back to overview]	Mean Change From Baseline in CD4 Cell Count at Week 96
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Body Weight at Week 96
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Body Weight at Week 48
NCT00272779 (88) [back to overview]	Mean Change From Baseline in BMI at Week 96
NCT00272779 (88) [back to overview]	Mean Change From Baseline in BMI at Week 96
NCT00272779 (88) [back to overview]	Mean Change From Baseline in BMI at Week 48
NCT00272779 (88) [back to overview]	Maximum Plasma Concentration (Cmax) of ATV/RTV and LPV/RTV in the Presence of an Antiretroviral (ARV) Regimen Including TDF at Week 4
NCT00272779 (88) [back to overview]	Inhibitory Quotient (IQ) of ATV and LPV When Dosed With RTV at Week 4
NCT00272779 (88) [back to overview]	Cmin of Tenofovir at Week 4
NCT00272779 (88) [back to overview]	Cmin of RTV at Week 4
NCT00272779 (88) [back to overview]	Cmax of Tenofovir at Week 4
NCT00272779 (88) [back to overview]	Cmax of RTV at Week 4
NCT00272779 (88) [back to overview]	AUC (TAU) of Tenofovir at Week 4
NCT00272779 (88) [back to overview]	AUC (0-24) of RTV at Week 4
NCT00272779 (88) [back to overview]	Area Under the Concentration-time Curve, in One Dosing Interval [AUC(TAU)] of ATV/RTV and LPV/RTV in the Presence of an ARV Regimen Including TDF at Week 4
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Quality of Life as Measured by the Impact of Gastro-intestinal Toxicity at Week 24 Using the Irritable Bowel Syndrome Quality of Life (IBS-QoL)
NCT00272779 (88) [back to overview]	Treatment Emergent Resistance in Isolates From Participants With Virologic Failure at Week 48
NCT00272779 (88) [back to overview]	Number of Participants With Virologic Failure Showing Treatment Emergent Resistance Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants With Single Nucleotide Polymorphisms (SNPs) Included in Genotype-Phenotype Analysis
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Urinalysis Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Urinalysis Through Week 48
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Serum Enzymes Levels Through Week 48
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Serum Enzyme Levels Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Renal Function Test Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Renal Function Test Through Week 48
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Liver Function Test Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Liver Function Test Through Week 48
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Hematology: Hemoglobin, Hematocrit, Platelet Count, INR, Neutrophils, PT and WBC Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Hematology Through Week 48: Hemoglobin, Hematocrit, Platelet Count, International Normalized Ratio (INR), Neutrophils, Prothrombin Time (PT) and White Blood Cells (WBC)
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Fasting Lipids Through Week 48
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Fasting Lipids Level Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Fasting Glucose Through Week 48
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Fasting Glucose Levels Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Electrolytes Through Week 48
NCT00272779 (88) [back to overview]	Number of Participants With Laboratory Abnormalities in Electrolytes Level Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Experienced Adverse Events (AEs) and Experienced Events Leading to Discontinuation Through Week 96
NCT00272779 (88) [back to overview]	Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Experienced Adverse Events (AEs) and Experienced AEs Leading to Discontinuation Through Week 48
NCT00272779 (88) [back to overview]	Median Changes From Baseline at Week 96 in VAT-to-TAT, VAT-to-SAT and, Trunk-to-limb Fat Ratio Measured by Computed Tomography (CT)/DEXA
NCT00272779 (88) [back to overview]	Mean Percent Changes From Baseline in Limb, Trunk and Total Body Fat Measured by DEXA at Week 96
NCT00272779 (88) [back to overview]	Mean Percent Changes From Baseline in Limb, Trunk and Total Body Fat Measured by DEXA at Week 48
NCT00272779 (88) [back to overview]	Mean Percent Changes From Baseline in Bone Mineral Density (BMD) Measured by DEXA at Week 48
NCT00272779 (88) [back to overview]	Mean Percent Changes From Baseline in BMD Measured by DEXA at Week 96
NCT00272779 (88) [back to overview]	Mean Changes in Fasting Lipids at Week 96
NCT00272779 (88) [back to overview]	Mean Change in Fasting Lipid at Week 48
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Visceral Adipose Tissue (VAT) Associated With BRUNOL_1842
NCT00272779 (88) [back to overview]	Mean Change From Baseline in VAT-to-TAT Ratio Associated With CCDA122_5980
NCT00272779 (88) [back to overview]	Mean Change From Baseline in VAT Associated With RETN_730
NCT00272779 (88) [back to overview]	Mean Change From Baseline in Subcutaneous Adipose Tissue (SAT)-To-Trunk Adipose Tissue (TAT) Ratio Associated With CCDC122_5980
NCT00298363 (38) [back to overview]	Percentage of Participants With Hepatitis B Early Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 48 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 96 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With Baseline ADV-R + LAM-R Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized Alanine Aminotransferase (ALT) (for Subjects With Elevated ALT at Baseline) at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 144
NCT00298363 (38) [back to overview]	Median Change in MELD Score From Baseline at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With Only Baseline Adefovir Dipivoxil Resistance (ADV-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
NCT00298363 (38) [back to overview]	Percentage of Participants With Only Baseline Lamivudine-resistance (LAM-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48
NCT00298363 (38) [back to overview]	In the Subset of Participants Undergoing Liver Transplantation, Time to Recurrence of Hepatitis B, Defined as 2 Consecutive Plasma HBV DNA Concentrations ≥ 400 Copies/mL or 2 Consecutive HBsAg(+) Results
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in Child-Pugh Turcotte (CPT) Score of ≥ 2 Points at Weeks 48
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 144
NCT00298363 (38) [back to overview]	Percent Probability of Tolerability Failure
NCT00298363 (38) [back to overview]	Percent Probability of a Confirmed Increase in Serum Creatinine of ≥ 0.5 mg/dL From Baseline or a Confirmed Serum Phosphorus Level < 2.0 mg/dL
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 144 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 168 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Median Time-averaged Change (DAVG) in Plasma Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels at 48 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median DAVG in Plasma HBV DNA Levels at 96 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median DAVG in Plasma HBV DNA Levels at 168 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median DAVG in Plasma HBV DNA Levels at 144 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median Change in Model for End-Stage Liver Disease (MELD) Score From Baseline at Week 48
NCT00298363 (38) [back to overview]	Median Change in MELD Score From Baseline at Week 96
NCT00298363 (38) [back to overview]	Median Change in MELD Score From Baseline at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Week 48
NCT00307489 (19) [back to overview]	Hepatitis B Early Antigen (HBeAg) Loss at Week 168
NCT00307489 (19) [back to overview]	Change From Baseline in log10 Plasma HBV DNA Levels at Week 168
NCT00307489 (19) [back to overview]	Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168
NCT00307489 (19) [back to overview]	Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48
NCT00307489 (19) [back to overview]	HBsAg Loss at Week 168
NCT00307489 (19) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48
NCT00307489 (19) [back to overview]	Percentage of Participants With Normalized ALT at Week 48
NCT00307489 (19) [back to overview]	HBeAg Seroconversion at Week 48
NCT00307489 (19) [back to overview]	Change From Baseline in log10 Plasma HBV DNA Levels at Week 48
NCT00307489 (19) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168
NCT00307489 (19) [back to overview]	HBsAg Loss at Week 48
NCT00307489 (19) [back to overview]	Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48
NCT00307489 (19) [back to overview]	Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168
NCT00307489 (19) [back to overview]	Percentage of Participants With Normalized ALT at Week 168
NCT00307489 (19) [back to overview]	Percentage of Participants With Normal ALT at Week 48
NCT00307489 (19) [back to overview]	Percentage of Participants With Normal ALT at Week 168
NCT00307489 (19) [back to overview]	Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48
NCT00307489 (19) [back to overview]	Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168
NCT00307489 (19) [back to overview]	Hepatitis B Early Antigen (HBeAg) Loss at Week 48
NCT00335322 (2) [back to overview]	Time Weighted Mean Change From Baseline Plasma HIV-RNA
NCT00335322 (2) [back to overview]	Time-weighted Mean Change From Baseline Plasma HIV-RNA.
NCT00357552 (11) [back to overview]	Number of Participants With Study-targeted Diagnoses and Clinical Events
NCT00357552 (11) [back to overview]	Probability of Grade 3 or 4 Sign or Symptom, or Laboratory Toxicity Over 24 Weeks on Study.
NCT00357552 (11) [back to overview]	Time to Treatment Failure, Defined as the First Occurrence of Death, Disease Progression, or Virologic Failure.
NCT00357552 (11) [back to overview]	Level of HIV-1 RNA as Ascertained From Paired DBS and Plasma
NCT00357552 (11) [back to overview]	Number of Screened Subjects With at Least One NNRTI, or NRTI-associated Resistance Mutation at A5230 Screening.
NCT00357552 (11) [back to overview]	Percentage of Subjects Reporting Not Skipping Medications in the Last Month.
NCT00357552 (11) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA Levels < 400 Copies/mL From Baseline to Week 104
NCT00357552 (11) [back to overview]	Percentage of Enrolled Participants With Virologic Success at Week 24 on LPV/r Monotherapy
NCT00357552 (11) [back to overview]	Number of Subjects With at Least One New PI-associated Resistance Mutation at Time of Virologic Failure.
NCT00357552 (11) [back to overview]	Time to First New Grade 3 or 4 Sign or Symptom or Laboratory Toxicity Following LPV/r Intensification
NCT00357552 (11) [back to overview]	Change in CD4+ Cell Counts From Study Entry to Week 104
NCT00364793 (28) [back to overview]	Apparent Oral Clearance Adjusted for Body Weight (CLT/F/kg) of EFV at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	Area Under the Plasma Concentration Time Curve (AUC) Over One Dosing Interval From Time Zero to 24 Hours Post-dose(TAU) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	AUC (TAU) of Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	CLT/F of Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	CLT/F/kg of Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	Terminal Phase Elimination Half-life (T-HALF) in Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	CD4 Cell Count Change From Baseline at Weeks 24 and 48 - Treated Participants
NCT00364793 (28) [back to overview]	Cmax and Cmin of Didanosine (ddI) at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	Log10 c/mL HIV RNA Changes From Baseline at Weeks 60, 72, 84 and 96 - Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 50 c/mL at Week 24 as Analyzed by Different Algorithms - All Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 50 c/mL at Week 48 as Analyzed by Different Algorithms - All Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 400 c/mL at Week 24 as Analyzed by Different Algorithms - All Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA < 400 Copies Per Milliliter (c/mL) at Week 48 as Analyzed by Different Algorithms - All Treated Participants
NCT00364793 (28) [back to overview]	Percent of CD4 Cells Change From Baseline at Weeks 60, 72, 84, and 96 - Treated Participants
NCT00364793 (28) [back to overview]	Percent of CD4 Cells Change From Baseline at Weeks 24 and 48 - Treated Participants
NCT00364793 (28) [back to overview]	Number of Participants With Acquisition of Resistance to EFV Categorized by AUC Relationship - Evaluable Pharmacokinetic Population
NCT00364793 (28) [back to overview]	Number of Treated Participants With Resistance Associated Genotypic and Phenotypic Changes in Viruses - Participants With Virologic Failure, Lack of Suppression or Viral Load Rebound
NCT00364793 (28) [back to overview]	Number of Participants With Serum Chemistry Abnormalities - Treated Participants
NCT00364793 (28) [back to overview]	Number of Participants With On-Treatment Adverse Events (AEs), Related Adverse Events, Serious Adverse Events (SAEs), Death, Discontinuation Due to Adverse Events, and CDC Class C AIDS Events
NCT00364793 (28) [back to overview]	Number of Participants With Liver Function Test Laboratory Abnormalities - Treated Population
NCT00364793 (28) [back to overview]	CD4 Cell Count Change From Baseline at Weeks 60, 72, 84, and 96 - Treated Participants
NCT00364793 (28) [back to overview]	Number of Participants With Lipid and Glucose Laboratory Abnormalities - Treated Participants
NCT00364793 (28) [back to overview]	Number of Participants With Hematologic Abnormalities - Treated Participants
NCT00364793 (28) [back to overview]	Apparent Oral Clearance (CLT/F) of EFV at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	Maximum Observed Plasma Concentration (Cmax) and Plasma Concentration 24 Hours Post-dose (Cmin) of EFV at Week 2 - Pharmacokinetic Evaluable Population
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 400 c/mL at Weeks 60, 72, 84 and 96 (Observed Cases) - All Treated Participants
NCT00364793 (28) [back to overview]	Log10 c/mL HIV RNA Changes From Baseline Through Week 48 - Treated Participants
NCT00364793 (28) [back to overview]	The Number of Participants With Plasma HIV RNA Levels < 50 c/mL at Weeks 60, 72, 84 and 96 (Observed Cases) - All Treated Participants
NCT00369941 (73) [back to overview]	Number of Participants With Clinical Adverse Experiences (CAEs) at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Laboratory Adverse Experiences (LAEs) at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Nervous System Symptoms Assessed by Review of Accumulated Safety Data up to Week 8
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 156
NCT00369941 (73) [back to overview]	Change From Baseline in CD4 Cell Count at Week 156
NCT00369941 (73) [back to overview]	Change From Baseline in CD4 Cell Count at Week 240
NCT00369941 (73) [back to overview]	Change From Baseline in CD4 Cell Count at Week 96
NCT00369941 (73) [back to overview]	Change From Baseline in Cluster of Differentiation Antigen 4 (CD4) Cell Count at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With CAEs at Week 96
NCT00414518 (3) [back to overview]	Number of Participants Experiencing Either an AIDS-defining Event, a Grade 3 or 4 Adverse Event, or Acute Retroviral Syndrome
NCT00414518 (3) [back to overview]	Plasma HIV-1 Viral Load (Copies/ml) at Week 24 as Compared Between the Two Arms
NCT00414518 (3) [back to overview]	Viral Set Point
NCT00442962 (11) [back to overview]	Time to First Safety Event
NCT00442962 (11) [back to overview]	Late Change in CD4 Count From Baseline
NCT00442962 (11) [back to overview]	Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm)
NCT00442962 (11) [back to overview]	Percentage of Participants With Early Virologic Suppression
NCT00442962 (11) [back to overview]	Percentage of Participants With Early Virologic Response
NCT00442962 (11) [back to overview]	Time to Initial Virological Failure
NCT00442962 (11) [back to overview]	Time to Initial Virologic Response
NCT00442962 (11) [back to overview]	Time to First Dose Modification
NCT00442962 (11) [back to overview]	Early Changes in CD4 Count From Baseline
NCT00442962 (11) [back to overview]	Percentage of Participants With Late Virologic Suppression
NCT00442962 (11) [back to overview]	Percentage of Participants With Late Virologic Response
NCT00448669 (6) [back to overview]	Antiretroviral (ARV) Resistance Patterns in Seroconverters
NCT00448669 (6) [back to overview]	CD4 Evaluation After HIV Seroconversion
NCT00448669 (6) [back to overview]	HIV Incidence in the Tenofovir/Emtricitabine and Placebo Arms
NCT00448669 (6) [back to overview]	Percentage of Participants With Adverse Drug Reactions in the Tenofovir/Emtricitabine and Placebo Arms
NCT00448669 (6) [back to overview]	Rates of Adherence to Study Medication
NCT00448669 (6) [back to overview]	Changes in Condom Use During Study: Number of Participants With >=1 Condomless Sex Acts
NCT00524173 (4) [back to overview]	Number of Subjects With Hepatitis b Virus (HBV) DNA <1000 IU/ml at Week 48
NCT00524173 (4) [back to overview]	Number of Participants With HBV DNA <1000 IU/ml at Week 192
NCT00524173 (4) [back to overview]	Number of Participants With Loss of HBsAg
NCT00524173 (4) [back to overview]	Number of Participants With Normalized Alanine Aminotransferase (ALT)
NCT00549198 (58) [back to overview]	Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 24
NCT00549198 (58) [back to overview]	Number of Participants Classified as Protocol-defined Failures With Treatment-emergent Resistance to Study Drug in the Indicated Viruses at Week 96
NCT00549198 (58) [back to overview]	"Number of Participants Who Indicated Yes or No to the Question of Whether Unplanned Healthcare Resources Were Utilized"
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 96
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96
NCT00549198 (58) [back to overview]	Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48
NCT00549198 (58) [back to overview]	Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 24
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Osteocalcin at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73 m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72 m^2, >=10%, and >=20% at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 24
NCT00549198 (58) [back to overview]	Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 96
NCT00549198 (58) [back to overview]	Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 48
NCT00549198 (58) [back to overview]	Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 24
NCT00549198 (58) [back to overview]	Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 96
NCT00549198 (58) [back to overview]	Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 96
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 6 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 48 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 4 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 36 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 24 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 2 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 12 of Treatment
NCT00552240 (46) [back to overview]	Incidence of Patients With AIDS Progression at Each Visit
NCT00552240 (46) [back to overview]	Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml
NCT00552240 (46) [back to overview]	Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants
NCT00552240 (46) [back to overview]	Proportion of Patients Reporting Rash of Any Severity
NCT00552240 (46) [back to overview]	Proportion of Patients Reporting Hepatic Events of Any Severity
NCT00552240 (46) [back to overview]	Proportion of Patients Reporting CNS Side Effects of Any Severity
NCT00552240 (46) [back to overview]	Percentage Adherence by Pill Count
NCT00552240 (46) [back to overview]	Change in Glomerular Filtration Rate (GFR) From Baseline to Week 48
NCT00552240 (46) [back to overview]	Change in Framingham Score
NCT00552240 (46) [back to overview]	Change in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio
NCT00552240 (46) [back to overview]	Change in Fasting Plasma Triglycerides Level
NCT00552240 (46) [back to overview]	Change in Fasting Plasma Total Cholesterol Level
NCT00552240 (46) [back to overview]	Change in Fasting Low Density Lipoprotein (LDL)Cholesterol Level
NCT00552240 (46) [back to overview]	Change in Fasting High Density Lipoprotein (HDL) Cholesterol Level
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 8.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 6.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 48.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 4.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 36.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 24.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 2.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 12.
NCT00552240 (46) [back to overview]	AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death
NCT00552240 (46) [back to overview]	Number of Participants With Loss of Virologic Response Following Confirmed Virologic Response
NCT00552240 (46) [back to overview]	Proportion of Patients With DAIDS Grade >= 2 Laboratory Abnormalities
NCT00552240 (46) [back to overview]	Number of Patients With Virologic Rebound to >400 Copies/ml
NCT00552240 (46) [back to overview]	Number of Participants With Virologic Success (FDA Definition)
NCT00552240 (46) [back to overview]	Number of Participants With Virologic Response According to the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00552240 (46) [back to overview]	Number of Participants With Virologic Response (VR)
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 8 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 6 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 4 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 36 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 24 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 2 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 12 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 8 of Treatment
NCT00557245 (11) [back to overview]	Head Circumference Among Infants Born to Female Participants Taking Study Drug
NCT00557245 (11) [back to overview]	Number of Seroconverters With an HIV-1 Mutation Conferring Resistance to TDF or FTC
NCT00557245 (11) [back to overview]	Weight Among Infants Born to Female Participants Taking Study Drug
NCT00557245 (11) [back to overview]	Study Drug Adherence: Self-reported Missed Doses of Study Drug
NCT00557245 (11) [back to overview]	Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants
NCT00557245 (11) [back to overview]	Length Among Infants Born to Female Participants Taking Study Drug
NCT00557245 (11) [back to overview]	Study Drug Adherence: Total Number of Study Drug Doses Taken of the Total Dispensed Doses.
NCT00557245 (11) [back to overview]	Prevalence of Unprotected Sex During Follow-up
NCT00557245 (11) [back to overview]	Number of Participants With a Sexually Transmitted Infection (STI) During Follow-up
NCT00557245 (11) [back to overview]	Number of Participants With Serious Adverse Events (SAEs)
NCT00557245 (11) [back to overview]	Congenital Abnormalities Among Infants Born to Female Participants Taking Study Drug.
NCT00594646 (2) [back to overview]	Number of HIV-1 Infected Participants
NCT00594646 (2) [back to overview]	Medication Regimen Completion Rates
NCT00608569 (8) [back to overview]	Confirmed Virologic Failure at or Prior to Week 48
NCT00608569 (8) [back to overview]	Confirmed Virologic Failure at or Prior to Week 24
NCT00608569 (8) [back to overview]	CD8 Count at Follow-up Visits
NCT00608569 (8) [back to overview]	Time to First Grade 3 or 4 Sign or Symptom
NCT00608569 (8) [back to overview]	Time to First Grade 3 or 4 Lab or Sign/Symptom Event
NCT00608569 (8) [back to overview]	CD4 Count at Follow-up Visits
NCT00608569 (8) [back to overview]	Adherence to Second Line HAART Regimen
NCT00608569 (8) [back to overview]	Time to First Grade 3 or 4 Lab Event
NCT00625404 (12) [back to overview]	Confirmed Grade 3 or Higher ALT Elevation
NCT00625404 (12) [back to overview]	FTC and/or Tenofovir Resistance
NCT00625404 (12) [back to overview]	HIV Infection
NCT00625404 (12) [back to overview]	Participant Report of Change in Number of Sexual Partners
NCT00625404 (12) [back to overview]	Pill Counts and Participant Report of Adherence to Once-daily Pill Taking
NCT00625404 (12) [back to overview]	Plasma HIV RNA Level (HIV-1 Viral Load)
NCT00625404 (12) [back to overview]	Pregnancy Complications
NCT00625404 (12) [back to overview]	Confirmed Grade 3 or Higher Reduction in Phosphorus
NCT00625404 (12) [back to overview]	Confirmed Grade 3 or Higher AST Elevation
NCT00625404 (12) [back to overview]	Frequency of Adverse Events (AEs) During and Within 4 Weeks After Study Product Administration
NCT00625404 (12) [back to overview]	CD4+ T-cell Count
NCT00625404 (12) [back to overview]	Confirmed Grade 2 or Higher Serum Creatinine Toxicity
NCT00632970 (1) [back to overview]	Absolute Change in CD4 Cell Counts
NCT00641641 (1) [back to overview]	Mean Change From Baseline Plasma HIV RNA (Log Copies/mL)
NCT00654147 (6) [back to overview]	Study Medication Toxicity-related Discontinuation .
NCT00654147 (6) [back to overview]	Time to Confirmed Virologic Failure
NCT00654147 (6) [back to overview]	Time to Virologic Failure
NCT00654147 (6) [back to overview]	Change From Baseline CD4+ and CD8+ Cell Counts
NCT00654147 (6) [back to overview]	Weeks to HIV-1 RNA <200 Copies/ml
NCT00654147 (6) [back to overview]	Study Medication Tolerability
NCT00662545 (5) [back to overview]	HIV RNA < 75 Copies/ml
NCT00662545 (5) [back to overview]	Hepatitis B Virus (HBV) DNA
NCT00662545 (5) [back to overview]	Incidence of Permanent Discontinuation Due to Toxicity
NCT00662545 (5) [back to overview]	Incidence of New Hepatic Decompensation( Ascites, Variceal Hemorrhage, Encephalopathy)
NCT00662545 (5) [back to overview]	Incidence of ALT Flares
NCT00705679 (11) [back to overview]	Person-years of Follow-up of Oral TDF and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
NCT00705679 (11) [back to overview]	Number of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
NCT00705679 (11) [back to overview]	Incidence Rate of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product
NCT00705679 (11) [back to overview]	Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
NCT00705679 (11) [back to overview]	Person-years of Follow-up of Oral TDF-FTC and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Incidence Rate of HIV-1 Infections of Oral TDF and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Extended Safety of Daily Tenofovir 1% Gel, Oral TDF, and Oral FTC/TDF in Women at Risk for Sexually Transmitted HIV Infection Based on Occurrence of Grade 2, 3, and 4 Adverse Events
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Lactate (Millimoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Temperature (°F)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Soluble Tumor Necrosis Factor Receptor-2 (Picograms/Milliliter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Soluble Tumor Necrosis Factor Receptor-1 (Picograms/Milliliter)
NCT00711009 (82) [back to overview]	Score on Side Effects Scale of Treatment Satisfaction Questionnaire for Medication
NCT00711009 (82) [back to overview]	Score on Global Satisfaction Scale of Treatment Satisfaction Questionnaire for Medication
NCT00711009 (82) [back to overview]	Score on Effectiveness Scale of Treatment Satisfaction Questionnaire for Medication (TSQM)
NCT00711009 (82) [back to overview]	Percentage of Participants Responding (Plasma HIV-1 Ribonucleic Acid [RNA] Levels Less Than 40 Copies/Milliliter [mL]) at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00711009 (82) [back to overview]	Number of Participants Who Developed Resistance, Defined Conservatively, to Lopinavir
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Sodium (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Sitting Systolic Blood Pressure (mm Hg)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Sitting Heart Rate (Beats Per Minute)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Sitting Diastolic Blood Pressure (mm Hg)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Red Blood Cell Count (x 10^12/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Potassium (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Platelet Count (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Neutrophils (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Monocytes (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Mid-Thigh Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Mid-Arm Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Lymphocytes (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Low Density Lipoprotein (LDL): High Density Lipoprotein (HDL) Ratio (Ratio)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Low Density Lipoprotein (LDL) (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Lipase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Leptin (Nanograms/Milliliter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Lactate Dehydrogenase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Interleukin-6 (Nanograms/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Insulin (Picomoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Inorganic Phosphate (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Hips Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in High Density Lipoprotein Cholesterol (HDL) (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Hemoglobin (Grams/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Hematocrit (Fraction)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Fasting Glucose (Millimoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Eosinophils (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Upper Extremity Total Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Upper Extremity Lean Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Upper Extremity Fat (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Trunk Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Trunk Lean Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Trunk Fat (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Total Body Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Total Body Lean Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Total Body Fat (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Lower Extremity Total Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Lower Extremity Fat (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Bone Mineral Density (Grams/cm^2)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Bone Mineral Content (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in DEXA Scan of Lower Extremity Lean Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Creatinine (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Creatine Phosphokinase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Cholesterol (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Chloride (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Chest Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Calculated Creatinine Clearance (Milliliters/Second)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Calcium (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Blood Urea Nitrogen (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Bicarbonate (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Basophils (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Aspartate Aminotransferase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Alkaline Phosphatase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Albumin (Grams/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Alanine Aminotransferase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Adiponectin (Micrograms/Milliliter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in White Blood Cell Count (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Change From Baseline on Mental Component of Medical Outcomes Study HIV Health Survey
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Weight (kg)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Waist Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Magnesium (Millimoles/Liter)
NCT00711009 (82) [back to overview]	Change From Baseline on Physical Component Score of the Medical Outcomes Study HIV Health Survey
NCT00711009 (82) [back to overview]	Primary Outcome: Percentage of Participants With Potentially Clinically Significant Laboratory Values
NCT00711009 (82) [back to overview]	Percentage of Participants With Moderate or Severe Treatment-emergent, Drug-related Adverse Events
NCT00711009 (82) [back to overview]	Percentage of Participants Responding (Plasma HIV-1 RNA Levels Below 40 Copies/Milliliter [mL]) at Each Visit Based on the FDA Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00711009 (82) [back to overview]	Number of Participants Who Developed Resistance to Each Drug in the Study Regimen, as Defined by the International AIDS Society-USA (IAS-USA) Panel.
NCT00711009 (82) [back to overview]	Mean Change in CD4+ T-Cell Counts From Baseline to Each Visit
NCT00711009 (82) [back to overview]	Time to Loss of Virologic Response - Percentage of Participants Still Categorized as Responders at Day 672
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Urine Specific Gravity
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Urine pH
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Uric Acid (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Triglycerides (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Total Protein (Grams/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Total Bilirubin (Micromoles/Liter)
NCT00724711 (14) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Estimated Glomerular Filtration Rate (eGFR) by Modified Diet in Renal Disease (MDRD) at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Calculated Creatinine Clearance (CLcr) Using Ideal Body Weight by Cockcroft-Gault Method at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline C-Reactive Protein at Week 48
NCT00724711 (14) [back to overview]	Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) < 200 Copies/mL Through Week 48 Based on Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00724711 (14) [back to overview]	Change From Baseline Fasting Glucose at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Fibrinogen at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Ratio of Fasting Total Cholesterol Over High-density Lipoprotein (HDL) Cholesterol at Week 48
NCT00724711 (14) [back to overview]	Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 200 Copies/mL Through Week 48
NCT00724711 (14) [back to overview]	Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 50 Copies/mL Through Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Fasting Lipid Parameters at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Tumor Necrosis Factor-alpha (TNF-alpha) at Week 48
NCT00724711 (14) [back to overview]	Percentage of Participants With HIV-1 RNA < 200 Copies/mL at Week 48
NCT00743340 (1) [back to overview]	Number of Participants Who Had Access to, and Received the Intervention
NCT00752856 (4) [back to overview]	Viral Suppression Efficacy at 48 Weeks
NCT00752856 (4) [back to overview]	To Compare the Phase 1 Viral Decay Rates Between LPV/r + RAL vs. EFV/TDF/FTC Treatment Combinations.
NCT00752856 (4) [back to overview]	Compare Late Activated CD4+ T-cell Recovery Rates Between Treatment Regimens From Baseline to Week 48
NCT00752856 (4) [back to overview]	Compare Early Activated CD4+ T-cell Recovery Rates From Baseline to Week 4.
NCT00757783 (16) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) 4 Cell Count at Week 12 and 48, Last Observation Carried Forward (LOCF).
NCT00757783 (16) [back to overview]	Change From Baseline in Insulin at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Apolipoprotein B in the LE Set at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Apolipoprotein A1 in the LE Set at Week 12 and 48.
NCT00757783 (16) [back to overview]	Antiviral Activity, Human Immunodeficiency Virus Type 1 (HIV-1) RNA.
NCT00757783 (16) [back to overview]	Number of Participants With Antiviral Activity, HIV-1 RNA, Missing Values as Treatment Failure (M=F)
NCT00757783 (16) [back to overview]	Change From Baseline in Total Cholesterol (TC) Levels in the LE Set at Week 12 and 48
NCT00757783 (16) [back to overview]	Change From Baseline in TC/HDL Ratio in the LE Set at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Low Density Lipoprotein (LDL) Direct in the LE Set at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in HIV-1 RNA Viral Load at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in High Density Lipoprotein (HDL) in the LE Set at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Glucose at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Fasting Triglyceride (TG) Levels in the Lipid Evaluable (LE) Set at Week12
NCT00757783 (16) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) 4 Percent at Week 12 and 48, Last Observation Carried Forward (LOCF).
NCT00757783 (16) [back to overview]	Change From Baseline in CD4 Cell Count at Week 12 and 48, Observed Values.
NCT00762892 (5) [back to overview]	Change From Baseline in Log HIV Viral Load at 48 Weeks
NCT00762892 (5) [back to overview]	Change From Baseline in Lipids at 48 Weeks
NCT00762892 (5) [back to overview]	Change From Baseline in Homocysteine at 6 Months
NCT00762892 (5) [back to overview]	Change From Baseline in Interleukin-6 (IL-6) at 48 Weeks
NCT00762892 (5) [back to overview]	Change From Baseline in CD4 Count at 48 Weeks
NCT00768989 (28) [back to overview]	Number of Participants With HIV RNA Levels <50 Copies/mL at Weeks 48 and 96
NCT00768989 (28) [back to overview]	Raltegravir AUC (0-12h) in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Mean Change From Baseline in Absolute Cluster of Differentiation 4 Cell Count
NCT00768989 (28) [back to overview]	Baseline and Mean Change From Baseline in Total Cholesterol Levels
NCT00768989 (28) [back to overview]	Raltegravir Tmax
NCT00768989 (28) [back to overview]	Raltegravir Terminal Elimination Half Life
NCT00768989 (28) [back to overview]	Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4 (Continued)
NCT00768989 (28) [back to overview]	Number of Participants With Enzyme and Urine Laboratory Test Results With Worst Toxicity of Grades 1 to 4
NCT00768989 (28) [back to overview]	Number of Participants With Hematology Laboratory Test Results With Worst Toxicity of Grades 1 to 4 Among All Treated Participants
NCT00768989 (28) [back to overview]	Raltegravir Cmin Prior to the Morning Dose
NCT00768989 (28) [back to overview]	Raltegravir Cmin 12 Hours Postdose
NCT00768989 (28) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Death as Outcome, AEs Leading to Discontinuation, SAEs Leading to Discontinuation
NCT00768989 (28) [back to overview]	Mean Change From Baseline in Total Bilirubin Level
NCT00768989 (28) [back to overview]	Mean Change From Baseline in Electrocardiogram Findings
NCT00768989 (28) [back to overview]	Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4
NCT00768989 (28) [back to overview]	Atazanavir Area Under the Concentration Curve From Time 0 to 12 Hours (AUC [0-12h]) in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Atazanavir Area Under the Concentration Curve From Time 0 to 24 Hours (AUC [0-24h]) in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Atazanavir Cmin Prior to the Morning Dose
NCT00768989 (28) [back to overview]	Atazanavir Individual Inhibitory Quotient (IQ)
NCT00768989 (28) [back to overview]	Atazanavir Maximum Observed Plasma Concentration (Cmax) in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Atazanavir Terminal Elimination Half Life
NCT00768989 (28) [back to overview]	Atazanavir Time of Maximum Observed Plasma Concentration (Tmax)
NCT00768989 (28) [back to overview]	Atazanavir Trough Plasma Concentration (Cmin) 12 Hours Postdose
NCT00768989 (28) [back to overview]	Number of Nonresponders at Week 8
NCT00768989 (28) [back to overview]	Raltegravir Cmax in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Number of Participants With HIV RNA Levels <400 Copies/mL at Week 48
NCT00768989 (28) [back to overview]	Number of Participants With HIV RNA Levels <400 Copies/mL at Week 24
NCT00768989 (28) [back to overview]	Number of Participants With Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) Level <50 Copies/mL at Week 24
NCT00811954 (19) [back to overview]	Change in Fasting HDL Cholesterol Level From Baseline
NCT00811954 (19) [back to overview]	CD4+ T-cell Count Changes From Baseline
NCT00811954 (19) [back to overview]	Incidence of Death or AIDS Defining Events (CDC Category C)
NCT00811954 (19) [back to overview]	CD4+ T-cell Count
NCT00811954 (19) [back to overview]	Change in Fasting Plasma Glucose Level From Baseline
NCT00811954 (19) [back to overview]	Change in Fasting Total Cholesterol Level From Baseline
NCT00811954 (19) [back to overview]	Change in Fasting Triglycerides Level From Baseline
NCT00811954 (19) [back to overview]	Change in Framingham 10-year Risk of MI or Coronary Death From Baseline
NCT00811954 (19) [back to overview]	Change in Waist Circumference From Baseline
NCT00811954 (19) [back to overview]	Change in Waist:Height Ratio From Baseline
NCT00811954 (19) [back to overview]	Self-reported Adherence
NCT00811954 (19) [back to overview]	Presence of Mutations Associated With NRTI Resistance
NCT00811954 (19) [back to overview]	Presence of Mutations Associated With INI Resistance
NCT00811954 (19) [back to overview]	Presence of Mutations Associated With ATV/RTV or DRV/RTV Resistance
NCT00811954 (19) [back to overview]	Incidence of Targeted Serious Non-AIDS Defining Events (Renal Failure, Liver Disease, Serious Metabolic Disorder, and CVD)
NCT00811954 (19) [back to overview]	Cumulative Probability of Time to Loss of Virologic Response (TLOVR) by Week 96
NCT00811954 (19) [back to overview]	Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96
NCT00811954 (19) [back to overview]	Cumulative Incidence of First Adverse Event by Week 96
NCT00811954 (19) [back to overview]	Cumulative Probability of First Virologic Failure by Week 96
NCT00827112 (16) [back to overview]	Percentage of Participants With Less Than 50 Copies/mL of HIV-1 RNA
NCT00827112 (16) [back to overview]	Change From Baseline in Plasma log10 Viral Load at Weeks 16, 24, 48 and 96
NCT00827112 (16) [back to overview]	Change From Baseline in HIV-1 RNA Levels of First 15 Participants at Days 4, 7, 10 and 14
NCT00827112 (16) [back to overview]	Average Observed Plasma Concentration (Cavg) of Maraviroc
NCT00827112 (16) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Maraviroc
NCT00827112 (16) [back to overview]	HIV-1 RNA Levels at Baseline
NCT00827112 (16) [back to overview]	Time-Averaged Difference (TAD) in log10 Viral Load
NCT00827112 (16) [back to overview]	Percentage of Participants With Less Than 400 Copies/mL of HIV-1 RNA
NCT00827112 (16) [back to overview]	Number of Participants With HIV-1 RNA Tropism Status Using Trofile Assay
NCT00827112 (16) [back to overview]	Change From Baseline in Cluster of Differentiation 4+T Lymphocyte (CD4) Cell Counts at Weeks 16, 24, 48 and 96
NCT00827112 (16) [back to overview]	Time to Loss of Virological Response (TLOVR)
NCT00827112 (16) [back to overview]	Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL)
NCT00827112 (16) [back to overview]	Number of Participants With Phenotypic Resistance
NCT00827112 (16) [back to overview]	Number of Participants With Genotypic Resistance
NCT00827112 (16) [back to overview]	Minimum Observed Plasma Concentration (Cmin) of Maraviroc
NCT00827112 (16) [back to overview]	Change From Baseline in Cluster of Differentiation 8+T Lymphocyte (CD8) Cell Count at Weeks 16, 24, 48 and 96
NCT00851799 (27) [back to overview]	Fold Change in High Sensitivity C-reactive Protein (hsCRP) From Study Entry to Weeks 48 and 96
NCT00851799 (27) [back to overview]	Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT)
NCT00851799 (27) [back to overview]	Change in Brachial Artery (BA) Flow Mediated Dilation (FMD) From Study Entry to Week 24
NCT00851799 (27) [back to overview]	Percent Change in Bone Mineral Density (BMD) of the Hip From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Percent Change in Bone Mineral Density (BMD) of the Lumber Spine From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Percent Change in Bone Mineral Density (BMD) of the Total Body From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Percent Change in Lean Mass From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Percent Change in Subcutaneous Abdominal Fat (SAT) From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Percent Change in Total Limb Fat From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Percent Change in Trunk Fat From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Percent Change in Visceral Abdominal Fat (VAT) From Study Entry to Week 96
NCT00851799 (27) [back to overview]	CD4+ T-cell Count at Study Entry and Weeks 24, 48, 96 and 144
NCT00851799 (27) [back to overview]	Change in Absolute Flow Mediated Dilation (FMD) From Study Entry to Weeks 4, 24 and 48
NCT00851799 (27) [back to overview]	Change in Brachial Artery Flow Mediated Dilation (FMD) From Study Entry to Weeks 4 and 48
NCT00851799 (27) [back to overview]	Change in CD4+ T-cell Count From Study Entry to Weeks 24, 48, 96 and 144
NCT00851799 (27) [back to overview]	Change in Fasting Calculated Low-density Lipoprotein Cholesterol (LDL-C) From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Change in Fasting Glucose Level From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Change in Fasting High-density Lipoprotein Cholesterol (HDL-C) From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Change in Fasting Insulin Level From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Change in Fasting Total Cholesterol (TC) From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Change in Fasting Triglyceride (TG) From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Fold Change in D-dimer From Study Entry to Weeks 48 and 96
NCT00851799 (27) [back to overview]	Fold Change in Interleukin-6 (IL-6) From Study Entry to Weeks 48 and 96
NCT00851799 (27) [back to overview]	Fold Change in Percent Expression of CD38+HLADR+ on CD4+ (Percent) From Study Entry to Weeks 24 and 96
NCT00851799 (27) [back to overview]	Fold Change in Percent Expression of CD38+HLADR+ on CD8+ (Percent) From Study Entry to Weeks 24 and 96
NCT00851799 (27) [back to overview]	Fold Change in Soluble CD14 From Study Entry to Weeks 48 and 96
NCT00851799 (27) [back to overview]	Fold Change in Soluble CD163 From Study Entry to Weeks 48 and 96
NCT00856323 (4) [back to overview]	Self-reported Methamphetamine Use in Previous 30 Days.
NCT00856323 (4) [back to overview]	Description of Incident STI Infections.
NCT00856323 (4) [back to overview]	Post-Exposure Prophylaxis Medication Adherence
NCT00856323 (4) [back to overview]	HIV-related Sexual Risk Behaviors in Previous 30 Days.
NCT00862823 (2) [back to overview]	Area Under the Concentration Time Curve for Tenofovir, Emtricitabine and Efavirenz
NCT00862823 (2) [back to overview]	Maximum Concentration for Tenofovir, Emtricitabine and Efavirenz
NCT00869960 (8) [back to overview]	Ritonavir Systemic Exposure During the Follicular Phase (Days 6-10 After Menses)
NCT00869960 (8) [back to overview]	Tenofovir Systemic Exposure During the Follicular Phase (Days 6-10 After Menses)
NCT00869960 (8) [back to overview]	Ritonavir Systemic Exposure During the Luteal Phase (Days 20-25 After Menses)
NCT00869960 (8) [back to overview]	Atazanavir Systemic Exposure During the Luteal Phase (Days 20-25 After Menses)
NCT00869960 (8) [back to overview]	Emtricitabine Systemic Exposure During the Follicular Phase (Days 6-10 After Menses)
NCT00869960 (8) [back to overview]	Tenofovir Systemic Exposure During the Luteal Phase (Days 20-25 After Menses)
NCT00869960 (8) [back to overview]	Atazanavir Systemic Exposure During the Follicular Phase (Days 6-10 After Menses)
NCT00869960 (8) [back to overview]	Emtricitabine Systemic Exposure During the Luteal Phase (Days 20-25 After Menses)
NCT00885664 (11) [back to overview]	SF-12 Physical Capacity Score
NCT00885664 (11) [back to overview]	INF Gamma
NCT00885664 (11) [back to overview]	IL-8
NCT00885664 (11) [back to overview]	IL-7
NCT00885664 (11) [back to overview]	IL-6
NCT00885664 (11) [back to overview]	IL-4
NCT00885664 (11) [back to overview]	IL-10
NCT00885664 (11) [back to overview]	IL-1 Beta
NCT00885664 (11) [back to overview]	SF-12 Mental Capacity Score
NCT00885664 (11) [back to overview]	TNF Alpha
NCT00885664 (11) [back to overview]	Symptom Score
NCT00924898 (6) [back to overview]	Number of Participants With Baseline Genotypic Resistance to Antiretroviral Medications
NCT00924898 (6) [back to overview]	Number of Participants Without Virologic Failure at Week 24
NCT00924898 (6) [back to overview]	Number of Participants Without Virologic Failure at Week 48
NCT00924898 (6) [back to overview]	Number of Participants With HIV RNA Suppression at Week 96
NCT00924898 (6) [back to overview]	Time to HIV RNA Suppression <50 Copies/mL
NCT00924898 (6) [back to overview]	Number of Participants With Baseline Genotypic Resistance to One or More Antiretroviral Drugs in the Study Treatment
NCT00928187 (13) [back to overview]	Development of Metabolic Syndrome
NCT00928187 (13) [back to overview]	Adherence
NCT00928187 (13) [back to overview]	Gain in CD4 Cells Between Baseline and W48
NCT00928187 (13) [back to overview]	Number of Patients Discontinuing Study Treatment
NCT00928187 (13) [back to overview]	Number of Patients With HIV Plasma Viral Load < 200 Copies/ml
NCT00928187 (13) [back to overview]	Number of Patients With HIV Plasma Viral Load < 50 Copies/ml
NCT00928187 (13) [back to overview]	Number of Patients With Plasma HIV RNA < 50 Copies/mL
NCT00928187 (13) [back to overview]	Number of Patients With Resistance Mutations
NCT00928187 (13) [back to overview]	Patients With Plasma HIV RNA < 200 Copies/ml
NCT00928187 (13) [back to overview]	Tolerance: Equal or Superior to a 25% Reduction in eGFR (Glomerular Filtration Rate)
NCT00928187 (13) [back to overview]	Tolerance: Gastrointestinal Complains
NCT00928187 (13) [back to overview]	Tolerance: Neuropathies (Grade 1 to 4)
NCT00928187 (13) [back to overview]	Number of Patients With WHO Stage 3 and 4 HIV Related Events
NCT00931801 (4) [back to overview]	Maintenance of Virologic Suppression
NCT00931801 (4) [back to overview]	Change in Quality of Life From Baseline to 48 Weeks of Study Treatment
NCT00931801 (4) [back to overview]	The Difference in CD4 From Baseline to Week 48
NCT00931801 (4) [back to overview]	The Change in Adherence to Study Treatment Arm From Baseline to Week 48
NCT00959894 (25) [back to overview]	Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <50 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <200 Copies/mL at Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Antiretroviral Activity of Etravirine 400 mg Given Once Daily, With Fixed-dose Truvada Once Daily, Among Treatment-naïve HIV-1 Infected Adults as Measured by the Percentage of Participants With HIV RNA < 50 Copies/mL at Week 24
NCT00959894 (25) [back to overview]	Probability of Remaining Free of a Safety/Tolerability Event at 96 Weeks
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <200 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <200 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Population Pharmacokinetics of Etravirine 400 mg Once Daily, in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-naïve HIV-1 Infected Adults: Etravirine AUC-24 Hours at Steady State
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <50 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Pharmacokinetics of Etravirine in Genital Secretions of up to 10 Men and up to 10 Women at Week 4 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Tolerability of Etravirine in HIV-1 Infected Adults Initiating Antiretroviral Therapy
NCT00959894 (25) [back to overview]	Resistance Mutations in the Subset of Patients With Confirmed Virologic Failure Who Have HIV RNA >500 Copies/mL and Genotype Resistance Results
NCT00959894 (25) [back to overview]	Population Pharmacokinetics of Etravirine 400 mg Once Daily, in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-naïve HIV-1 Infected Adults
NCT00959894 (25) [back to overview]	Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Fat Mass Ratio as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Fat Mass Ratio as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00960622 (1) [back to overview]	Change in Peak Oxygen Uptake.
NCT01003990 (1) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Treatment Related SAEs, Treatment Related Adverse Events (AEs), AEs Leading to Discontinuation of Study Therapy, Grade 3 to Grade 4 AEs, Grade 3 to Grade 4 AEs, CDC Class C AIDS Events, or Death
NCT01025427 (1) [back to overview]	Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 16
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 20
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 24
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 24
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 4
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 8
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 12
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 16
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 20
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 24
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 4
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 4
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 8
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Actual Number of Study Visits Completed by 24 Weeks
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Overall
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 12
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 16
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 20
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 4
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 8
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 12
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Baseline
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Ran Out of Study Pills
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Had Too Many Study Pills to Take
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Had a Change in Daily Routine
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Felt Sick or Ill
NCT01033942 (96) [back to overview]	Acceptability of Risk Reduction Counseling at Every Visit
NCT01033942 (96) [back to overview]	Acceptability of Questions About Sexual Behavior at Every Visit
NCT01033942 (96) [back to overview]	Acceptability of Physical Examination by a Doctor
NCT01033942 (96) [back to overview]	Acceptability of Participating in Group Sessions
NCT01033942 (96) [back to overview]	Acceptability of Health Clinic for Study Visits
NCT01033942 (96) [back to overview]	Acceptability of Having an HIV Test at Every Visit
NCT01033942 (96) [back to overview]	Acceptability of Being Randomly Assigned to a Group
NCT01033942 (96) [back to overview]	Acceptability of Being Contacted by the Research Team in Between Visits
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 8
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Felt Depressed/Overwhelmed
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Fell Asleep/Slept Through Dose Time
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Didn't Think it Was Needed Because he/She Was Not Engaged in Risky Sex
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Did Not Want Others to Notice Participant Was Taking Medications
NCT01033942 (96) [back to overview]	Frequency of Missing Pills Because Participant Felt Like the Study Pill Was Toxic/Harmful
NCT01033942 (96) [back to overview]	Acceptability of the Taste of the Pill
NCT01033942 (96) [back to overview]	Acceptability of the Color of the Pill
NCT01033942 (96) [back to overview]	Acceptability of Taking the Pill Everyday
NCT01033942 (96) [back to overview]	Acceptability of Taking Part in the Study
NCT01033942 (96) [back to overview]	Acceptability of Size of Pill
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Simply Forgot
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 8
NCT01033942 (96) [back to overview]	Number of Missed Doses Over Time Based on Self-Report Calendar Data
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Baseline
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 24
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 20
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 16
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 4
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 12
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 16
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 20
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Wanted to Avoid Side Effects
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Was Away From Home
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 12
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 16
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 20
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 24
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 4
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 8
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Was Too Busy With Other Things
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 12
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Obstetrical Complications
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of HIV/AIDS-related Event or World Health Organization (WHO) Clinical Stage 2 or 3 Events
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of Progression to AIDS-defining Illness or Death
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of Tuberculosis
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence Rate of Cardiovascular or Other Metabolic Events
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Obstetrical Complications
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)
NCT01061151 (28) [back to overview]	Postpartum Component: Proportion of Mother-Infant Pairs With no Death or HIV Diagnosis Through 24 Months Post-delivery
NCT01061151 (28) [back to overview]	Postpartum Component: Incidence of Grade 3 or Higher Adverse Events and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events
NCT01061151 (28) [back to overview]	Postpartum Component: Incidence of Confirmed Infant HIV Infection
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of HIV/AIDS-related Events
NCT01061151 (28) [back to overview]	Maternal Health Component: Toxicity: Incidence of Grade 3 or Greater Laboratory Results or Signs and Symptoms and Selected Grade 2 Hematologic, Renal, and Hepatic Laboratory Results
NCT01061151 (28) [back to overview]	Maternal Health Component: Other Targeted Medical Conditions
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence Rate of Progression to AIDS-defining Illness, Death, or a Serious Non-AIDS Cardiovascular, Hepatic, or Renal Event
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence Rate of Death or Any Condition of Particular Concern
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of HIV/AIDS-related Event or Death
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of Death
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of AIDS-defining Illness
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Infant HIV Infections
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Confirmed Infant HIV Infections
NCT01061151 (28) [back to overview]	Postpartum Component: Adherence to the Maternal and/or Infant ARV Regimens, as Measured by Maternal Report and Hair Measures
NCT01061151 (28) [back to overview]	Antepartum Component: Maternal HIV RNA Less Than 400 Copies/mL at Delivery
NCT01061151 (28) [back to overview]	Postpartum Component: Proportion of Infants Alive Through 12 and 24 Months Post-delivery
NCT01061151 (28) [back to overview]	Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)
NCT01061151 (28) [back to overview]	Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)
NCT01140880 (4) [back to overview]	Course Completion
NCT01140880 (4) [back to overview]	Abstinence From Stimulant Drug Use (Cocaine, Amphetamine, Methamphetamine)
NCT01140880 (4) [back to overview]	Time From Exposure to Truvada Initiation
NCT01140880 (4) [back to overview]	Medication Adherence
NCT01154673 (1) [back to overview]	Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo in Addition to Standard HAART.
NCT01195467 (2) [back to overview]	The Rate of Neuropsychiatric and Central Nervous System (CNS) Toxicity of Raltegravir Therapy After 12 Weeks on Treatment
NCT01195467 (2) [back to overview]	The Rate of Neuropsychiatric and Central Nervous System (CNS) Toxicity of Raltegravir Therapy After 4 Weeks on Treatment
NCT01214759 (2) [back to overview]	Safety and Tolerability as Assessed by the Number of Participants Who Completed the 28-day Course of the Antiretroviral Drugs Being Explored in This Study
NCT01214759 (2) [back to overview]	Efficacy as Assessed by the Number of Participants Who Were HIV Positive at 6 Months
NCT01270802 (2) [back to overview]	Change in Flow-mediated Dilation (FMD) of the Brachial Artery
NCT01270802 (2) [back to overview]	Change in Serum Levels of Vitamin D
NCT01285050 (1) [back to overview]	HCV RNA
NCT01327651 (28) [back to overview]	The Total Pills Actually Used Over the Follow-up Period
NCT01327651 (28) [back to overview]	The Percentage of Correctly Timed Adherence (Number of Pills Taken Within the Recommended Time Frame/Number of Pills Recommended) During 24 Weeks of Follow-up Based on Weekly Interviews and Adjusted EDM (Electronic Drug Monitoring) Data
NCT01327651 (28) [back to overview]	The (Minimum) Total Number of Pills Needed for 100% Coverage Over the Follow-up Period (Based on Randomization Arm and Self-reported Sexual History in the Weekly Interviews)
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing of Adverse Events (AEs) by Grade, Relationship to Study Product, and Arm
NCT01327651 (28) [back to overview]	Self-reported Side Effect or Symptom Scores
NCT01327651 (28) [back to overview]	Proportion of Sexual Exposures Covered by Pre- and Post-exposure Dosing
NCT01327651 (28) [back to overview]	Measurement of TFV-DP (Tenofovir Diphosphate) in PBMC (Peripheral Blood Mononuclear Cell)
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing of Adverse Events (AEs) by Grade, Relationship to Study Product, and Arm
NCT01332227 (7) [back to overview]	Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 24
NCT01332227 (7) [back to overview]	Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Treatment-emergent Adverse Events (AEs) Leading to Discontinuation, and Treatment-emergent AEs
NCT01332227 (7) [back to overview]	Number of Participants With Virologic Rebound at Weeks 24 and 48
NCT01332227 (7) [back to overview]	Number of Participants With Genotypable/Phenotypable Isolates, Emergent Genotypic Substitutions in Patients With Genotypable Isolates, and Phenotypic Resistance in Patients With Phenotypable Isolates at Week 48
NCT01332227 (7) [back to overview]	Number of Participants With Genotypable/Phenotypable Isolates, Emergent Genotypic Substitutions in Patients With Genotypable Isolates, and Phenotypic Resistance in Patients With Phenotypable Isolates at Week 24
NCT01332227 (7) [back to overview]	Mean Changes in Fasting Lipid Levels From Baseline to Week 48
NCT01332227 (7) [back to overview]	Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 48
NCT01335620 (2) [back to overview]	Drug Levels in Blood
NCT01335620 (2) [back to overview]	Cerebral Function; Changes in Global Cognitive Z-score
NCT01338025 (4) [back to overview]	Number of Participants Non-adherent as Measured by 3-day Recall
NCT01338025 (4) [back to overview]	Number of Participants With Immunologic Deterioration
NCT01338025 (4) [back to overview]	Change in CD4+ T Cell Count
NCT01338025 (4) [back to overview]	Change in HIV-1 RNA Levels
NCT01345630 (25) [back to overview]	Virologic Outcomes at Week 48 Using Protocol-Defined Treatment Failure (PDTF).
NCT01345630 (25) [back to overview]	Tropism Change Between Screening or Baseline and PDTF
NCT01345630 (25) [back to overview]	Severity of Abnormal Laboratory Values
NCT01345630 (25) [back to overview]	Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD8 (%)
NCT01345630 (25) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.
NCT01345630 (25) [back to overview]	Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD4 (%)
NCT01345630 (25) [back to overview]	Number of Treatment-related AEs
NCT01345630 (25) [back to overview]	Changes in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 48
NCT01345630 (25) [back to overview]	Frequency of Adverse Events (AE).
NCT01345630 (25) [back to overview]	Number of Participants With Viral Resistance to Maraviroc (Maraviroc Treated Participants Only) in Participants Meeting PDTF Criteria.
NCT01345630 (25) [back to overview]	Number of Participants With Resistance to Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI), and Protease Inhibitors (PI) in Participants Meeting PDTF Criteria
NCT01345630 (25) [back to overview]	Number of Participants With Abnormal Laboratory Values
NCT01345630 (25) [back to overview]	Absolute Change in CD4+/CD8+ Ratio From Baseline to Week 48
NCT01345630 (25) [back to overview]	Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 8 (CD8, Cell/mm^3)
NCT01345630 (25) [back to overview]	Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 4 (CD4, Cell/mm^3)
NCT01345630 (25) [back to overview]	Number of Participants With Treatment-emergent Serious Adverse Events
NCT01345630 (25) [back to overview]	Number of Participants With Grade 3 or 4 AEs
NCT01345630 (25) [back to overview]	Changes in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48.
NCT01345630 (25) [back to overview]	Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD
NCT01345630 (25) [back to overview]	Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD
NCT01345630 (25) [back to overview]	Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD
NCT01345630 (25) [back to overview]	Change in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1)
NCT01345630 (25) [back to overview]	Change in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin
NCT01345630 (25) [back to overview]	The Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA).
NCT01345630 (25) [back to overview]	Number of Participants Who Discontinued Due to AEs
NCT01352117 (12) [back to overview]	Cumulative Incidence of Initial KS Partial or Complete Response by Week 96
NCT01352117 (12) [back to overview]	Percentage of Participants With ARV Dose Modification
NCT01352117 (12) [back to overview]	Percentage of Participants With HIV-1 RNA Suppression
NCT01352117 (12) [back to overview]	Percentage of Participants With Etoposide Dose Modification
NCT01352117 (12) [back to overview]	Change in Peripheral Blood CD4+ Lymphocyte Cell Count
NCT01352117 (12) [back to overview]	Change in Peripheral Blood CD4+ Lymphocyte Cell Count
NCT01352117 (12) [back to overview]	Number of Participants With Grade 3 or Higher Adverse Events
NCT01352117 (12) [back to overview]	Cumulative Incidence of KS-IRIS
NCT01352117 (12) [back to overview]	Cumulative Incidence of KS Response After Initiation of Delayed Etoposide in Arm A
NCT01352117 (12) [back to overview]	Cumulative Incidence of KS Progressive Disease After Initiation of Delayed Etoposide in Arm A
NCT01352117 (12) [back to overview]	Percentage of Participants With HIV-1 RNA Suppression
NCT01352117 (12) [back to overview]	Cumulative Incidence of Initial KS Progressive Disease by Week 96
NCT01352715 (9) [back to overview]	Number of Participants With HIV-1 Drug Resistance Mutations in Protease, Reverse Transcriptase, and Integrase in Participants With Virologic Failure at Baseline and at Time of Virologic Failure
NCT01352715 (9) [back to overview]	Percentage of Time Spent in Hospital
NCT01352715 (9) [back to overview]	Number of Participants With Grade 3 or Higher Adverse Event (AE) at Least One Grade Higher Than Baseline
NCT01352715 (9) [back to overview]	Number of Participants With a Targeted Serious Non-AIDS-defining Event or Death
NCT01352715 (9) [back to overview]	Number of Participants With a New AIDS-defining Events or Death
NCT01352715 (9) [back to overview]	Number of Participants Discontinuing Randomized Treatment for Toxicity
NCT01352715 (9) [back to overview]	Cumulative Probability of Virologic Failure by Week 48
NCT01352715 (9) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 48
NCT01352715 (9) [back to overview]	Changes in Fasting Total Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol, Triglycerides, and Glucose From Baseline
NCT01400412 (20) [back to overview]	Number of Participants Who Died During the Study
NCT01400412 (20) [back to overview]	Number of Participants Who Experienced Bone Fractures
NCT01400412 (20) [back to overview]	Percent Change From Baseline in Total Hip Bone Mineral Density (BMD)
NCT01400412 (20) [back to overview]	Percent Change in Expression of CD28+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Expression of CD28+/CD57+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Expression of CD57+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Expression of RANKL+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Lumbar Spine Bone Mineral Density (BMD)
NCT01400412 (20) [back to overview]	Percentage Change in Expression of CD38+/HLA-DR+ on CD4+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percentage Change in Expression of CD38+/HLA-DR+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	CD8+ T-cell Change From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in CD4 Count From Baseline to Week 24
NCT01400412 (20) [back to overview]	Change in CD4 Count From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in Level of IP-10 From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in Levels of D-dimer From Baseline
NCT01400412 (20) [back to overview]	Change in Levels of IL-6 From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in Levels of sCD14 From Baseline
NCT01400412 (20) [back to overview]	Cumulative Probability of Virologic Failure by Week 48
NCT01400412 (20) [back to overview]	Change in Levels of sCD163 From Baseline to Week 48
NCT01400412 (20) [back to overview]	Number of Participants Who Developed Grade 3 or 4 Primary Adverse Events
NCT01435018 (37) [back to overview]	Duration of Objective Response for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Duration of Objective Response for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death for BV+ART vs PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Objective Response for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Objective Response for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2
NCT01435018 (37) [back to overview]	Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3
NCT01435018 (37) [back to overview]	Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4
NCT01435018 (37) [back to overview]	Number of Participants With Peripheral Neuropathy (PN)
NCT01435018 (37) [back to overview]	Number of Participants With Symptomatic Peripheral Neuropathy (SPN)
NCT01435018 (37) [back to overview]	Number of Participants With Treatment-related Toxicities and Adverse Events (AEs)
NCT01435018 (37) [back to overview]	Self-reported Adherence to ART Therapy
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Week - 52 Weeks
NCT01450189 (30) [back to overview]	Number of Partners Reporting for HIV Testing
NCT01450189 (30) [back to overview]	Proportion of Participants Completing Full Course of ARVs in Arm BIA
NCT01450189 (30) [back to overview]	Proportion of Participants in Arm BI and BIA (Combined) Who Complete the 4 Behavioral Sessions Within 3 Weeks of Enrollment.
NCT01450189 (30) [back to overview]	Proportion of Partners Reporting for HIV Testing
NCT01450189 (30) [back to overview]	Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening
NCT01450189 (30) [back to overview]	Proportion of Persons Completing All Scheduled Visits in Each Study Arm
NCT01450189 (30) [back to overview]	Proportion of Persons With AHI Successfully Recruited Into the Study
NCT01450189 (30) [back to overview]	Suppression of HIV RNA to <1000c/ml at 12 Weeks
NCT01450189 (30) [back to overview]	Prevalence of AHI Among Persons Screened
NCT01450189 (30) [back to overview]	Time to HIV RNA Suppression <1000 c/ml
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Month - 12 Weeks
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Month - 26 Weeks
NCT01450189 (30) [back to overview]	Blood HIV RNA Concentration at Week 52
NCT01450189 (30) [back to overview]	Cumulative Incidence Herpes Simplex Virus Type 2
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Week - 26 Weeks
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 12, Men
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Week - 12 Weeks
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Month - 52 Weeks
NCT01450189 (30) [back to overview]	Cumulative Incidence of Gonorrhea, Chlamydial Infection and Trichomoniasis (Composite)
NCT01450189 (30) [back to overview]	Cumulative Incidence of Gonorrhea, Chlamydial Infection and Trichomoniasis (Composite)
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 12, Women
NCT01450189 (30) [back to overview]	Cumulative Incidence Herpes Simplex Virus Type 2
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 26, Men
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 26, Women
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 52, Men
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 52, Women
NCT01450189 (30) [back to overview]	Blood HIV RNA Concentration at Week 26
NCT01450189 (30) [back to overview]	Number of Adverse Events
NCT01450189 (30) [back to overview]	Blood HIV RNA Concentration at Week 12
NCT01505114 (1) [back to overview]	Occurrence of Grade 3 or Higher Adverse Events (AEs)
NCT01605890 (12) [back to overview]	Number of Participants With >6 Copies of HIV-2 DNA in Plasma at Week 48
NCT01605890 (12) [back to overview]	Number of Participants With >6 Copies of HIV-2 DNA in Plasma at Week 24
NCT01605890 (12) [back to overview]	Number of Virological Failure Participants With Resistance Mutations
NCT01605890 (12) [back to overview]	Number of Participants With Treatment Switch or Discontinuation
NCT01605890 (12) [back to overview]	Number of Clinical and Biological Events
NCT01605890 (12) [back to overview]	Percentage of Patients With Plasma HIV-2 RNA < 40 Copies/mL
NCT01605890 (12) [back to overview]	Number of Participants With Clinical Progression
NCT01605890 (12) [back to overview]	Median Change in CD4 Lymphocytes Count at Week 12
NCT01605890 (12) [back to overview]	Percentage of Participants in Therapeutic Success
NCT01605890 (12) [back to overview]	Minimal Median of the Lower Dimension Out of the 4 Dimensions of the Quality of Life Questionnaire
NCT01605890 (12) [back to overview]	Minimal Observed Percentage of Participants With Moderate to Good Adherence Evaluated With ANRS Self-administered Questionnaire of Adherence
NCT01605890 (12) [back to overview]	Median Change of CD4 Lymphocytes at Week 48
NCT01632891 (7) [back to overview]	Change in log10(Pf Parasite Density) From Entry to Day 30
NCT01632891 (7) [back to overview]	Number of Participants With Uncomplicated Clinical Malaria
NCT01632891 (7) [back to overview]	Time to First Pf SCP Clearance
NCT01632891 (7) [back to overview]	Number of Participants With Detectable Pf Gametocyte Density
NCT01632891 (7) [back to overview]	Proportion of Participants With Plasmodium Falciparum (Pf) Subclinical Parasitemia (SCP) Clearance
NCT01632891 (7) [back to overview]	Log10(Pf Parasite Density)
NCT01632891 (7) [back to overview]	Change in log10(Pf Gametocyte Density) From Entry to Day 30
NCT01641367 (60) [back to overview]	Percent of Participants With Treatment Modification or Discontinuation by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants With Treatment Modification or Discontinuation by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in CD4+ T-cell Count
NCT01641367 (60) [back to overview]	Change From Baseline in CD4+ T-cell Count [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Triglycerides [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Triglycerides
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Total Cholesterol [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Total Cholesterol
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the First of Death or Hospitalization [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Glucose
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Treatment Modification or Discontinuation.
NCT01641367 (60) [back to overview]	Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study
NCT01641367 (60) [back to overview]	Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Treatment Modification or Discontinuation [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity
NCT01641367 (60) [back to overview]	Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing
NCT01641367 (60) [back to overview]	Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time to First Dose Modification Due to Grade 3 or 4 Toxicity
NCT01641367 (60) [back to overview]	Time to First Dose Modification Due to Grade 3 or 4 Toxicity [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Death or Hospitalization by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Death or Hospitalization by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants With Confirmed Virologic Failure by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Confirmed Virologic Failure by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the First of Death or Hospitalization.
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS) [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS)
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Glucose [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Death [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Death
NCT01641367 (60) [back to overview]	Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study
NCT01641367 (60) [back to overview]	Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing
NCT01641367 (60) [back to overview]	Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Number of Weeks of Follow-up
NCT01641367 (60) [back to overview]	Number of Weeks of Follow-up [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants Experiencing Death by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants Experiencing Death by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48
NCT01641809 (57) [back to overview]	Absolute Values for Platelet Count, Total Neutrophils and WBC Count During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Plasma Logarithm to the Base 10 (log10) HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Absolute Values for Plasma Logarithm to the Base 10 (log10) HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Absolute Values for Hemoglobin During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Creatinine and Total Bilirubin During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Cluster of Differentiation 4+ (CD4+) Cell Count During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (mL) at Week 48 Using the Missing, Switch, Discontinuation Equals Failure (MSDF) Algorithm
NCT01641809 (57) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to Adverse Events-Maintenance Phase
NCT01641809 (57) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to Adverse Events-Induction Phase
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL Over Time by Visit Using the MSDF Algorithm
NCT01641809 (57) [back to overview]	Percentage of Participants Who Discontinued Investigational Product Due to Adverse Events
NCT01641809 (57) [back to overview]	Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
NCT01641809 (57) [back to overview]	Maximum Observed Concentration (Cmax) for GSK1265744 at Week 2
NCT01641809 (57) [back to overview]	Concentration at the End of a Dosing Interval (Ctau) for GSK1265744 at Week 2
NCT01641809 (57) [back to overview]	Area Under the Concentration Time Curve Over the Dosing Interval (AUC[0-tau]) for GSK1265744 at Week 2
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL Over Time by Visit Using Observed Case Analysis
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Absolute Values for ALT, AST, CK During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Change From Baseline in ALT, AST and CK Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in ALT, AST and CK Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in CD4+ Cell Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in CD4+ Cell Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Creatinine and Total Bilirubin Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Creatinine and Total Bilirubin Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Hemoglobin Level Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Hemoglobin Level Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Plasma log10 HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Plasma log10 HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Total Neutrophils, Platelet Count and WBC Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Total Neutrophils, Platelet Count and WBC Count Over Time by Visit
NCT01641809 (57) [back to overview]	Number of Participants With Adherence to Study Treatment
NCT01641809 (57) [back to overview]	Number of Participants With Adherence to Study Treatment
NCT01641809 (57) [back to overview]	Number of Participants With Adherence to Study Treatment
NCT01641809 (57) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Maintenance Phase
NCT01641809 (57) [back to overview]	Number of Participants With AEs and SAEs Over Time
NCT01641809 (57) [back to overview]	Number of Participants With AEs and SAEs-Induction Phase
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Clinical Chemistry Toxicities Over Time
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Clinical Chemistry Toxicities-Maintenance Phase
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Clinical Chemistry Toxicity-Induction Phase
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Hematology Toxicities Over Time
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Hematology Toxicities-Induction Phase
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Hematology Toxicities-Maintenance Phase
NCT01641809 (57) [back to overview]	Number of Participants With Post-Baseline HIV-1 Associated Conditions Progression of Disease
NCT01641809 (57) [back to overview]	Number of Participants With Treatment Emergent Genotypic Mutations Associated With Development of Resistance
NCT01641809 (57) [back to overview]	Number of Participants With Treatment Emergent Phenotypic Resistance
NCT01641809 (57) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 16 and Week 24 Using MSDF Algorithm-Induction Phase
NCT01641809 (57) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL From Week 24 Through Week 96 by Visit Using MSDF Algorithm-Maintenance Phase
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <400 Copies/mL Until Week 96 Using the MSDF Algorithm
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <400 Copies/mL Until Week 96 Using the Observed Case Analysis
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL Over Time by Visit Using Observed Case Analysis
NCT01687218 (12) [back to overview]	Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mL) in Blood Plasma
NCT01687218 (12) [back to overview]	Adherence: Percentage of Prescribed Doses Taken Orally or Administered Rectally in an 8-week Period
NCT01687218 (12) [back to overview]	Acceptability: Participant Self-report of Liking the Product. H1-Overall How do You Feel About the Product You Used Recently?
NCT01687218 (12) [back to overview]	Acceptability: Participant Self-report of Likelihood of Product Use if Shown to be Effective. N1-If This Product Provides Some Protection How Likely Would You be to Take it?
NCT01687218 (12) [back to overview]	Acceptability: Participant Self-report of Ease of Use. I1-Overall How Easy or Difficult Was it to Use the Product?
NCT01687218 (12) [back to overview]	Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Sponge
NCT01687218 (12) [back to overview]	Safety: Grade 2 or Higher Adverse Events
NCT01687218 (12) [back to overview]	Pharmacokinetics: End Period Tenofovir-Diphosphate (TFV-DP) Concentrations (log10 ng/mg) in Rectal Tissue
NCT01687218 (12) [back to overview]	Pharmacokinetics: End Period Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Tissue
NCT01687218 (12) [back to overview]	Pharmacokinetics: End Period Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Tissue
NCT01687218 (12) [back to overview]	Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mL) in Blood Plasma
NCT01687218 (12) [back to overview]	Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Sponge
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Levels More Than or Equal to (>=) 400 Copies/mL at Week 48 Based on Time to Loss of Virologic Response (TLOVR) [Non-virologic Failure Censored] Imputation Method.
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Levels < 50 Copies/mL at Week 48
NCT01709084 (6) [back to overview]	Percentage of Participant With Treatment Adherence Based on Tablet Count
NCT01709084 (6) [back to overview]	Number of Participants With Treatment-Emergent Nucleoside Reverse Transcriptase Inhibitor (N[t]RTI) or Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NNRTI) Mutations
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Levels >= 50 Copies Per Milliliter (Copies/mL) at Week 48 Based on Time to Loss of Virologic Response (TLOVR) [Non-virologic Failure Censored] Imputation Method.
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma Human Immunodeficiency Virus - Type 1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 400 Copies Per Milliliter (Copies/mL) at Week 48
NCT01769456 (12) [back to overview]	Total Body Bone Mineral Density: Percent Change From Baseline to Week 48
NCT01769456 (12) [back to overview]	Number of Participants Using Text Messaging Reminders
NCT01769456 (12) [back to overview]	Number of Participants With Decrease in Bone Mineral Density
NCT01769456 (12) [back to overview]	Acceptability of PrEP Regimen and Study Visits
NCT01769456 (12) [back to overview]	Total Hip Bone Mineral Density: Percent Change From Baseline to Week 48
NCT01769456 (12) [back to overview]	Rating of the Reasons for Missing Medications on a 4-point Likert Scale.
NCT01769456 (12) [back to overview]	Estimation of Medication Adherence by Dried Blood Spot (DBS) Results
NCT01769456 (12) [back to overview]	Behavioral Disinhibition/Risk Compensation: Number of Male Sexual Partners
NCT01769456 (12) [back to overview]	Behavioral Disinhibition/Risk Compensation: Number of Participants Reporting Unprotected Sex
NCT01769456 (12) [back to overview]	Femoral Neck Bone Mineral Density: Percent Change From Baseline to Week 48
NCT01769456 (12) [back to overview]	Lumbar Spine Bone Mineral Density: Percent Change From Baseline to Week 48
NCT01769456 (12) [back to overview]	Number of Participants With Serum Creatinine Event of Grade 1 or Higher Over the Course of the Study
NCT01772823 (15) [back to overview]	Total Body Bone Mineral Density at Baseline and at Week 48
NCT01772823 (15) [back to overview]	Patterns of Use, Rates of Adherence and Measured Levels of Open Label FTC/TDF (Truvada®) Drug Exposure
NCT01772823 (15) [back to overview]	Number of Participants With Unprotected Sex Acts
NCT01772823 (15) [back to overview]	Number of Participants With Decrease in Absolute Bone Mineral Density (BMD) From Baseline to Week 48
NCT01772823 (15) [back to overview]	Measured Levels of Drug Exposure (DBS RBC TFV-DP) When YMSM Are Provided Open Label FTC/TDF (Truvada®)
NCT01772823 (15) [back to overview]	Lumbar Spine Bone Mineral Density at Baseline and at Week 48
NCT01772823 (15) [back to overview]	Femoral Neck Bone Mineral Density at Baseline and at Week 48
NCT01772823 (15) [back to overview]	Number of Participants With Serum Creatinine Event of Grade 1 or Higher
NCT01772823 (15) [back to overview]	Demographic and/or Behavioral Difference Between Study Groups. Behavioral Disinhibition/Risk Compensation Endpoints Will be Compared. (Log 10 Viral Load)
NCT01772823 (15) [back to overview]	Measured Levels of Drug Exposure (DBS RBC FTC-TP) When YMSM Are Provided Open Label FTC/TDF (Truvada®)
NCT01772823 (15) [back to overview]	Demographic and/or Behavioral Difference Between Study Groups. Behavioral Disinhibition/Risk Compensation Endpoints Will be Compared. (Age)
NCT01772823 (15) [back to overview]	Number of Sex Partners
NCT01772823 (15) [back to overview]	Total Hip Bone Mineral Density at Baseline and at Week 48
NCT01772823 (15) [back to overview]	Acceptability and Feasibility of Text Message Reminders: Number Discontinuing Text Messaging Reminders
NCT01772823 (15) [back to overview]	Acceptability and Feasibility of Text Message Reminders: Number Using Text Messaging Reminders
NCT01777997 (9) [back to overview]	Number of Subjects Who Experience Grade 3 or 4 Signs and Symptoms or Laboratory Abnormalities, Diagnoses (Any Grade), or Other Serious Adverse Events (SAEs)
NCT01777997 (9) [back to overview]	Change in CD4+ T-cell Count
NCT01777997 (9) [back to overview]	Change in Levels of CD4+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+)
NCT01777997 (9) [back to overview]	Change in Levels of Interleukin (IL)-6
NCT01777997 (9) [back to overview]	Change in Quality of Life (QoL) Index
NCT01777997 (9) [back to overview]	Plasma HIV-1 RNA Level Measured by Single Copy Assay Using Primer in Integrase (iSCA) as the Proportion of Participants Below the Limit of the Assay
NCT01777997 (9) [back to overview]	Change in Levels of D-dimer
NCT01777997 (9) [back to overview]	Change in Levels of CD8+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+) From Baseline to Weeks 24 and 48 on ART
NCT01777997 (9) [back to overview]	Change in Levels of CD8+ T-cell Activation
NCT01781806 (3) [back to overview]	Cohort H PrEP Engagement by Study Visit
NCT01781806 (3) [back to overview]	Number of HIV Seroconversions by Cohort.
NCT01781806 (3) [back to overview]	Number of Participants With a Grade 2 or Higher Adverse Event by Cohort
NCT01803074 (28) [back to overview]	Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC([Tau]) - Part A and C
NCT01803074 (28) [back to overview]	Plasma Concentration 24 Hours Post-Dose (C24) - Part B
NCT01803074 (28) [back to overview]	Number of Participants With Clinically Significant Grade 3/4 Laboratory Abnormalities From Baseline
NCT01803074 (28) [back to overview]	Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part B
NCT01803074 (28) [back to overview]	Apparent Total Body Clearance: Part A and C
NCT01803074 (28) [back to overview]	Average Observed Plasma Concentration at Steady State (Css-avg): Part A and C
NCT01803074 (28) [back to overview]	Change in Plasma Log10 HIV-1 Ribonucleic Acid (RNA) Levels From Baseline to Day 11
NCT01803074 (28) [back to overview]	Degree of Fluctuation (DF): Part A and C
NCT01803074 (28) [back to overview]	Maximum Decline From Baseline in Log10 HIV-1 RNA - Part A and C
NCT01803074 (28) [back to overview]	Maximum Decline From Baseline in Log10 HIV-1 RNA - Part B
NCT01803074 (28) [back to overview]	Number of Participants With Clinically Significant Changes in Heart Rate
NCT01803074 (28) [back to overview]	Plasma Half-life: Part A and C
NCT01803074 (28) [back to overview]	Time to Maximum Decline in Log 10 HIV-1 RNA - Part A and C
NCT01803074 (28) [back to overview]	Time to Maximum Decline in Log 10 HIV-1 RNA - Part B
NCT01803074 (28) [back to overview]	Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part A and C
NCT01803074 (28) [back to overview]	Accumulation Index (AI): Part A and C
NCT01803074 (28) [back to overview]	Plasma Concentration 24 Hours Post-Dose (C24) - Part A and C
NCT01803074 (28) [back to overview]	Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC[Tau]) - Part B
NCT01803074 (28) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part A and C
NCT01803074 (28) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part B
NCT01803074 (28) [back to overview]	Maximum Observed Plasma Concentrations (Cmax) - Part A and C
NCT01803074 (28) [back to overview]	Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), and Discontinuations Due to AEs During the Study
NCT01803074 (28) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) - Part B
NCT01803074 (28) [back to overview]	Maximum Observed Plasma Concentrations (Cmax) - Part B
NCT01803074 (28) [back to overview]	Number of Participants With Abnormal Changes in Physical Examination
NCT01803074 (28) [back to overview]	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)
NCT01803074 (28) [back to overview]	Number of Participants With Clinically Significant Changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT01803074 (28) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) - Part A and C
NCT01855867 (3) [back to overview]	Number of Participants With Self-Reported Missed Doses
NCT01855867 (3) [back to overview]	Number of Adverse Event Occurrences
NCT01855867 (3) [back to overview]	nPEP Failure (HIV Infection During Study Participation)
NCT01869634 (4) [back to overview]	Change in Systemic Immune Activation
NCT01869634 (4) [back to overview]	Number of CD4+ T-cells in the Lamina Propria/mm2 Before and After 12 Months of Therapy Compared to Age-matched Control Volunteers Without HIV
NCT01869634 (4) [back to overview]	Number of CD4+ T-cells in the Lamina Propria/mm2 Before and After 12 Months of Therapy Compared to Age-matched Control Volunteers Without HIV
NCT01869634 (4) [back to overview]	Change in Percentage of Total Artery Diameter
NCT01910402 (48) [back to overview]	Number of Participants Who Withdrew From Treatment Due to AEs-Continuation Phase
NCT01910402 (48) [back to overview]	Absolute Values in Plasma HIV-1 RNA at Indicated Time Points-Randomized Phase
NCT01910402 (48) [back to overview]	Absolute Values in Plasma HIV-1 RNA at Indicated Time Points-Continuation Phase
NCT01910402 (48) [back to overview]	Absolute Values in CD4+ Cell Count at Indicated Timepoints-Randomized Phase
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48 by Subgroups
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48 by Subgroups
NCT01910402 (48) [back to overview]	Change From Baseline in TC/HDL Ratio at Week 48
NCT01910402 (48) [back to overview]	Change From Baseline in Triglycerides at Week 48
NCT01910402 (48) [back to overview]	Number of Participants Who Withdrew From Treatment Due to AEs-Randomized Phase
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48
NCT01910402 (48) [back to overview]	Absolute Values in CD4+ Cell Count at Indicated Timepoints-Continuation Phase
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL in Continuation Phase
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 and <400 c/mL Over Time-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With Treatment Emergent Resistances for DTG 50 mg/ABC 600 mg/3TC 300 mg QD (Randomized + Continuation Phase)
NCT01910402 (48) [back to overview]	Number of Participants With Treatment Emergent Resistances for ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200mg QD (Randomized Phase)
NCT01910402 (48) [back to overview]	Number of Participants With Post-Baseline HIV-1 Disease Progression-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With Post-Baseline HIV-1 Disease Progression for DTG 50 mg/ABC 600 mg/3TC 300 mg QD (Randomized + Continuation Phase)
NCT01910402 (48) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities-Continuation Phase
NCT01910402 (48) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities-Continuation Phase
NCT01910402 (48) [back to overview]	Number of Participants With Any AEs, and SAEs in Continuation Phase
NCT01910402 (48) [back to overview]	Number of Participants With Any Adverse Events (AEs), and Serious Adverse Events (SAEs)-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With AEs by Maximum Toxicity-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With AEs by Maximum Toxicity-Continuation Phase
NCT01910402 (48) [back to overview]	HIVTSQs Total Score at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Vitamin D, Vitamin D2 and Vitamin D3 at Week 24 and Week 48
NCT01910402 (48) [back to overview]	Change From Baseline in Urine Albumin Creatinine Ratio at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Type I Collagen C-telopeptides at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Total CHLS/HDL CHLS Ratio at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Plasma HIV-1 RNA at Indicated Time Points-Randomized Phase
NCT01910402 (48) [back to overview]	Change From Baseline in Plasma HIV-1 RNA at Indicated Time Points-Continuation Phase
NCT01910402 (48) [back to overview]	Change From Baseline in Hematocrit Count at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Erythrocytes at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Erythrocyte Mean Corpuscular Volume at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Creatinine Clearance at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in CD4+ Cell Count at Indicated Timepoints-Randomized Phase
NCT01910402 (48) [back to overview]	Change From Baseline in CD4+ Cell Count at Indicated Timepoints-Continuation Phase
NCT01910402 (48) [back to overview]	Change From Baseline in Carbon Dioxide, Electrolytes, Lipids, Glucose, Urea at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Carbon Dioxide, Electrolytes, Lipids, Glucose, Urea at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Bone Specific Alkaline Phosphatase, Osteocalcin and Procollagen 1 N-terminal Propeptide at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Lipase at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Bilirubin and Creatinine at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Albumin at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline at Week 48 in SF-12 Total Score, MCS and PCS
NCT01910402 (48) [back to overview]	Bone Specific Alkaline Phosphatase, Osteocalcin, Procollagen 1 N-terminal Propeptide, Type 1 Collagen C-Telopeptide, Vitamin D Ratio of Week 48 Results Over Baseline
NCT01929759 (8) [back to overview]	Change in Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS)
NCT01929759 (8) [back to overview]	Change in Other Neurometabolite Measured by MRS Between Week 0 and Week 8
NCT01929759 (8) [back to overview]	Effect of EFV and Its Metabolites
NCT01929759 (8) [back to overview]	Fasting Lipid Profile
NCT01929759 (8) [back to overview]	Sleep Quality
NCT01929759 (8) [back to overview]	Neurocognitive Changes
NCT01929759 (8) [back to overview]	Neural Activation Networks Using Functional Magnetic Resonance Imaging (fMRI)
NCT01929759 (8) [back to overview]	Markers of Immune Activation
NCT02022657 (1) [back to overview]	Steady State Concentrations of TFV-DP for Different Dosing Patterns of Truvada
NCT02116660 (1) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
NCT02180438 (12) [back to overview]	Interim Analysis at 24 Weeks of Grade 3 and 4 Adverse Events
NCT02180438 (12) [back to overview]	Grade 3 or 4 Adverse Events
NCT02180438 (12) [back to overview]	Virologic Failure, FDA Snapshot (HIV-2 Plasma Viral Load >50 and >400 Copies/ml)
NCT02180438 (12) [back to overview]	Switching Off Stribild Prior to 48 Weeks
NCT02180438 (12) [back to overview]	Death
NCT02180438 (12) [back to overview]	New WHO Stage 3 or 4 Event
NCT02180438 (12) [back to overview]	Interim Analysis at 24 Weeks of New WHO Stage 3 or 4 Event
NCT02180438 (12) [back to overview]	Interim Analysis at 24 Weeks of HIV-2 Virologic Failure
NCT02180438 (12) [back to overview]	Interim 24 Weeks Analysis of Death
NCT02180438 (12) [back to overview]	Development of Drug Resistance Mutations to Elvitegravir or Emtricitabine or Tenofovir DF
NCT02180438 (12) [back to overview]	CD4 T-cell Count at 48 Weeks < Baseline
NCT02180438 (12) [back to overview]	< 50 CD4 T-cell Increase at 48 Weeks From Baseline
NCT02213328 (11) [back to overview]	Reported Alcohol and Substance Use as Evidenced by Participant Responses to Interviewer-administered Questionnaires at the Enrolment Visit
NCT02213328 (11) [back to overview]	Number of Participants With Grades 2, 3, and 4 Clinical and Laboratory Adverse Events
NCT02213328 (11) [back to overview]	Number of Adolescents Who Continue to Use PrEP (as Indicated by Dried Blood Spot [DBS] Levels) After the Initial 3-month Period
NCT02213328 (11) [back to overview]	Proportion of Adolescents With Detectable Drug Levels Who Report Using PrEP
NCT02213328 (11) [back to overview]	Percentage of Study Participants Who Seroconverted During the Study, Measured Until Month 52
NCT02213328 (11) [back to overview]	Number of Adolescents Enrolled and Retained in the Study
NCT02213328 (11) [back to overview]	Reported Consistent Condom Use as Evidenced by Participant Responses to Interviewer-administered Questionnaires Adminstered at the Enrolment Visit
NCT02213328 (11) [back to overview]	Number of Participants With Acceptability as Per Questionnaire Administered at Week 48
NCT02213328 (11) [back to overview]	Number of Participants Who Used PrEP at Any Time Point During the Study, Measured With Drug Levels at M4/8/12/24/36
NCT02213328 (11) [back to overview]	Number of Participants Reporting Multiple Partners in the Preceding Year as Evidenced by Participant Responses to Interviewer Administered Questionnaires at Enrolment
NCT02213328 (11) [back to overview]	The Percentage of Participants Who Report Willingness to Use the Study Regimen, Take up PrEP, and Remain on PrEP as Part of a Comprehensive Prevention Package
NCT02251236 (4) [back to overview]	Concentration of Elvitegravir in Cerebrospinal Fluid at Baseline
NCT02251236 (4) [back to overview]	Concentration of Elvitegravir in Cerebrospinal Fluid at Week 24
NCT02251236 (4) [back to overview]	Concentration of Tenofovir in Cerebrospinal Fluid at Baseline
NCT02251236 (4) [back to overview]	Concentration of Tenofovir in Cerebrospinal Fluid at Week 24
NCT02401230 (13) [back to overview]	Median Plasma Emtricitabine (FTC) Concentration
NCT02401230 (13) [back to overview]	Median Plasma Tenofovir (TDF) Concentration
NCT02401230 (13) [back to overview]	Median Percentage of CD4 Positive T-Cells
NCT02401230 (13) [back to overview]	Median Rectal Tissue Tenofovir (TDF) Concentration
NCT02401230 (13) [back to overview]	Median Cumulative Amount of p24
NCT02401230 (13) [back to overview]	Median Peripheral Blood Mononuclear Cell (PBMC) Tenofovir (TDF) Concentration
NCT02401230 (13) [back to overview]	Median Peripheral Blood Mononuclear Cell (PBMC) Emtricitabine (FTC) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Tissue Emtricitabine (FTC) Concentration
NCT02401230 (13) [back to overview]	Median Peripheral Blood Mononuclear Cell (PBMC) Deoxyadenosine Triphosphate (dATP) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Secretion Emtricitabine (FTC) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Secretion Tenofovir (TDF) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Tissue Deoxycytidine Triphosphate (dCTP) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Tissue Deoxyadenosine Triphosphate (dATP) Concentration
NCT02431247 (64) [back to overview]	Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 96
NCT02431247 (64) [back to overview]	Percentage of Participants With Grade 3 and 4 AEs, SAEs, and Premature Discontinuations Due to Adverse Events Post-Week 96 to End of Extension
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV RNA <50, <20, and <200 Copies/mL Post-week 96 to End of Extension
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach
NCT02431247 (64) [back to overview]	Percentage of Participants With Non-PDVF by Kaplan-Meier Estimates
NCT02431247 (64) [back to overview]	Percentage of Participants With PDVF Post-week 96 to End of Extension
NCT02431247 (64) [back to overview]	Percentage of Participants With Protocol-defined Virologic Failure (PDVF)
NCT02431247 (64) [back to overview]	Percentage of Participants With Protocol-defined Virologic Failure (PDVF)
NCT02431247 (64) [back to overview]	Percentage of Participants With Protocol-defined Virologic Failure (PDVF)
NCT02431247 (64) [back to overview]	Percentage of Participants With Time to Treatment Failure by Kaplan-Meier Estimates
NCT02431247 (64) [back to overview]	Percentage of Participants With Time to Treatment Failure by Kaplan-Meier Estimates
NCT02431247 (64) [back to overview]	Percent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)
NCT02431247 (64) [back to overview]	Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide
NCT02431247 (64) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir
NCT02431247 (64) [back to overview]	Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in log10 HIV-1 RNA Levels at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Serum Creatinine at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48
NCT02431247 (64) [back to overview]	Change From Reference in ALP Levels
NCT02431247 (64) [back to overview]	Change From Reference in CD4+ Cell Count at Week 96
NCT02431247 (64) [back to overview]	Change From Reference in eGFRcr by CKD-EPI Formula
NCT02431247 (64) [back to overview]	Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine by Cockcroft-Gault Formula
NCT02431247 (64) [back to overview]	Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula
NCT02431247 (64) [back to overview]	Change From Reference in Levels of 25-OH Vitamin D
NCT02431247 (64) [back to overview]	Change From Reference in Levels of PTH
NCT02431247 (64) [back to overview]	Change From Reference in Levels of Serum CTX
NCT02431247 (64) [back to overview]	Change From Reference in Levels of Serum P1NP
NCT02431247 (64) [back to overview]	Change From Reference in log10 HIV-1 RNA Levels at Week 96
NCT02431247 (64) [back to overview]	Change From Reference in Serum Creatinine
NCT02431247 (64) [back to overview]	Change From Reference in UACR
NCT02431247 (64) [back to overview]	Change From Reference in UB2MGCR
NCT02431247 (64) [back to overview]	Change From Reference in UPCR
NCT02431247 (64) [back to overview]	Change From Reference in URBPCR
NCT02431247 (64) [back to overview]	Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48
NCT02431247 (64) [back to overview]	Percent Change From Reference in Urine FEPO4
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies Per mL at Week 96 Defined by FDA Snapshot Approach
NCT02431247 (64) [back to overview]	Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach
NCT02431247 (64) [back to overview]	Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide
NCT02431247 (64) [back to overview]	Predose (Trough) Plasma Concentration (C0h) of Darunavir
NCT02431247 (64) [back to overview]	CD4+ Cell Count Post-Week From 96 to End of Extension
NCT02431247 (64) [back to overview]	Change From Baseline in Alkaline Phosphatase (ALP) Levels at Weeks 24 and 48
NCT02431247 (64) [back to overview]	Change From Baseline in BMD T-score of Hip and Spine
NCT02431247 (64) [back to overview]	Change From Baseline in Levels of 25-Hydroxyvitamin D (25-OH Vitamin D), at Week 24 and 48
NCT02431247 (64) [back to overview]	Change From Baseline in Levels of Parathyroid Hormone (PTH) at Weeks 24 and 48
NCT02431247 (64) [back to overview]	Change From Baseline in Levels of Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) at Weeks 24 and 48
NCT02431247 (64) [back to overview]	Change From Baseline in Levels of Serum Procollagen 1 N-Terminal Propeptide (P1NP) at Weeks 24 and 48
NCT02431247 (64) [back to overview]	Change From Reference in BMD T-score of Hip and Spine at Week 96
NCT02431247 (64) [back to overview]	Number of Participants With ARV Resistance
NCT02431247 (64) [back to overview]	Percent Change From Reference in Hip and Spine BMD
NCT02431247 (64) [back to overview]	Percentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability
NCT02431247 (64) [back to overview]	Percentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability
NCT02431247 (64) [back to overview]	Percentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability
NCT02431247 (64) [back to overview]	Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 48
NCT02495779 (1) [back to overview]	Number of Participants With PrEP Adherence
NCT02556333 (1) [back to overview]	HIV RNA Change From Baseline to Day 10
NCT02603120 (7) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm
NCT02603120 (7) [back to overview]	Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm
NCT02603120 (7) [back to overview]	Spine Bone Mineral Density (BMD) at Baseline
NCT02603120 (7) [back to overview]	Change From Baseline in CD4+ Cell Count at Week 48
NCT02603120 (7) [back to overview]	Hip Bone Mineral Density at Baseline
NCT02603120 (7) [back to overview]	Percentage Change From Baseline in Hip BMD at Week 48
NCT02603120 (7) [back to overview]	Percentage Change From Baseline in Spine BMD at Week 48
NCT02815566 (2) [back to overview]	Percent Change in Bone Mineral Density From Baseline at the Lumbar Spine
NCT02815566 (2) [back to overview]	% Change in Bone Mineral Density From Baseline at the Femoral Neck
NCT02831673 (64) [back to overview]	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in EQ-5D-5L Utility Score at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in EQ-5D-5L Utility Score at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144
NCT02831673 (64) [back to overview]	CD4+ Cell Counts at Week 96
NCT02831673 (64) [back to overview]	CD4+ Cell Counts at Week 144
NCT02831673 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144
NCT02831673 (64) [back to overview]	Number of Participants Who Discontinue Treatment Due to AEs Over Week 144
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 96
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 144
NCT02831673 (64) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum RBP at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum RBP at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96
NCT02831673 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48
NCT02831673 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96
NCT02831673 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144
NCT02831673 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48
NCT02831673 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24
NCT02831673 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96
NCT02831673 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48
NCT02831673 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144
NCT02831673 (64) [back to overview]	Percentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48
NCT02831673 (64) [back to overview]	Percentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48
NCT02831673 (64) [back to overview]	Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With HIV-1 Disease Progression up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With Any AE and SAE up to Week 148
NCT02831673 (64) [back to overview]	Number of Participants With AEs by Maximum Severity Grades up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 48 by Subgroups
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 24 by Subgroups
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 24 and 48
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48
NCT02831673 (64) [back to overview]	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24 48
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48
NCT02831673 (64) [back to overview]	CD4+ Cell Counts at Weeks 24 and 48
NCT02831673 (64) [back to overview]	Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144
NCT02831673 (64) [back to overview]	Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48
NCT02831673 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96
NCT02831673 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
NCT02831673 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48
NCT02831673 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96
NCT02831764 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96
NCT02831764 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144
NCT02831764 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48
NCT02831764 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24
NCT02831764 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48
NCT02831764 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144
NCT02831764 (64) [back to overview]	Percentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma High Density Lipoprotein (HDL) Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48
NCT02831764 (64) [back to overview]	Number of Participants With AEs by Maximum Severity Grades up to Week 148
NCT02831764 (64) [back to overview]	Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 48 by Subgroups
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 24 by Subgroups
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 24 and 48
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in European Quality of Life [EuroQoL] - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48
NCT02831764 (64) [back to overview]	CD4+ Cell Counts at Weeks 24 and 48
NCT02831764 (64) [back to overview]	Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144
NCT02831764 (64) [back to overview]	Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48
NCT02831764 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96
NCT02831764 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
NCT02831764 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144
NCT02831764 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96
NCT02831764 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144
NCT02831764 (64) [back to overview]	Number of Participants Who Discontinue Treatment Due to AEs Over Week 144
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 96
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum RBP at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum RBP at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144
NCT02831764 (64) [back to overview]	Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 148
NCT02831764 (64) [back to overview]	Number of Participants With HIV-1 Disease Progression up to Week 144
NCT02831764 (64) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144
NCT02831764 (64) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144
NCT02831764 (64) [back to overview]	Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144
NCT02831764 (64) [back to overview]	Number of Participants With Any Adverse Event (AE) and Serious AE (SAE) up to Week 148
NCT02831764 (64) [back to overview]	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96
NCT02831764 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144
NCT02831764 (64) [back to overview]	CD4+ Cell Counts at Week 96
NCT02831764 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48
NCT02831764 (64) [back to overview]	Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144
NCT02831764 (64) [back to overview]	CD4+ Cell Counts at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144
NCT02831764 (64) [back to overview]	Percentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in EQ-5D-5L Utility Score at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in EQ-5D-5L Utility Score at Week 96
NCT02859558 (4) [back to overview]	HIV-1-specific CD4+ and T-cell Responses to Nef, Gag, Pol and Env by Flow Cytometry
NCT02859558 (4) [back to overview]	Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD)
NCT02859558 (4) [back to overview]	HIV-1-specific CD8+ and T-cell Responses to Nef, Gag, Pol and Env by Flow Cytometry
NCT02859558 (4) [back to overview]	Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) Prior to ART Initiation
NCT02962739 (1) [back to overview]	Steady State Concentrations of TFV-DP for Different Dosing Patterns of Descovy
NCT02968576 (2) [back to overview]	Peak Plasma Concentration (Cmax)
NCT02968576 (2) [back to overview]	Area Under the Concentration-time Curve (AUC)
NCT03048422 (23) [back to overview]	Time to First HIV-1 RNA Less Than 200 Copies/mL Through Delivery
NCT03048422 (23) [back to overview]	Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at Delivery Based on FDA Snapshot Algorithm
NCT03048422 (23) [back to overview]	Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum Based on FDA Snapshot Algorithm
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 RNA Less Than 50 Copies/mL at Delivery Measured at Central Laboratory
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 ARV Drug Resistance Mutations at the Time of Maternal Virologic Failure
NCT03048422 (23) [back to overview]	Percentage of Mother-Infant Pairs With Preterm Deliveries
NCT03048422 (23) [back to overview]	Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome or Major Congenital Anomaly
NCT03048422 (23) [back to overview]	Percentage of Mother-Infant Pairs With an Adverse Pregnancy Outcome
NCT03048422 (23) [back to overview]	Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome
NCT03048422 (23) [back to overview]	Percentage of Infants Born Small for Gestational Age
NCT03048422 (23) [back to overview]	Maternal Change in Creatinine Clearance
NCT03048422 (23) [back to overview]	Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event
NCT03048422 (23) [back to overview]	Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event
NCT03048422 (23) [back to overview]	Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event
NCT03048422 (23) [back to overview]	Cumulative Probability of Infant HIV-infection
NCT03048422 (23) [back to overview]	Cumulative Probability of Infant Deaths
NCT03048422 (23) [back to overview]	Count of Infants With HIV-1 Antiretroviral Drug Resistance Mutations at the Time of Infant HIV Diagnosis
NCT03048422 (23) [back to overview]	Change in Maternal Weight Postpartum
NCT03048422 (23) [back to overview]	Change in Maternal Weight Antepartum
NCT03048422 (23) [back to overview]	Change in Maternal Weight Overall
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery
NCT03048422 (23) [back to overview]	Infant Creatinine Clearance
NCT03126370 (6) [back to overview]	Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR
NCT03126370 (6) [back to overview]	Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks
NCT03126370 (6) [back to overview]	Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks
NCT03126370 (6) [back to overview]	Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)
NCT03126370 (6) [back to overview]	Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio
NCT03126370 (6) [back to overview]	Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR
NCT03164564 (2) [back to overview]	Number of Pariicipants With Documented Incident HIV Infections
NCT03164564 (2) [back to overview]	Number of Participants Who Experienced Grade 2 or Higher Clinical and Laboratory Adverse Events (AEs) in Steps 1 and 2
NCT03202511 (2) [back to overview]	PBMC TFV-DP AUC GMR
NCT03202511 (2) [back to overview]	Plasma TFV AUC0-INF GMR
NCT03218592 (4) [back to overview]	Whole Blood Antiretroviral Concentrations
NCT03218592 (4) [back to overview]	Plasma Antiretroviral Concentrations
NCT03218592 (4) [back to overview]	Peripheral Blood Mononuclear Cells (PBMC) Antiretroviral Concentrations
NCT03218592 (4) [back to overview]	Hair Antiretroviral Imaging
NCT03387462 (4) [back to overview]	DOT Diary Mobile App Ease of Use
NCT03387462 (4) [back to overview]	Adherence and Persistence of Use of the DOT and Sexual Diary Components of DOT Diary by Young MSM on PrEP
NCT03387462 (4) [back to overview]	DOT Diary Mobile App Acceptability
NCT03387462 (4) [back to overview]	Assessment of Situations and Reasons for Sub-optimal Use of the App
NCT03512964 (4) [back to overview]	Number of Patients Offered Rapid HIV Treatment Initiation
NCT03512964 (4) [back to overview]	Number of Patients Who Accepted Rapid HIV Treatment Initiation
NCT03512964 (4) [back to overview]	Rapid HIV Treatment Initiation Acceptability as Assessed by the Number of Patients Who Respond Yes to Starting ART Same Day
NCT03512964 (4) [back to overview]	Number of Patients Who Receive Rapid HIV Treatment Initiation
NCT03593655 (4) [back to overview]	Number of Participant-Visits With No Product Use
NCT03593655 (4) [back to overview]	Number of Participant-Visits Reporting Acceptability of Study Product
NCT03593655 (4) [back to overview]	Number of Participants With Grade 2 or Higher Adverse Events (AEs)
NCT03593655 (4) [back to overview]	Percentage of Participants Reporting Preference for Dapivirine VR as Compared to FTC/TDF Oral Tablets
NCT03656783 (5) [back to overview]	Change in Serum Biomarkers of Inflammation (Hs-CRP (in mg/L))
NCT03656783 (5) [back to overview]	Change in Myocyte Injury and Strain (NT-proBNP (in pg/mL))
NCT03656783 (5) [back to overview]	Change in Myocyte Injury and Strain (hs Troponin (in ng/L))
NCT03656783 (5) [back to overview]	Change in Global CFR
NCT03656783 (5) [back to overview]	Change in Peak Stress Global MBF
NCT03717129 (9) [back to overview]	FTC Cmax
NCT03717129 (9) [back to overview]	EVG Half-life
NCT03717129 (9) [back to overview]	AUC0-∞ for Tenofovir (TFV)
NCT03717129 (9) [back to overview]	AUC0-∞ for FTC
NCT03717129 (9) [back to overview]	Area Under the Curve From 0 to Infinity (AUC0-∞) for EVG
NCT03717129 (9) [back to overview]	FTC Half-life
NCT03717129 (9) [back to overview]	TFV Half-life
NCT03717129 (9) [back to overview]	TFV Cmax
NCT03717129 (9) [back to overview]	EVG Cmax
NCT03797014 (10) [back to overview]	HBV DNA at Week 48
NCT03797014 (10) [back to overview]	CD4 Cell Count Change at Week 48
NCT03797014 (10) [back to overview]	HBeAg Loss at Week 48
NCT03797014 (10) [back to overview]	HIV-1 RNA at Week 24
NCT03797014 (10) [back to overview]	HBsAg Loss at Week 48
NCT03797014 (10) [back to overview]	CD4 Cell Count Change at Week 24
NCT03797014 (10) [back to overview]	HIV-1 RNA at Week 48
NCT03797014 (10) [back to overview]	ALT Normalization at Week 24
NCT03797014 (10) [back to overview]	ALT Normalization at Week 48
NCT03797014 (10) [back to overview]	HBV DNA at Week 24
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Lipase and Amylase
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Heart Rate
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of Erythrocytes
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of Hematocrit
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of Hemoglobin
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of MCH
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of MCV
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in pH of Urine
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Pulse Rate
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Respiratory Rate
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Specific Gravity of Urine
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Temperature
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Urine Urobilinogen
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Chemistry Parameters of Lipase and Amylase
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Heart Rate
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Pulse Rate
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Specific Gravity of Urine
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Temperature
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: Erythrocytes
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: Hematocrit
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: Hemoglobin
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: MCH
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: MCV
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Urine Urobilinogen
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Blood Pressure
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Alkaline Phosphatase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactate Dehydrogenase (LDH), Gamma-glutamyl Transferase (GGT), and Creatine Phosphokinase (CK)
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), Carbon Dioxide (CO2), Chloride and Phosphorus
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Lipase and Amylase
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF) Interval, and Bazett QT Correction Formula (QTcB) Interval
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Heart Rate
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Erythrocytes
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Hematocrit
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Hemoglobin
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Mean Corpuscle Volume (MCV)
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Potential of Hydrogen (pH) of Urine
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Pulse Rate
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Respiratory Rate
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Specific Gravity of Urine
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Temperature
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Urine Urobilinogen
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Respiratory Rate
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Blood Pressure
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Chemistry Parameters of Lipase and Amylase
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Heart Rate
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of pH of Urine
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Pulse Rate
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Specific Gravity of Urine
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Temperature
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of pH of Urine
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: Erythrocytes
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: Hematocrit
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: Hemoglobin
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: MCH
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: MCV
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Urine Urobilinogen
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Blood Pressure
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Respiratory Rate
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Mean Corpuscle Hemoglobin (MCH)
NCT03836729 (107) [back to overview]	Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of TAF
NCT03836729 (107) [back to overview]	Period 1: AUC (0-tau) of FTC
NCT03836729 (107) [back to overview]	Period 1: AUC (0-tau) of Tenofovir (TFV)
NCT03836729 (107) [back to overview]	Period 1: Cmax of TFV
NCT03836729 (107) [back to overview]	Period 1: Ctau of TFV
NCT03836729 (107) [back to overview]	Period 1: Maximum Observed Concentration (Cmax) of TAF
NCT03836729 (107) [back to overview]	Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of FTC
NCT03836729 (107) [back to overview]	Period 1: Tmax of FTC
NCT03836729 (107) [back to overview]	Period 1: Tmax of TAF
NCT03836729 (107) [back to overview]	Period 1: Tmax of TFV
NCT03836729 (107) [back to overview]	Period 1:Cmax of FTC
NCT03836729 (107) [back to overview]	Period 2: AUC (0-tau) of FTC
NCT03836729 (107) [back to overview]	Period 2: AUC (0-tau) of GSK3640254
NCT03836729 (107) [back to overview]	Period 2: AUC (0-tau) of TAF
NCT03836729 (107) [back to overview]	Period 2: AUC (0-tau) of TFV
NCT03836729 (107) [back to overview]	Period 2: Cmax of GSK3640254
NCT03836729 (107) [back to overview]	Period 2: Cmax of TAF
NCT03836729 (107) [back to overview]	Period 2: Cmax of TFV
NCT03836729 (107) [back to overview]	Period 2: Ctau of FTC
NCT03836729 (107) [back to overview]	Period 2: Ctau of GSK3640254
NCT03836729 (107) [back to overview]	Period 2: Ctau of TFV
NCT03836729 (107) [back to overview]	Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254
NCT03836729 (107) [back to overview]	Period 2: Tmax of FTC
NCT03836729 (107) [back to overview]	Period 2: Tmax of TAF
NCT03836729 (107) [back to overview]	Period 2: Tmax of TFV
NCT03836729 (107) [back to overview]	Period 2:Cmax of FTC
NCT03836729 (107) [back to overview]	Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAE)
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Blood Pressure
NCT03917420 (11) [back to overview]	Average Testosterone Concentrations in Serum.
NCT03917420 (11) [back to overview]	Average Emtricitabine Triphosphate Concentrations Measured in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle.
NCT03917420 (11) [back to overview]	Average Emtricitabine Concentrations in Plasma.
NCT03917420 (11) [back to overview]	Average Emtricitabine Concentrations in Peripheral Blood Mononuclear Cells.
NCT03917420 (11) [back to overview]	Average Emtricitabine Triphosphate Concentrations Measured in Mixed Rectal Cells During the Late (High Estradiol) Follicular Phases of the Menstrual Cycle.
NCT03917420 (11) [back to overview]	Average Estradiol Concentrations in Serum.
NCT03917420 (11) [back to overview]	Average Progesterone Concentrations in Serum.
NCT03917420 (11) [back to overview]	Average Tenofovir Concentrations in Plasma.
NCT03917420 (11) [back to overview]	Average Tenofovir Diphosphate Concentrations in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle.
NCT03917420 (11) [back to overview]	Average Tenofovir Diphosphate Concentrations in Peripheral Blood Mononuclear Cells.
NCT03917420 (11) [back to overview]	Average Tenofovir Diphosphate Concentrations Measured in Mixed Rectal Cells During the Late (High Estradiol) Follicular Phases of the Menstrual Cycle.
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Plasma Concentration of Tenofovir (TFV)
NCT03976752 (40) [back to overview]	Plasma Concentration of Tenofovir (TFV)
NCT03976752 (40) [back to overview]	Plasma Concentration of Tenofovir (TFV)
NCT03976752 (40) [back to overview]	Plasma Concentration of Tenofovir (TFV)
NCT03976752 (40) [back to overview]	Plasma Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Plasma Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Plasma Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Plasma Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Plasma Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir (TFN)
NCT03976752 (40) [back to overview]	Plasma Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Plasma Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Plasma Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir (TFN)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir (TFN)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir (TFN)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03998176 (4) [back to overview]	Percentage of Participants With Grade 3 or Greater Adverse Events
NCT03998176 (4) [back to overview]	Percentage of Participants With Grade 3 or Greater Adverse Events
NCT03998176 (4) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm
NCT03998176 (4) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm
NCT04050371 (3) [back to overview]	Total Testosterone
NCT04050371 (3) [back to overview]	Estradiol Concentration
NCT04050371 (3) [back to overview]	Tenofovir Diphosphate Concentration in Dried Blood Spots (DBS)
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal DPV Concentrations From Breastmilk by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal DPV Concentrations From Plasma by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal FTC Concentrations From Breastmilk by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Infant DPV Concentrations From Plasma by Visit
NCT04140266 (26) [back to overview]	Proportion of Participants Who Find Their Study Product to be at Least as Acceptable as Other HIV Prevention Methods
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Tenofovir Diphosphate (TFV-DP) Concentrations
NCT04140266 (26) [back to overview]	The Number of Mothers Non-adherent to Study Product for Each Month of Product Use by Study Product
NCT04140266 (26) [back to overview]	Residual Drug Levels in Returned VRs
NCT04140266 (26) [back to overview]	Geometric Mean of Infant FTC-TP Concentration by Visit
NCT04140266 (26) [back to overview]	Participant Willingness to Use Their Assigned Study Products During Breastfeeding in the Future (Y/N)
NCT04140266 (26) [back to overview]	Number of Mother Participants With Serious Adverse Events (SAEs) Including Maternal Deaths in Both Study Arms
NCT04140266 (26) [back to overview]	Number of Infant Participants With Grade 3 or Higher AEs in Both Study Arms
NCT04140266 (26) [back to overview]	Number of Mother Participants With Grade 3 or Higher Adverse Events (AEs) in Both Study Arms
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal FTC-TP Concentrations by Visit
NCT04140266 (26) [back to overview]	Number of Infant Participants With SAEs Including Infant Deaths in Both Study Arms
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Plasma Dapivirine (DPV) Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Emtricitabine Triphosphate (FTC-TP) Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Breastmilk TFV Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Breastmilk FTC Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Breastmilk DPV Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Infants With Detectable TFV-DP Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Infants With Detectable Plasma DPV Concentrations
NCT04140266 (26) [back to overview]	Geometric Mean of Infant TFV-DP Concentrations by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal TFV Concentrations From Breastmilk by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal TFV-DP Concentrations by Visit
NCT04140266 (26) [back to overview]	Number and Proportion of Infants With Detectable FTC-TP Concentrations
NCT04233879 (8) [back to overview]	Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48
NCT04233879 (8) [back to overview]	Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48
NCT04233879 (8) [back to overview]	Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
NCT04233879 (8) [back to overview]	Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
NCT04233879 (8) [back to overview]	Change From Baseline in Body Weight at Week 48
NCT04233879 (8) [back to overview]	Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 48
NCT04233879 (8) [back to overview]	Incidence of Viral Resistance-Associated Substitutions (RASs) at Week 48
NCT04233879 (8) [back to overview]	Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48
NCT04318210 (7) [back to overview]	Extracellular Tenofovir (TFV) for Recent Drug Exposure
NCT04318210 (7) [back to overview]	Self-reported Drug Adherence Over the Past 3 Days
NCT04318210 (7) [back to overview]	Number of Sex Partners
NCT04318210 (7) [back to overview]	Number of Sex Acts by Condom Usage
NCT04318210 (7) [back to overview]	Intracellular Tenofovir-diphosphate (TFV-DP)
NCT04318210 (7) [back to overview]	HIV Seroconversion
NCT04318210 (7) [back to overview]	Serious Adverse Events

Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment.

"Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004, Clarification August 2009, which is available on the RCC website at (http://rcc.tech-res.com/). Adverse Events of Grade 3 or 4 laboratory abnormalities or signs and symptoms that were judged by the study team to be possibly or probably related to the study treatment.~Comparisons between age groups were not required as per protocol." (NCT00016718)
Timeframe: At study entry, weeks 2 and 4, every 4 weeks up to week 96 and every 6 weeks thereafter for Group 1 participants and at study entry, weeks 2 and 4, every 4 weeks up to week 144 and every 12 weeks thereafter for Groups 2 and 3

Intervention	proportion of participants (Number)
Age Group 1	0.17
Age Group 2	0.1
Age Group 3	0.19

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG	53.96	55.25
EFV 600mg q.d. With ENG	53.64	56.65

Intervention	Participants (Count of Participants)
	3rd Trimester	Postpartum
EFV 600mg q.d.	20	21
MVC 150 or 300mg b.i.d.	8	7

Intervention	Participants (Count of Participants)
	2nd Trimester	3rd Trimester	Postpartum
ATV/RTV Arm 1: 300/100mg q.d.	1	12	12
DRV/COBI 800/150 mg q.d.	3	4	14
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	7	16	22
DRV/RTV 600/100mg b.i.d.	7	19	22
DRV/RTV 800/100mg q.d.	9	19	22
DTG 50mg q.d.	9	20	23
EFV 600 mg q.d. (Outside THA)	12	33	34
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	8	29	27
ETR 200mg b.i.d.	5	13	7
EVG/COBI 150/150mg q.d.	8	10	18
FPV/RTV 700/100mg b.i.d.	8	26	22
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	10	19	26
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	9	30	27
ATV/COBI 300/150 mg q.d.	1	2	5
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.	NA	15	14
RAL 400mg b.i.d.	11	33	30
RPV 25mg q.d.	14	26	25
TAF 10mg q.d. w/COBI	15	23	22
TAF 25mg q.d.	13	23	24
TAF 25mg q.d. w/COBI or RTV Boosting	10	24	18
TFV 300mg q.d.	2	27	27
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.	1	11	12
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	7	23	32

Intervention	mcg/mL (Median)
	2-10 hours after birth	18-28 hours after birth	36-72 hours after birth	5-9 days after birth
DRV/COBI 800/150 mg q.d.	0.35	1.43	1.87	1.72
DTG 50mg q.d.	1.73	1.53	1.00	0.06
EFV 600 mg q.d. (Outside THA)	1.1	1.0	0.9	0.4
EVG/COBI 150/150mg q.d.	0.132	0.032	0.005	0.005

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG	115.97	100.20

Intervention	unitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	0.15
DTG 50mg q.d.	1.25
EVG/COBI 150/150mg q.d.	0.91
DRV/COBI 800/150 mg q.d.	0.07
ATV/COBI 300/150 mg q.d.	0.07
TFV 300mg q.d.	0.88

Intervention	hour (Median)
DTG 50mg q.d.	32.8
EVG/COBI 150/150mg q.d.	7.6
DRV/COBI 800/150 mg q.d.	NA
EFV 600 mg q.d. (Outside THA)	65.6

Intervention	weeks (Number)
	1st percentile	5th percentile	10th percentile
TDF/FTC+EFV	48	104	NA
ZDV/3TC+EFV	48	128	NA

Intervention	weeks (Number)
	5th percentile	10th percentile	25th percentile
TDF/FTC+EFV	0	0	NA
ZDV/3TC+EFV	0	0	32

Intervention	participants (Number)
	Week 24: Number with RNA <400 c/mL (N=495; N=506)	Week 48: Number with RNA <400 c/mL (N=476; N=478)
ddI+FTC+ATV	431	424
ZDV/3TC+EFV	459	437

Intervention	cells/mm^3 (Median)
	Change from screening to week 24 (N=490; N=498)	Change from screening to week 48 (N=480; N=485)	Change from screening to week 96 (N=458; N=471)
TDF/FTC+EFV	120.5	159	226
ZDV/3TC+EFV	112.5	151.5	220.5

Intervention	cells/mm^3 (Median)
	Change from screening to week 24 (N=490; N=502)	Change from screening to week 48 (N=474; N=477)	Change from screening to week 96 (N= 188; N=188)
ddI+FTC+ATV	146.5	187.0	256.0
ZDV/3TC+EFV	112.5	152.0	216.0

Intervention	participants (Number)
	Week 24: Number with RNA <400 c/mL (N=495; N=500)	Week 48: Number with RNA <400 c/mL (N=482; N=487)
TDF/FTC+EFV	448	455
ZDV/3TC+EFV	459	442

Intervention	weeks (Number)
	10th percentile	25th percentile	50th percentile
TDF/FTC+EFV	4	32	224
ZDV/3TC+EFV	4	12	112

Intervention	Percent of participants (Number)
	week 48 percent of virologic failure or death	week 96 percent of virologic failure or death
NoNVP/LPV_r	14	20
NoNVP/NVP	14	17
NVP/LPV_r	4	12
NVP/NVP	23	31

Intervention	cells/mm^3 (Median)
	Week 48 CD4 count change from randomization	Week 96 CD4 count change from randomization
NoNVP/LPV_r	172	256
NoNVP/NVP	172	223
NVP/LPV_r	201	278
NVP/NVP	191	291

Intervention	percent of participants (Number)
	week 48 percent of full adherence in past month	week 96 percent of full adherence in past month
NoNVP/LPV_r	86	87
NoNVP/NVP	90	93
NVP/LPV_r	88	95
NVP/NVP	89	94

Intervention	Change in Log10 transformed CD4 Counts (Mean)
	IT arm (wk 60- wk 36) vs. DT arm (wk 24- wk 0)	IT arm (wk 72- wk 36) vs. DT arm (wk 36- wk 0)	IT arm (wk 84- wk 36) vs. DT arm (wk 48- wk 0)	IT arm (wk 96- wk 36) vs. DT arm (wk 60- wk 0)
DT Arm	-0.02	-0.03	-0.06	-0.02
IT Arm	-0.11	-0.10	-0.10	-0.12

Intervention	participants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)	1
21-day Lamivudine/Zidovudine (3TC/ZDV)	0
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)	0
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)	0
7-day Lopinavir/Ritonavir (LPV/r)	3
21-day Lopinavir/Ritonavir (LPV/r)	1

Intervention	cells/mm^3 (Median)
	Baseline (n=166,169)	Week 48 (n=122,131)	Change from Baseline to Week 48 (n=121,130)
Lopinavir/Ritonavir	142.0	348.0	204.0
Saquinavir/Ritonavir	141.5	319.0	178.0

emtricitabine

Description

Cross-References

Synonyms (137)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Protein Targets (6)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (46)

Molecular Functions (35)

Ceullar Components (26)

Bioassays (217)

Research

Studies (1,638)

Market Indicators

Research Demand Index: 85.28

Study Types

Clinical Trials (372)

Trial Overview

Trial Outcomes

Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment.

Proportion of Participants With Suppression of HIV Viral Load to Less Than 400 Copies/ml at Week 16

Proportion of Participants With Suppression of HIV Viral Load to Less Than 50 Copies/ml at Week 16

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Plasma Concentration for Contraceptives

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms

All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms

Time to Immunologic Failure (NRTI Comparison)

Time to Immunologic Failure (PI Comparison)

Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)

Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)

Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(PI Comparison)

Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)

Time to Treatment Failure (PI Comparison)

Time to Treatment Failure (NRTI Comparison)

Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (PI Comparison)

Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)

Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(PI Comparison)

Change in CD4 Count From Screening to Weeks 24, 48, 96 (NRTI Comparison)

Change in CD4 Count From Screening to Weeks 24, 48, 96 (PI Comparison)

Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (NRTI Comparison)

Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (NRTI Comparison)

Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (PI Comparison)

Time to First Dose Modification or Grade 3 or 4 Adverse Event (NRTI Comparison)

Time to First Dose Modification or Grade 3 or 4 Adverse Event (PI Comparison)

Intervention	copies/mL (Mean)
	Baseline	Week 48 (n=126,133)	Change from Baseline to Week 48 (n=126,133)
Lopinavir/Ritonavir	5.17	1.83	-3.36
Saquinavir/Ritonavir	5.20	1.80	-3.39

Intervention	participants (Number)
	Patients with <50 Copies/mL	Patients with <400 Copies/mL
Lopinavir/Ritonavir	108	127
Saquinavir/Ritonavir	108	121

Intervention	participants (Number)
	Pts. with HIV-1 RNA Viral Load <50 copies/mL - YES	Pts. with HIV-1 RNA Viral Load <50 copies/mL - NO
Lopinavir/Ritonavir	108	62
Saquinavir/Ritonavir	108	59

Intervention	Percentage of Participants (Number)
EFV+FTC+TDF/Atripla (From Study Baseline)	87
All Atripla (From Atripla Baseline)	85

Intervention	Participants (Number)
	Bothers me (W 144 and W 240)	Does not bother me (W 144 and W 240)	Bothers me (W 144); does not bother me (W 240)	Does not bother me (W 144); bothers me (W 240)
All Atripla	41	126	31	28

Intervention	Participants (Number)
	Very satisfied (W 144 and W 240)	Not very satisfied (W 144 and W 240)	Very satisfied (W 144); not very satisfied (W 240)	Not very satisfied (W 144); very satisfied (W 240)
All Atripla	180	10	9	23

Intervention	participants (Number)
EFV, FTC/TDF, and Placebo ABC/3TC	152
EFV, Placebo FTC/TDF, and ABC/3TC	239
RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC	138
RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC	216

Intervention	Weeks (Median)
EFV, FTC/TDF, and Placebo ABC/3TC	141.4
EFV, Placebo FTC/TDF, and ABC/3TC	133.3
RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC	141.6
RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC	137.3

Intervention	percentage of participants (Number)
	Week 48	Week 96
EFV, FTC/TDF, and Placebo ABC/3TC	80	73
EFV, Placebo FTC/TDF, and ABC/3TC	67	56
RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC	86	77
RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC	73	62

Intervention	Weeks (Number)
	5th percentile time to regimen failure	10th percentile time to regimen failure	25th percentile time to regimen failure
EFV, FTC/TDF, and Placebo ABC/3TC	4	16	72
EFV, Placebo FTC/TDF, and ABC/3TC	4	4	24
RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC	4	16	84
RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC	4	4	36